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ABSTRACT 
Activation of the NF-κB pathway is linked to cancer development and progression. 
Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) encodes vFLIP which binds to 
the NEMO/IKKγ subunit of IKK and constitutively activates NF-κB, leading to 
tumourigenesis. Cellular FLIPs, which share sequence homology with KSHV vFLIP and 
induce NF-κB activation, are upregulated in a variety of malignancies and are therefore 
promising targets for anti-cancer therapies. The cFLIP family consists of three splice 
variant isoforms (cFLIPL, cFLIPS and cFLIPR) and two proteolytic fragments (p43-FLIP 
and p22-FLIP). Much is known about how cFLIPs regulate apoptosis but the 
mechanisms by which they activate NF-κB are not well understood. Potential similarities 
to vFLIP-induced activation have been suggested but not investigated.  
Here we show that, unlike KSHV vFLIP, cFLIP variants are not found in stable 
complexes with NEMO and all require upstream events to mediate signalling to IKK. By 
mutational analysis on NEMO and protein expression knockdowns, we demonstrate that 
all cFLIP isoforms require the ubiquitin binding domain (UBD) of NEMO while it is 
redundant for vFLIP’s function. Similarly, our data reveals that TAK1 is essential for 
induction of IKK by cFLIP isoforms but not vFLIP.  We further show that different 
cFLIP isoforms have different requirements for IKK activation. While cFLIPL needs 
LUBAC to activate NF-κB, cFLIPS and p22-FLIP require FADD and RIP1. Contrary to 
existing reports, our results suggest that processing of cFLIPL to p22-FLIP or p43-FLIP 
fragments by caspase-8 is not necessary for its IKK activation. Finally, we propose that 
vFLIP-mediated activation of IKK is most likely to occur through induction of 
multimerisation and re-orientation of the IKK complexes within higher order IKK 
assemblies that lead to autophosphorylation of the enzymatic subunits, IKKα and β. 
In conclusion, the work in this thesis provides evidence that vFLIP, cFLIPL, cFLIPS 
and p22-FLIP have specific and different mechanisms of inducing IKK activation. This 
has implications for the design of therapeutics to block pathological NF-κB activation in 
viral and non-viral tumours. 
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1.1 NF-κB signalling pathway: an overview 
Nuclear Factor-κB (NF-κB) is one of the crucial signalling pathways which regulates 
a wide variety of physiological processes such as innate and adaptive immunity, 
proliferation, differentiation and cell death. In 1986, NF-κB was identified in David 
Baltimore’s laboratory as an inducible nuclear protein which binds to specific DNA 
sequences within κ light chain enhancer in B cells, referred to as κB sites (Sen and 
Baltimore, 1986a, 1986b). Extensive research over the past 27 years has revealed an 
enormous number of biological roles for this pathway in almost all cell types. The 
activation of NF-κB is strictly controlled at multiple levels by positive and negative 
regulatory elements whose malfunction can give rise to various pathologies, notably 
inflammatory diseases and cancers (Oeckinghaus et al., 2011).  
In the following sections, I provide a brief description of NF-κB signalling 
components and their mechanisms of action. 
1.1.1 NF-κB related proteins 
In resting conditions, NF-κB is sequestered in cell cytoplasm by inhibitor of κB 
(IκB). Upon activation by various stimuli such as IL-1 or TNFα, the IκB is 
phosphorylated by IκB kinase (IKK) complex leading to its ubiquitination and subsequent 
proteasomal degradation. The released NF-κB is further regulated by post-translational 
modifications and migrates to nucleus where it promotes the transcription of target genes. 
In principle, three major families of protein form the backbone of NF-κB signalling 
network: NF-κB transcription factors, IκB family and IKK complex (Hayden and Ghosh, 
2008). 
1.1.1.1 NF-κB transcription factors 
In mammals, NF-κB family consists of five transcription factors: RelA (p65), RelB, 
c-Rel, NF-κB1 (p105/p50) and NF-κB2 (p100/p52) encoded by RELA, RELB, REL, 
NFKB1 and NFKB2 genes, respectively (Gilmore, 2006) (Figure 1.1A). Except for RelA, 
transcription of the other subunits is upregulated by NF-κB, producing a positive 
feedback loop on stimulated cells (Huxford et al., 2011). Synthesised as large precursor 
proteins, p105 and p100 undergo proteolytic processing to generate the transcriptionally 
active mature polypeptides, p50 and p52, respectively (Ghosh et al., 1998). Processing of 
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p105 occurs constitutively (Karin and Ben-Neriah, 2000; Lin et al., 1998), whereas p100 
processing is mediated through regulated signals (Liou et al., 1994).  
All members of the NF-κB family share a conserved N-terminal region of roughly 
300 amino acids, known as the rel homology domain (RHD) which is responsible for 
hetero- and homo-dimerisation, nuclear localisation, DNA binding  and association with 
IκBs (Hayden and Ghosh, 2004). In RelA, RelB and c-Rel, the RHD is followed by a 
transcription activation domain (TAD) which mediates their association with trans-acting 
factors leading to positive regulation of gene expression (Hayden and Ghosh, 2008). On 
the contrary, p50 and p52 which lack a TAD fail to mediate transcription as homo-dimers 
and may act as repressors unless hetero-dimerised with one of the TAD containing NF-
κB subunits or other cofactor-recruiting proteins (Hayden and Ghosh, 2008; Zhong et al., 
2002). Some studies, however, suggest that these homo-dimers are able to mediate 
activation through interaction with nuclear IκB proteins which can act as coactivators 
(Smale, 2012).  Unlike the Rel proteins, p100 and p105 precursors contain an ankyrin 
repeat domain (ARD) in their carboxy terminal halves, similar to that found in the IκB 
family (Hoffmann et al., 2006). RelB is unique in that it contains a further N-terminal 
lucine zipper-like (LZ) motif  which - in addition to the TAD - is necessary for its full 
activation (Hayden and Ghosh, 2008).  
 Through combinatorial interactions, NF-κB subunits can form up to 15 distinct 
homo- and hetero-dimers (Gilmore, 2006). Although 12 out of the 15 possible dimers 
have been identified in various tissues,  other yet undetected dimers may exit in some 
specific cellular conditions (Huxford et al., 2011). RelA: p50 is the most abundant of NF-
κB dimers, identified in almost all cell types (Oeckinghaus and Ghosh, 2009). The 
composition of NF-κB dimers can vary depending on cell type, stimulus and duration of 
signalling (Sen and Smale, 2009). In addition to the combinatorial specificity, various post-
translational modifications of NF-κB polypeptides as well as diverse interactions with 
other coactivators contribute further to remarkable complexity of cell- and stimuli-specific 
NF-κB responses (Sen and Smale, 2009).  
1.1.1.2 IκB family 
IκBs consist of structurally related proteins, characterised by the presence of a 
conserved ARD that mediates their interaction with NF-κB subunits (Li et al., 2006a; 
Zheng et al., 2011). Based on their subcellular localisation as well as functional and 
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structural characteristics, the IκB family can be subdivided into two groups of typical and 
atypical IκBs (Figure 1.1B).  
IκBα, Iκβ and IκBε represent the typical cytoplasmic IκBs that function in part by 
masking the nuclear localisation sequence (NLS) of NF-κB polypeptides - contained 
within the RHD - and therefore, inhibit their nuclear translocation (Vallabhapurapu and 
Karin, 2009). In case of IκBα, the NLS masking is incomplete but a nuclear export 
sequence (NES) within IκBα mediates quick export of NF-κB:IκBα complexes from the 
nucleus. This leads to continuous shuttling of the complexes between cytoplasm and 
nucleus. Upon stimulation-induced degradation of IκBα, this balance shifts in favour of 
nuclear localisation and leads to transactivation (Hayden and Ghosh, 2008). Selective 
binding of the typical IκBs to specific homo- or hetero-dimers ties them to their distinct 
functions(Malek et al., 2001; Tran et al., 1997). Discrete degradation dynamics as well as 
different stimuli-dependant expression modes contribute further to specificity of their 
transcriptional activities (Hinz et al., 2012).  
The atypical IκBs consist of IκBζ, IκBη, IκBNS and B cell lymphoma-3 (Bcl-3) that 
all predominantly reside in the cell nucleus. Nuclear IκBs can bind to DNA-bound NF-
κB, inhibit their degradation and mediate their interaction with various cofactors resulting 
in positive or negative regulation of transcription (Ghosh and Hayden, 2008). Expression 
of atypical IκBs, except for IκBη, is limited in resting cells but can be greatly induced 
upon NF-κB stimulation (Hinz et al., 2012). 
Through their C-terminal ankyrin repeat motifs, NF-κB precursors p100 and p105 
can also function as IκB-like proteins, sequestering their dimeric partners in the cytoplasm 
(Naumann et al., 1993a, 1993b) (Figure 1.1B). In contrast to typical IκBs which 
demonstrate subunit-specific inhibitory function, p105 binds to and inhibits all NF-κB 
subunits including its own processed form, p50. Recent studies have shown that multiple 
units of p100 and p105 can form large complexes (referred to as IκBsomes) that contain 
various NF-κB subunits. Different structural organisation and subunit binding preferences 
of atypical IκBs suggests that they might have distinct kinetic properties in activation and 
post-induction termination of NF-κB signalling as compared with typical IκBs (Huxford 
et al., 2011).  
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Figure 1.1. Molecular architecture of the NF-κB, IκB and IKK family members. 
The number of amino acids in each human protein is indicated on the right. A) All 
members of the NF-κB share a rel homology domain (RHD) that is required for their 
dimerisation, nuclear localisation, DNA binding and sequestration of IκBs. In RelA, RelB 
and c-Rel, this domain is followed by a transactivation domain (TAD) that mediates 
transcription initiation at κB sites-containing promoters. RelB additionally harbours a 
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leucine zipper domain in its N-terminus that is required for its maximal activity. The 
RHD in the p100 and p105 precursors is followed by a glycine-rich region (GRR), ankryin 
repeat motifs (ANK) and a C-terminal death domain (DD). The p52 and p50 subunits are 
shown below the p100 and p105 structures, generated after their proteolysis. B) IκB 
family members are characterised by the presence of multiple ANK motifs which mediate 
interactions with NF-κB dimers. IκBα and IκBβ contain an additional C-terminal PEST 
domain (sequences rich in proline (P), glutamate (E), serine (S), and threonine (T) 
residues) that is important for normal protein turnover. C) The core IKK complex 
consists of the enzymatic subunits, IKKα and IKKβ, and the regulatory subunit, NEMO. 
Serine residues within the activation loop of the IKKα/β kinase domain (KD) that 
undergo phosphorylation have been indicated. The previously designated leucine zipper 
(LZ) and helix-loop-helix (HLH) regions are shown in parentheses. ULD: ubiquitin-like 
domain, SDD: scaffold/dimerisation domain, NBD: NEMO-binding domain, HLX: 
helical domain, CC: coiled coli. 
 
1.1.1.3 IκB kinase complex 
The IκB Kinase complex is the master regulator of the NF-κB signalling and 
consists of two enzymatic subunits: IKKα (IKK1) and IKKβ (IKK2) as well as a 
regulatory subunit known as NF-κB essential modulator (NEMO) or IKKγ (Scheidereit, 
2006) (Figure 1.1C). Several biochemical studies on purified IKK complex have proposed 
a 2:1:1 ratio of the subunits where a dimer of NEMO associates with 1 IKKα hetero-
dimerised with 1 IKKβ. However, other combinations of IKK core complex have also 
been suggested to exist, including the homodimers of IKKα and IKKβ either associated 
with or distinct from NEMO or separate (Liu et al., 2012). In vitro experiments provide 
evidence that IKK complexes can further assemble to form high-order structures through 
multimerisation (Drew et al., 2007). This can explain the high molecular weight of the 
endogenous IKK complexes (700-900 kDa) when separated by gel filtration 
chromatography. However, it is thought that the elongated shape of NEMO may also be 
the reason for the apparent molecular weight of IKK (Hayden and Ghosh, 2008). 
1.1.1.3.1 The catalytic subunits 
IKKα and IKKβ are structurally very similar and share 51% amino acid sequence 
homology (Mercurio et al., 1997). Both kinases contain an N-terminal kinase domain 
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(KD) -with two serine residues within the activation loop (S176 and S180 for IKKα, S177 
and S181 for IKKβ) that require phosphorylation for the kinase activity, followed by a 
dimerisation domain and a C-terminal NEMO binding domain (NBD)(Israël, 2010; Liu et 
al., 2012; Scheidereit, 2006) (Figure 1.1C). IKKα, but not IKKβ, has a putative nuclear 
localisation signal (NLS) that has been linked to its NF-κB-independent nuclear activities 
(Sil et al., 2004).  
Crystal structures of IKKβ (from human and Xenopus laevis) were recently resolved, 
leading to a significant progress in understanding the domain organisation and function of 
this enzyme (Liu et al., 2013; Polley et al., 2013; Xu et al., 2011). Based on these studies, 
IKKβ has a trimodular architecture comprising the N-terminal KD, a central ubiquitin-
like domain (ULD) and C-terminal elongated α-helical scaffold/dimerisation domain 
(SDD) (Figure 1.1C). Interestingly, neither of the previously predicted helix-loop-helix 
(HLH) and leucine zipper (LZ) motifs form these structures but they are part of the SDD 
(Xu et al., 2011). The ULD is required for catalytic activity of IKKβ and, together with 
SDD, is involved in determining the substrates specificity towards IκBα. The SDD 
mediates dimersiation of IKKβ which is required for kinase activation, but not important 
for maintaining the kinase activity once the activation loop is phosphorylated (Xu et al., 
2011).   
In both IKKα and IKKβ, the NBD contains a shared six amino acid sequence 
(LDWSWL) that is necessary for their interaction with NEMO (May et al., 2002). Cell 
permeable peptides containing this sequence have been utilised to specifically disrupt 
IKK-NEMO interaction and prevent cytokine-induced NF-κB activation. Interestingly, 
competition assays using the peptide mimic of the NBD indicate a considerably weaker 
interaction of NEMO with IKKα compared to IKKβ (May, 2000). The higher affinity of 
IKKβ might be due to a unique 12 amino acid region that is not found in IKKα. This 
extension occurs immediately after the NBD and contains five negatively charged 
glutamic acid residues (Delhase, 1999). Remarkably, swapping the C-termini of IKKα and 
IKKβ generates an IKKα with IKKβ-like behaviour. These results suggest that 
differences in the NEMO binding affinity of IKKα and IKKβ might be responsible for 
their distinct functions (Kwak, 2000). 
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1.1.1.3.2 NEMO/IKKγ 
The regulatory subunit of IKK complex, NEMO, is a 49 kDa polypeptide predicted 
to have two helical (HLX) domains interleaved with two coiled-coil (CC) domains, 
followed by a leucine zipper motif and a C-terminal zinc finger (ZF) (Zheng et al., 
2011)(Figure 1.1C). Unlike IKKα and IKKβ, NEMO lacks any intrinsic enzymatic 
activity. The N-terminal region of NEMO (amino acids 40-120 contained within HLX1 
region) mediates its binding to the C-termini of the catalytic subunits (May, 2000). The 
CC2 domain together with the adjacent LZ form the ubiquitin binding domain of 
NEMO, generally referred to as the NUB (NEMO ubiquitin binding), CoZi (coil-zipper 
domain) or UBAN (ubiquitin-binding in ABIN and NEMO)(Bloor et al., 2008; Ea et al., 
2006; Wu et al., 2006a). The ZF motif was suggested by a recent study to be required for 
directing the substrate-specificity of IKKβ towards IκBα (Schröfelbauer et al., 2012). This 
domain has also been implicated in enhancing affinity of NEMO for binding to ubiquitin 
chains (Laplantine et al., 2009). 
Except for the C-terminus, the α-helical sequence of NEMO is capable of forming 
coiled-coil structure either alone or in association with a partner protein. The CC regions 
of NEMO are disrupted in multiple points by amino acids out of coiled-coil register. 
These breaks can serve as docking sites for interaction with various regulatory proteins 
and the flexible nature of CC region enhances the efficiency of these interactions (Ghosh 
et al., 2012). 
NEMO is encoded by the IKKBG gene located on the chromosome X. In humans, 
amorphic mutations of NEMO that lead to a lack of NEMO-dependant NF-κB activation 
are lethal in males but in females cause the disease incontinentia pigmenti (IP). IP is 
characterised by abnormalities of skin, hair, teeth, nails, and in some cases, neurological 
complications (Berlin et al., 2002). Hypomorphic mutations of NEMO that result in a 
weakened, but not obliterated, NF-κB induction have been associated with the X-linked 
recessive disease of anhidrotic ectodermal dysplasia associated with immunodeficiency 
(EDA-ID) in males. Symptoms of EDA-ID include severe defects in immunological 
functions, sparse hair, dental defects and hypohydrosis (Döffinger et al., 2001). Mutations 
in NEMO have been also identified in patients with Mendelian susceptibility to 
mycobacterial disease (MSMD) who have recurrent infections with bacteria of the 
tuberculosis family (Al-Muhsen and Casanova, 2008). 
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1.1.1.3.3 Other IKK-associated components 
Apart from IKKα, IKKβ, and IKKγ which form the core of IKK complex, other 
proteins have been also reported to participate in the architecture and function of the 
complex. The chaperones heat shock protein 90 (HSP90) and HSP70 are two such 
components detected in association with the IKK complex. HSP90 constitutively 
associates with IKK through its co-chaperone Cdc-37 and has been suggested to stabilise 
the complex through facilitating its folding. Inhibition of HSP90 by Geldanamycin (an 
ATPase inhibitor of HSP90) suppresses NF-κB signalling in response to various stimuli 
such as IL-1, TNFα and PMA (Broemer et al., 2004; Chen et al., 2002). Unlike HSP90, 
HSP-70 appears to function as a NEMO interacting inhibitor of the IKK through 
preventing the formation of the complex (Ran et al., 2004). Another component that 
associates with IKK and regulates its function is a 105-kDa protein, ELKS (a protein rich 
in glutamate (E), leucine (L), lysine (K) and serine (S)).  Immunodepletion analyses 
suggested that ELKS is a stoichiometric component of IKK (Häcker and Karin, 2006). 
siRNA-mediated knockdown of ELKS results in reduced levels of IKK activation in 
response to TNFα and IL-1. Recent studies support a role for ELKS in ATM- and 
NEMO-dependent NF-κB activation in response to genotoxic stress induced by DNA 
double stranded breaks (Hadian and Krappmann, 2011; Yang et al., 2011). Although the 
association of ELKS, HSP90 and HSP70 with IKK have been well-established, the 
detailed mechanisms by which they regulate IKK have yet to be identified. 
1.1.2 Two pathways to NF-κB 
Numerous receptor-mediated cascades that lead to activation of NF-κB are 
classified into two major pathways, the canonical (or classical) and the non-canonical (or 
alternative) NF-κB pathway. These pathways are distinct in respect to the triggering 
stimuli, the IKK components involved and the targeted NF-κB subunits. 
1.1.2.1 Canonical NF-κB pathway 
The canonical pathway is triggered by a broad range of stimuli including 
inflammatory cytokines (such as IL-1, TNFα, etc), pathogen-associated molecular patterns 
(PAMPs) and antigen receptors (Bonizzi and Karin, 2004).  This pathway is mainly 
activated through phosphorylation of IκBs at serine residues (equivalent to Ser32 and 
Ser36 of IκBα) by IKKβ in a NEMO-dependant manner. The phospho-IκBs are then 
recognised and polyubiquitinated (at residues equivalent to Lys21 and Lys22 of IκBα) by 
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the E3 ubiquitin ligase complex SCFβTRCP (Skp1, Cdc53/Cullin1 and F-box protein β 
transducin repeat-containing protein). Subsequently, the K48-linked polyubiquitin chains 
mark IκB for degradation by 26S proteasome resulting in the release and nuclear 
translocation of RelA-containing NF-κB heterodimers, most commonly RelA:50 dimers 
(Vallabhapurapu and Karin, 2009) (Figure 1.2, left). 
 
Although IKKβ appears to be the predominant kinase of the canonical NF-κB 
pathway, several lines of evidence support a role for IKKα in this pathway. For example, 
receptor activator of NF-κB (RANK)-induced classical NF-κB activation in mammary 
cells depends on IKKα as the key kinase (Cao et al., 2001). Furthermore, IL-1 (but not 
TNFα)-induced canonical NF-κB induction has been shown to be intact in IKKβ 
deficient MEF cells (Solt et al., 2007).  A recent study showed that IKKα is also involved 
in negative regulation of classical pathway through phosphorylating Tax1-binding protein 
1 (TAX1BP1) and recruitment of the A20 deubiquitinase complex to IKK (Shembade et 
al., 2011). These findings indicate that IKKα may be involved in both activation and 
deactivation of canonical NF-κB signalling in response to at least a subset of stimuli.  
The ultimate outcome of the canonical pathway is transcriptional activation of the 
genes that are mainly involved in innate immunity such as pro-inflammatory cytokines 
(e.g., IL-1, IL-2, IL-6, TNF), chemokines (e.g.,CCL2, CCL3, CXCL8), leukocyte adhesion 
molecules (e.g., E-selectin, ICAM-1, and VCAM-1), and multiple pro-survival and anti-
apoptotic genes (e.g., Bcl-2, Bcl-XL, XIAP) (Bonizzi and Karin, 2004). Substantial 
increase in susceptibility to infections in conditional IKKβ or RelA KO mice reveals the 
importance of canonical pathway in immune functions (Pasparakis et al., 2006). 
1.1.2.2 Alternative NF-κB pathway 
Unlike the canonical NF-κB pathway, the non-canonical NF-κB pathway is 
activated by a limited number of receptors that belong to the TNF receptor superfamily. 
These include CD40, lymphotoxin β receptor (LTβR), B-cell activating factor receptor 
(BAFFR), CD27, RANK, and Fn14 (Razani et al., 2011). Although most signals that 
activate canonical NF-κB pathway do not activate the non-canonical pathway, the non-
canonical signals are able to activate both pathways (Bonizzi and Karin, 2004). 
The alternative NF-κB pathway strictly relies on IKKα and appears to be 
independent of IKKβ and NEMO (Senftleben et al., 2001) (Figure 1.2, right). Activation 
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of IKKα by NF-κB-inducing kinase (NIK), a member of the mitogen-associated protein 3 
kinase (MAP3K) family, is an absolute requirement for switching on the non-canonical 
pathway (Xiao et al., 2001a, 2004). In resting cells, NIK is constitutively synthesised but 
cannot be detected due to a rapid degradation mediated by an E3 ubiquitin ligase complex 
composed of TNFα receptor associated factor-2 (TRAF2), TRAF3, cellular inhibitor of 
apoptosis-1 (cIAP1) and cIAP2 (Qing et al., 2005; Zarnegar et al., 2008).  Evidences 
suggest that cIAP1/2 are responsible for the K48-linked ubiquitination of NIK while 
TRAF2 and TRAF3 cooperate to recruit NIK to cIAPs. Upon receptor ligation, the 
TRAF/cIAP complex is recruited to the receptor whereupon cIAP1/2 synthesises K48- 
linked Ub chains on TRAF3 instead of NIK. The subsequent degradation of TRAF3 
results in the accumulation of NIK that in turn phosphorylates and activates IKKα 
(Vallabhapurapu et al., 2008; Zarnegar et al., 2008). The activated IKKα then 
phosphorylates p100 (at ser866 and ser870) and marks it for proteasomal degradation, 
resulting in the release of the p52: RelB heterodimers that translocate to the nucleus and 
bind to the relevant DNA sequences (Senftleben et al., 2001; Xiao et al., 2004). The 
activated IKKα also phosphorylates NIK that leads to its destabilisation and 
downregulation of downstream signalling events (Razani et al., 2010). 
Biological roles of the alternative pathway that are mainly in regulating adoptive 
immunity include development of secondary lymphoid organs, B-cell maturation and 
survival, thymic epithelial cell differentiation, dendritic cells (DC) maturation and the 
osteoclastogenesis. Moreover, recent studies suggest a role or this pathway in regulating 
T-cell differentiation (Sun, 2012). 
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Figure 1.2. A simplified scheme of the canonical and alternative NF-κB activation 
pathways. Canonical pathway (right) is induced by a diverse range of surface receptors 
(e.g, TNFR or TLR) which converge on the tripartite IKK complex, comprising IKKα, 
IKKβ and NEMO. IKK activity results in phosphorylation of the IκB, followed by its 
K48-ubiquitination and proteasomal degradation. This leads to liberation of the Rel:p50 
dimers which can then translocate to nucleus and induce plethora of  target genes. Unlike 
the canonical cascade, the alternative pathway (right) is induced by a small subset of 
receptors and depends on the NIK-mediated phosphorylation and activation of IKKα 
homo-dimers. Activated IKKα phosphorylates p100 to induce its partial proteolysis to 
p52 subunit. Transcriptionally active p52 preferentially hetero-dimerises with RelB to 
migrate into the nucleus and initiate transcription of target genes. 
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1.2 Mechanisms behind positive and negative regulation of IKK 
To become active, the IKK complex requires phosphorylation of the T loop serines 
of at least one of the kinases. Similar to other kinases, this phosphorylation is more likely 
to confer activation through inducing conformational changes in the activation loop 
(Hayden and Ghosh, 2008).  Mutation of these serines (S176 and S180 on IKKα, and 
S177 and S181 on IKKβ) to alanine prevents kinase activity of the IKK while replacement 
with phosphomimetic glutamates renders them constitutively active (Mercurio et al., 
1997).  The exact mechanisms by which the kinase subunits are phosphorylated remain 
controversial to date. However, three major activation mechanisms have been proposed:  
(i) Direct phosphorylation of the kinase subunits by upstream IKK-activating 
kinases (IKK-K)  
 
(ii) Trans-autophosphorylation of IKK induced by oligomerisation 
 
 
(iii) Trans-autophosphorylation of IKK induced by conformational changes 
through protein-protein interaction or posttranslational modifications  
 
These mechanisms are not mutually exclusive and might integrate in various cell- 
and pathway-specific manners (Häcker and Karin, 2006). Regulation of these mechanisms 
and the relevant responsible components including various kinases, phosphatases, adaptor 
proteins and polyubiquitin chains are the subject of the following discussions. 
1.2.1 IKK-activating kinases 
The role of NIK for the phosphorylation and activation of IKKα in the alternative 
NF-κB pathway provided compelling evidence for the existence and function of IKK-Ks 
(Senftleben et al., 2001). Other studies have suggested a role for several other members of 
the MAP3K family as IKK-Ks in the canonical pathway. The most notable IKK-K is 
transforming growth factor-β kinase-1 (TAK1, aka MAP3K7) that was initially proposed 
to activate NF-κB through phosphorylating NIK (Ninomiya-Tsuji et al., 1999). Later on,  
in vitro experiments showed that TAK1, alongside its regulatory cofactors TAK1-binding 
protein1 (TAB1) and TAB2, can directly phosphorylate IKKβ on the activation loop in a 
ubiquitin-dependent manner (Wang et al., 2001). In cells, TAB2 or its homologues TAB3, 
but not TAB1, link TAK1 to upstream components by binding to K63-linked 
polyubiquitin chains on TRAF6 (in IL-1 signalling) or TRAF2 and RIP1 (in TNFα 
signalling) (Ea et al., 2006; Ishitani et al., 2003; Takaesu et al., 2000). This bridging is 
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mediated by a highly conserved C-terminal zinc finger domain on TAB2/3 (Kanayama et 
al., 2004). The mechanisms by which K63 ubiquitin chains induce TAK1 activation are 
not well-understood. However, it has been postulated that TAB2/3 binding to ubiquitin 
chains facilitates oligomerisation of TAK1 complexes leading to autophosphorylation and 
activation of TAK1 (Chen et al., 2006). In support of this hypothesis, TAK1 becomes 
phosphorylated at threonine187 within its activation loop and a mutation of this residue 
blocks its kinase activity (Singhirunnusorn et al., 2005).  
siRNA-mediated silencing of TAK1 as well as studies with deletion mutants of 
functional domains indicated that TAK1 is required for NF-κB activation (Besse et al., 
2007; Takaesu et al., 2003). Furthermore, analysis of MEFs derived from TAK1-deficient 
mice supported a role for this enzyme in IKK activation by stimuli such as IL-1 and 
TNFα. Nevertheless, animal studies suggest that TAK1 might be dispensable in vivo, at 
least in some cell types. For instance, absence of TAK1 does not impair BCR-induced 
NF-κB activation (Sato et al., 2005). In addition, deletion of TAK1 blocks TCR induced 
NF-κB signalling in thymocytes, but not in effector T cells (Liu et al., 2006; Wan et al., 
2006). Based on these results, it seems plausible that the requirement for TAK1 to 
activate IKK may be cell type-specific. 
Other studies have provided a role for mitogen-activated protein/ERK kinase 
kinase 3 (MEKK3, aka MAP3K3) as an IKK-K. Initial studies with MEKK3-/-  fibroblasts 
suggested its importance in TNFα-induced NF-κB activation downstream of TRAF2 and 
RIP1. These cells showed reduced levels of IκBα degradation and the p65/p50 DNA 
binding in gel shift assays was severely impaired in response to TNFα. Since MEKK3 
physically interacted with RIP1, it was proposed to mediate RIP1 signalling to IKK (Yang 
et al., 2001a). Later, Blonksa et al., were able to restore NF-κB activation in RIP1-
defiecient cells using a fusion protein composed of full length MEKK3 and RIP1 death 
domain (Blonska et al., 2005). This protein could directly associate with TRADD, 
indicating that RIP1 is likely responsible for recruiting MEKK3 to the TNFα receptor 
complex.  
MEKK3 is also implicated in IKK activation by IL-1R/TLR pathways and 
lysophosphatidic acid (LPA) (Huang et al., 2004b; Sun et al., 2009a). Similar to TAK1, 
MEKK3 interacts with TRAF6 upon induction of IL-1R/TLR pathways (Huang et al., 
2004b). Yao et al., described independent pathways for IL-1 induced NF-κB activation by 
TAK1 and MEKK3. The TAK1-mediated pathway was shown to result in activation of 
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IKKβ, followed by IκBα phosphorylation and degradation; whereas the MEKK3-
dependent pathway led to NF-κB activation by NEMO phosphorylation and IKKα 
activation resulting in IκBα phosphorylation and dissociation from NF-κB subunits 
without its degradation (Yao et al., 2007). LPA-induced IKK activation, on the other 
hand, appears to be dependent on MEKK3, but not TAK1 (Sun et al., 2009a). Despite 
these findings, the physiologic importance of MEKK3 in NF-κB pathways has yet to be 
determined in vivo. Animal studies are partially hindered by the fact that MEKK3 
knockout mice die at embryonic day 11 due to defects in angiogenesis and cardiovascular 
development (Yang et al., 2000). 
Two other MAP3Ks, MEKK1 and MEKK2, also exhibit ability to activate the IKK 
complex. Overexpression of MEKK1 and MEKK2 results in phosphorylation of 
IKKα/β in cells (Lee et al., 1997, 1998; Zhao, 1999). Although recombinant MEKK1 is 
shown to activate IKKs in vitro, there is no evidence for direct phosphorylation of IKKs 
by MEKK2. An analysis of biphasic cytokine-induced NF-κB activation demonstrated a 
mechanism in which MEKK2 regulates delayed NF-κB responses by assembling into 
IκBβ:NF-κB/IKK complexes; while MEKK3 inducibly associates with IκBα:NF-κB/IKK 
complexes and mediates rapid activation of NF-κB (Schmidt et al., 2003).  
Taken together, results from different studies suggest that IKK-Ks might have 
either redundant roles, cooperate to signal to IKK or function in distinct NF-κB 
pathways. Depending on the cell- and pathway-specific conditions, all three possibilities 
may exist. That being said, the exact role of IKK-Ks in IKK activation is still a matter for 
debate. Considering that IKK complexes can be activated by artificially enforced 
oligomerisation in vitro (Tang et al., 2003), IKK-Ks may contribute to amplification of 
IKK activity where it has been already initiated by trans-autophosphorylation. These 
functions, nevertheless, might be interchangeable in cells. 
Attempts to identify additional IKK-phosphorylating kinases have been hampered 
in part by the limitations of siRNA screenings. This is due to the fact that achieving 
complete protein knockdown in the whole cell population is almost impossible and the 
residual expression of a kinase is often sufficient to activate a signalling pathway normally 
(Liu et al., 2012).  
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1.2.2 IKK-regulating phosphatases 
Negative regulation of the MAPK signalling pathways by numerous MAPK 
phosphatases (MKPs) is well-established (Liu et al., 2007). By contrast, only a few 
phosphatases have been implicated in the modulation and termination of NF-κB pathway. 
The most prominent of all is a ubiquitously expressed serine/threonine phosphatase 
known as protein phosphatase type2A (PP2A). PP2A exists as heterotrimeric 
holoenzymes composed of one catalytic C subunit (PP2Acα or β isoforms) and a 
scaffolding A subunit (PR65α or β) which together form the core dimer, as well as a 
regulatory B subunit (Janssens and Goris, 2001). There are at least 18 regulatory B 
subunits whose binding to the ‘AC’ core is speculated to control PP2A substrate 
selectivity, catalytic activity and subcellular localisations (Cho and Xu, 2007). 
Several early studies associated PP2A activity with down-regulation of NF-κB on 
the observation that treatment with PP2A inhibitors enhanced IKK activation and 
blocked RelA phosphorylation in response to cytokines (DiDonato et al., 1997; 
Maggirwar, 1995; Yang et al., 2001b). In addition, recombinant PP2A could inhibit IKK 
activity and dephosphorylate RelA in vitro (DiDonato et al., 1997; Li et al., 2006b). In 
agreement with these findings, a more recent study demonstrated that siRNA-mediated 
silencing of various catalytic and regulatory PP2A subunits results in prolonged TNFα-
induced NF-κB activation. Using co-immunoprecipitation and in vitro phosphatase assays, 
distinct PP2A complexes including PP2Acβ/PP2R1A , PP2Acα/PP2R1B  and  
PP2Acα/PP2R1A/PP2R5C were detected to associate with and dephosphorylate IKKβ 
(on S181), RelA (on S536) and TRAF2 (on T117), respectively (Li et al., 2006b).  In T-
cells, through the regulatory subunit PP2R1A, PP2A interacts with Carma1 and removes 
the PKCθ-dependent phosphorylation of this protein on serine 645, thereby inhibiting the 
TCR-induced IKK activation (Eitelhuber et al., 2011). These results suggest that different 
combinations of PP2A holoenzymes may operate at different levels of the NF-κB 
pathway.  
Although dephosphorylation of IKKβ by PP2A has been reported by multiple 
research groups (Hong et al., 2007; Prajapati et al., 2004; Witt et al., 2009), some 
contradictory reports also exist. In a study by Sun et al., PP2A did not target IKKβ but 
rather dephosphorylated the upstream IKK-K, MEKK3. PP2A was shown to physically 
bind to phosphorylated MEKK3 and specifically dephosphorylate it on threonine516 and 
serine520 (Sun et al., 2010). Another study from the same group described the 
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magnesium-dependant phosphatases PPM1A and PPM1B, but not PP2A, as IKKβ 
phosphatases in the TNFα-induced NF-κB pathway (Sun et al., 2009b).  
Interestingly, PP2A is also implicated in positive regulation of the IKK activity 
(Kray et al., 2005). This is presumably mediated by reversing the inhibitory 
phosphorylation of NEMO and IKKβ following stimulus-dependant NF-κB activation 
(See 3.1.1.2). PP2A was detected in stable complexes with NEMO in resting conditions 
and the deletion of the putative PP2A-binding region on CC1 region of NEMO (amino 
acids 121-179) resulted in reduced IKKβ phosphorylation and activation in response to 
TNF-α (Kray et al., 2005). The discrepancies in the reported functions of PP2A and other 
IKK-regulating phosphatases may be explained by the distinct patterns of the 
phosphatase expression and/or substrate-specificity within different NF-κB pathways and 
cell types.   
PP1 is another phosphatase demonstrated to associate with and dephosphorylate 
IKKβ. The adaptor protein CUE domain-containing 2 (CUEDC2) mediates this 
interaction by recruiting GADD34, a regulatory subunit of PP1, to the IKK complex (Li 
et al., 2008a). Formation of the ternary complex of IKK/PP1/CUEDC2 was shown to 
retain IKK in an inactive, non-phosphorylated state but following TNFα stimulation, 
IKK was transiently dissociated from complex and bound to TRAF2, indicating that PP1 
is likely responsible for controlling basal levels of IKK activity..  
A recent siRNA screen conducted to identify NF-κB modulating phosphatases in 
T-cells pulled out PP4R1A as another negative regulator of IKK. PP4R1 which stably and 
specifically binds to the catalytic subunit PP4c was shown to associate with IKK complex 
subsequent to TCR-induced NF-κB activation and direct PP4c to dephosphorylate and 
deactivate IKK complex (Brechmann et al., 2012). Interestingly, PP4c has been linked to 
positive regulation of NF-κB based on the evidence that it can remove inhibitory 
phosphate groups from threonine435 of RelA (Yeh et al., 2004). Since PP4c subunit 
participates in a wide collection of PP4 holoenzymes, the associated regulatory subunits 
most likely determine the functional outcome of the phosphatase in NF-κB pathways 
(Chowdhury et al., 2008; Gingras et al., 2005; Lee et al., 2010). 
Wild-type p53-induced phosphatase1 (WIP1), which belongs to the magnesium 
dependent PP2C family of phosphatases, was found to directly interact with RelA and 
dephosphorylate it on serine536 in response to TNFα stimulation. WIP1 can also 
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dephosphorylate p38, which appears to be important for induction of a subset of NF-κB 
target genes such as IL-6, ICAM, and IRF1. Mice lacking WIP1 were reported to have 
hyperactivated immune responses based on the evidence that following LPS challenge, 
splenocytes of WIP1−/−  mice produced higher levels of κB-dependent inflammatory 
cytokines, compared with WIP1+/− animals (Chew et al., 2009). However, in contrast to 
these results, Choi et al., showed that both T- and B-cells exhibit compromised functions 
in WIP1-deficient mice (Choi et al., 2002).  
A few other phosphatases such as Shp-2, PP6c and PTPN21, have been associated 
with negative regulation of the NF-κB pathway (Li et al., 2006b; Stefansson and 
Brautigan, 2006; You et al., 2001). However, more work is needed to elucidate distinct 
roles of these and other NF-κB-regulating phosphatases, in tissue- and pathway-specific 
conditions. 
1.2.3 Ubiquitin-mediated control of IKK 
The ability to bind to ubiquitin chains, in free form or conjugated to other proteins, 
serves as a major mechanism in activating IKK. Ubiquitin-mediated control of IKK that 
in large depends on NEMO has been suggested to be involved in all possible IKK 
activation processes of oligomerisation, conformational change induction and recruiting 
IKK-Ks.  
1.2.3.1 The ubiquitin system 
Ubiquitin (Ub) is a highly conserved 76 amino acid protein that is expressed in all 
eukaryotic cells (Hershko and Ciechanover, 1998). The term ‘Ubiquitination’ or 
‘Ubiquitiylation’ refers to the covalent attachment of ubiquitin molecules to target 
proteins that is executed by a concerted action of three enzymes (Hoeller et al., 2006). 
First, the E1 ubiquitin-activating enzyme is loaded with ubiquitin through formation of a 
thio-ester bond between the C-terminal Glycine of the ubiquitin and the catalytic site 
Cysteine of E1. The activated ubiquitin is then discharged onto the active site of a 
ubiquitin-conjugating enzyme (E2), generating an E2-ubiquitin thiol-ester. Finally, an E3 
ubiquitin ligase transfers the ubiquitin molecule to the target protein by forming an 
isopeptide bond between C-terminal carboxyl group of the ubiquitin and the ε-amino 
group of a lysine residue on a target protein (Ciechanover et al., 1982; Hershko, 1983; 
Hershko et al., 1983). Interestingly, some proteins without lysine residues have been also 
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found to be ubiquitinated. In these cases, serine or threonine residues are likely to 
participate in conjugation to ubiquitin (Cadwell and Coscoy, 2005; Wang et al., 2007b). 
To date, two E1s and approximately 50 E2s have been identified in mammals. E3s 
constitute the largest and the most diverse group of ubiquitin editing enzymes with over 
600 members (Bhoj and Chen, 2009; Malynn and Ma, 2010). The E3 enzymes are 
classified into two families: the really interesting new gene (RING)-type and homologous 
to the E6-associated protein C terminus (HECT)-type E3 ligases (Bernassola et al., 2008; 
Petroski and Deshaies, 2005). The HECT-type ligases contain a conserved cysteine 
residue at the C-terminal part of the HECT motif that forms a thiol-ester bond with 
ubiquitin. HECT-domain bound ubiquitin can be transferred directly onto target protein 
(Pickart, 2001). Unlike HECT-type E3s, members of the RING-type family do not appear 
to form thiol-ester intermediates; instead they serve as scaffolds that bring the E2 and the 
target protein into close proximity. The RING finger domain contains a conserved 
pattern of cysteine and histidine residues whose folding allows coordination of two zinc 
cations (Deshaies and Joazeiro, 2009). 
Substrate proteins can be modified either by a single ubiquitin molecules 
(monoubiquitination) or ubiquitin polymers (polyubiquitination) (Haglund and Dikic, 
2005). Each type of modification leads to a distinct regulatory fate. Monoubiquitination 
has been shown to regulate receptor endocytosis, vesicle sorting, gene silencing and  
DNA repair events [reviewed in (Hicke, 2001)] . It has been also implicated in regulating 
enzymatic activity of IKKβ (Carter et al., 2005) and transcriptional activity of the viral 
oncoprotein HTLV-1 Tax (Gatza and Marriott, 2006; Gatza et al., 2007). Ubiquitin 
harbours seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) all of which can 
serve as ubiquitin acceptor sites, promoting formation of seven distinct polyubiquitin 
chains. In addition, ubiquitin linkages can be formed in a head-to-tail configuration 
through the N-terminal amino group, to produce so called ‘linear’ or ‘M1-linked’ ubiquitin 
chains (Komander, 2009). Depending on the linkage type, ubiquitin chains adopt distinct 
structural and functional characteristics (Pickart and Fushman, 2004). Based on the early 
studies on K48-linked ubiquitin chains, the ubiquitin system was thought to be merely in 
charge of proteasomal degradation, however the identification and study of other linkage 
types has revealed diverse biological roles of ubiquitin. All eight types of ubiquitin linkages 
have been detected in vivo and are suggested to regulate functions such as DNA repair 
(K63), protein interactions (K33), signalling pathway activation (K63, K27, K11, linear), 
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trafficking (K63) and the well-known proteasomal degradation (K48 , K11, K29) 
(Behrends and Harper, 2011). 
To recognise the signals encoded by ubiquitin moieties, cells have developed a 
series of modular motifs known as ubiquitin binding domains (UBD) that non-covalently 
bind to different forms of ubiquitin and transduce their signals into specific cellular 
pathways (Hicke et al., 2005). Using biochemical and bioinformatics approaches more 
than 150 types of UBDs have been identified to date. These domains are quite diverse in 
size (20-150 amino acids), structure and the functions of the UBD-containing proteins 
(Dikic et al., 2009). UBDs exist in E3s, deubiquitinases and binding adaptor proteins and 
contribute to their specificity. Most often, the binding affinity of the UBDs and ubiquitin 
are relatively low (about 10-500 µM) (Hicke et al., 2005). Nevertheless, specific mutations 
of UBDs, which disrupt ubiquitin binding, lead to impairment of protein function in vivo 
indicating the physiologic importance of these weak interactions (Ea et al., 2006; 
Kanayama et al., 2004; Wu et al., 2006a).  
Most UBDs show little discrimination between different linkages; although some 
prefer a certain type of polyubiquitin chains (Haglund and Dikic, 2005). For example, the 
NZF domain of TAB preferentially binds to K63-linked chains; this binding is essential 
for TAK1 activation (Kanayama et al., 2004; Komander et al., 2009). On the other hand, 
UBAN domain which is present in proteins such as NEMO, optineurin and A20-binding 
inhibitor of NF-κB (ABIN), shows high affinities towards linear polyubiquitin chains 
(Nagabhushana et al., 2011; Nanda et al., 2011; Rahighi et al., 2009). 
Ubiquitination processes are employed at multiple stages of both canonical and 
non-canonical NF-κB pathways. Indeed, cooperative functions of numerous ubiquitin 
editing enzymes, ubiquitin-binding proteins and different polyubiquitin chains appear to 
be essential for both negative and positive regulation of NF-κB pathway. 
1.2.3.2 Roles of the linear and K63-linked PolyUb chains in IKK activation 
Much of our understanding of how polyubiquitin chains activate IKK comes from 
studying TNF and IL-1 receptor induced NF-κB signalling. In TNF signalling, following 
the trimerisation of the receptor by TNF, adapter protein (TRADD) (Hsu et al., 1995) 
and RIP1 (Hsu et al., 1996a) are recruited the to the death domain of TNF receptor 
(TNFR). TRADD then mediates recruitment of E3 ubiquitin ligase TRAF2 (and 
TRAF5)(Ermolaeva et al., 2008; Tsao et al., 2000) which in turn provides a platform for 
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binding of two more E3s, cIAP1 and cIAP2 (Mace et al., 2010; Vince et al., 2009). Next, 
cIAPs synthesise K63-linked ubiquitin chains on RIP1 (and cIAPs themselves)(Bertrand 
et al., 2008; Varfolomeev et al., 2008) that serve as a scaffold to bring IKK and TAK1 to 
close proximity via binding to UBD of their respective subunits, NEMO and TAB2 (or 
TAB3). K63-linked ubiquitin chains are especially important for TAK1-TAB recruitment 
and activation since the regulatory subunit TAB2 binds specifically to this type of linkages 
and not any other (Kulathu et al., 2009). 
Similarly, K63 polyubiquitin chains play an essential role in IL-1 and Toll-like 
receptor (TLR) induced NF-κB activation. Upon IL1R/TLR ligation, adapter protein 
MyD88 is recruited to the receptor complex which further associates with IRAK1 and 
IRAK4 via another adaptor protein TRAF-interacting protein with a forkhead-associated 
domain (TIFA) (Chen, 2012). IRAK1 induces K63-linked autoubiquitination of TRAF6 
which depends on the E2 complex, Ubc13/Uev1A E2s (Deng et al., 2000; Lamothe et al., 
2007).  Activated TRAF6 also catalyses unanchored K63-ubiquitin chains which together 
with TRAF6-bound ubiquitin chains can recruit TAK1 and IKK, thereby facilitating 
phosphorylation of IKK by TAK1 (Wang et al., 2001).  
Initially, it was thought that UBAN domain of NEMO specifically binds to K63- 
ubiquitinated components. However, several groups later showed that UBAN is able to 
discriminate linear and K63-linked Ub chains and remarkably, has 100-fold higher affinity 
for the first of these (Lo et al., 2009; Rahighi et al., 2009). In keeping with these studies, 
later a 600 kDa E3 ubiquitin ligase complex, so called LUBAC (linear ubiquitin binding 
assembly complex) was reported to mediate linear chains synthesis (Kirisako et al., 2006) 
and activate NF-κB independent of K63 ubiquitination (Tokunaga et al., 2009). LUBAC is 
composed of three subunits: HOIL-1L (longer isoform of heme-oxidised IRP2 ubiquitin 
ligase-1), SHARPIN (SHANK-associated RH domain interacting protein) and the 
catalytic subunit HOIP (HOIL-1L interacting protein) (Gerlach et al., 2011; Ikeda et al., 
2011; Kirisako et al., 2006; Tokunaga et al., 2011). Generation of linear linkages is 
determined by LUBAC independent of the E2 involved. To date, LUBAC is the only 
known E3 capable of synthesising linear polyubiquitin chains (Iwai et al., 2014). 
An interesting recent study showed that most of linear ubiquitin chains formed in 
response to IL-1 are covalently conjugated to K63-linked ubiquitin oligomers. 
Furthermore, it was demonstrated that while HOIL-1L preferentially binds to linear 
chains, the catalytic subunit HOIP specifically interacts with K63-linked ubiquitin chains 
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as the preferred substrate (Emmerich et al., 2013). These findings indicate that the K63-
linked ubiquitin chains formed by upstream E3s like TRAFs and cIAPs might serve as a 
platform for recruitment of other regulators such as TAK1 and LUBAC. The linear 
ubiquitin oligomers synthesised by LUBAC can then associate strongly with NEMO and 
put IKK into a context where it can be phosphorylated by upstream kinases like TAK1, 
MEKK2 or MEKK3.  
Alternatively, ubiquitin binding of NEMO may promote IKK activation through 
oligomerisation or inducing conformational changes, leading to trans-
autophosphorylation of the kinase subunits. The latter hypothesis is supported by the 
notion that the recognition of linear di-ubiquitin by UBAN of NEMO induces 
straightening of the coiled-coil region (Rahighi et al., 2009). This conformational alteration 
may then extend towards N-terminus and provide enzymatic subunits with optimal 
positioning for trans-phosphorylation. Interestingly, mutating K270 of murine NEMO 
(equivalent to K277 of human NEMO) can overcome the requirement for ubiquitin 
binding and renders the IKK complex constitutively active in the absence of any 
inflammatory stimuli (Bloor et al., 2008). It is possible that the K270A NEMO mimics the 
conformational changes induced by the ubiquitin binding to WT NEMO. Collectively, 
these findings propose a model in which NEMO keeps the catalytic subunits in an 
inactive conformation and ubiquitin binding induces a conformational change that 
removes this inhibition to promote activation of IKKs by upstream kinases or trans-
autophosphorylation. 
Besides binding to ubiquitin chains, NEMO is also directly ubiquitinated by 
LUBAC at lysine residues K285 and K309 (Tokunaga et al., 2009). Reconstitution of 
NEMO-deficient cells with K285R/K309R double mutant NEMO did not rescue NF-κB 
activation in response or IL-1 or LUBAC overexpression. Since K309 is located within 
UBAN, its ubiquitination prevents binding to linear chains while in case of K285, 
theoretically conjugation and binding to linear polyubiquitin can coexist (Rahighi et al., 
2009). However, because of the parallel nature of binding, the UBAN motif of NEMO is 
unlikely to recognize linear chains in cis and binds to ubiquitin chains of another NEMO 
molecule which may lead to oligomerisation-induced activation of IKK (Iwai and 
Tokunaga, 2009).  
The significance of ubiquitin chain binding and conjugation in canonical NF-κB 
pathways manifests both in human genetics and mouse models. Mutations in the UBAN 
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domain of NEMO (D311N, D311G) with deleterious effects on ubiquitin binding ability 
of NEMO have been associated with EDA-ID (Döffinger et al., 2001; Hubeau et al., 
2011). In addition, cpdm (chronic proliferatory dermatitis in mice)  mice, which have 
mutations in the Sharpin gene (Sharpin cpdm/cpdm), develop inflammatory disorders, severe skin 
lesions and defects in secondary lymphoid organs (Gerlach et al., 2011; Seymour et al., 
2007). Cells derived from SHARPIN deficient as well as HOIL-1 knockout mice are 
sensitive to TNFα-induced apoptosis and have defects in NF-κB activation (Tokunaga et 
al., 2009, 2011).  
1.2.3.3 DUBs and the negative regulation of IKK 
Deubiquitinases (DUBs) are a group of cysteine- or metallo-proteases that reverse 
the activity of E3s by cleaving ubiquitin moieties form target proteins (Harhaj and Dixit, 
2011). Counter-regulation of ubiquitination processes by E3s and DUBs plays a crucial 
role in the regulation of NF-κB pathway and thereby, innate and adoptive immune 
responses (Sun, 2008). Approximately 100 DUBs are encoded in the human genome 
which are classified into five families based on the domain structure: ubiquitin-specific 
proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumour proteases 
(OTUs), Machado–Joseph disease protein domain proteases (MJDs) and the 
JAB1/PAB1/MPN domain-containing metallo-enzymes (JAMMs) (Nijman et al., 2005). 
Similar to E3s, DUBs display intrinsic specificity towards different types of linkages. 
Recognition and recruitment of various linkages is mainly mediated by UBD of the DUBs 
but in some cases depends on the ubiquitin-binding adapter proteins or selectivity of the 
catalytic core (Komander, 2010; Komander and Barford, 2008; Komander et al., 2008). 
Several DUBs have been implicated in the negative regulation of IKK including CYLD, 
A20, cellular zinc finger anti-NF-κB (Cezanne), ubiquitin-specific protease 11(USP11), 
USP15 and USP21. 
CYLD was originally identified as a tumour suppressor since the mutation of the 
encoding cylindromatosis gene predisposes individuals for familial cylindromatosis, a genetic 
disorder characterised by benign tumours of skin (Bignell et al., 2000). DUB activity of 
this enzyme is mediated by its C-terminal USP domain (Komander et al., 2008). siRNA-
mediated knockdown of CYLD enhances NF-κB activation in response to inflammatory 
stimuli while overexpression of CYLD, but not the mutants lacking DUB activity, reduces 
NF-κB activation (Kovalenko et al., 2003; Trompouki et al., 2003). Several studies show 
that CYLD deficient mice are highly susceptible to chemically induced colitis as well as 
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colon and skin tumours (Reiley et al., 2006; Zhang et al., 2006). CYLD also plays an 
important role in T-cell development and activation, by regulating lymphocyte-specific 
protein tyrosin kinase (LCK), an important kinase in T cell receptor signalling (Reiley et 
al., 2006). CYLD has been demonstrated to target multiple components of the NF-κB 
pathway for deubiquitination such as NEMO (Kovalenko et al., 2003; Saito et al., 2004), 
TRAF2 (Brummelkamp et al., 2003), TRAF6 (Jin et al., 2008), RIP1 (Wright et al., 2007), 
TAK1(Reiley et al., 2007), LCK (Reiley et al., 2006) and the NF-κB subunit co-activator 
Bcl-3 (Massoumi et al., 2006). CYLD directly interacts with NEMO and TRAF2; 
however, in certain pathways, it requires ubiquitin-binding adaptor proteins to ensure 
target specificity. Optineurin and p62 have been suggested to link CYLD with RIP1 and 
TRAF6, respectively (Jin et al., 2008; Nagabhushana et al., 2011). 
In vitro experiments indicate that CYLD preferentially removes linear and K63-
linked ubiquitin chains compared to K48-linked oligomers (Komander et al., 2009). 
Results from two other studies show that CYLD cleaves K48-linked ubiquitin chains of 
some targets both in vitro (Stokes et al., 2006) and in vivo (Reiley et al., 2006).  Taken 
together, it is possible that linkage-specificity of CYLD is determined in part by the target 
proteins.  
A20, also known as TNFα-induced protein 3 (TNFAIP3), is an NF-κB inducible 
protein that contains an N-terminal OTU domain and seven C-terminal zinc fingers 
(Krikos et al., 1992). A20-deficient mice die prematurely due to extensive inflammation of 
numerous organs including liver, kidneys, intestines and bone marrow (Lee et al., 2000). 
These mice are also highly susceptible to sublethal doses of LPS and TNF-α, indicating 
the substantial role of A20 in terminating inflammatory stimuli. In humans, 
polymorphisms of the A20 gene have been associated with multiple autoimmune diseases 
such as systemic lupus erythematous, Crohn’s disease, psoriasis and rheumatoid arthritis 
(Arsenescu et al., 2008; Fung et al., 2009; Musone et al., 2008; Nair et al., 2009; Thomson 
et al., 2007). Furthermore, inactivating mutations of A20 are found in a large number of 
human lymphomas (Honma et al., 2009; Kato et al., 2009).  
The unique feature of A20 is that it harbours both DUB and E3 activities which are 
mediated by the OTU and ZF4 domains, respectively (Wertz et al., 2004). In TNFR1 
signalling, A20 first removes the K63-linked ubiquitin chains from RIP1, it then 
synthesises K48-linked ubiquitin polymers on RIP1 which marks it for proteasomal 
degradation (Wertz et al., 2004). An alternative mechanism has been described for A20 
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inhibition of the IL-1R/TLR pathways, whereby it blocks TRAF6 ubiquitination by 
disrupting its association with the E2 enzymes, Ubc13 and UbcH5C (Shembade et al., 
2010). Similarly, A20 can inhibit TRAF2 and cIAPs by promoting disassembly of the 
E2:E3 complexes and triggering ubiquitin-mediated proteasomal degradation of the E2 
enzymes. These functions depend on both ZF4 and OTU catalytic domains (Bosanac et 
al., 2010; Shembade et al., 2010; Wertz et al., 2004). Interestingly, two groups showed that 
overexpression of A20 mutant (C103A) lacking DUB activity blocks NF-κB activation as 
efficiently as WT-A20 (Evans et al., 2004; Li et al., 2008b). Consistent with these findings, 
a recent study demonstrated a non-catalytic mechanism of IKK inhibition by A20 (Skaug 
et al., 2011). Skaug et al., showed that linear and K63-linked ubiquitin chains on NEMO 
recruit A20 (via its ZF4 and ZF7) to the IKK complex which then can inhibit 
phosphorylation of IKK by TAK1, without reducing RIP1 ubiquitination. A20 can also 
bind directly to the N-terminal region of NEMO; this weak interaction is further 
stabilised by the interactions between A20 and polyubiquitin chains (Skaug et al., 2011). It 
is possible that A20 binding to NEMO blocks the IKK oligomersiation or reverses the 
conformational changes required for the activation of IKK. Taken together, these results 
suggest that A20 might utilise distinct mechanisms to terminate IKK activation in 
different NF-κB pathways. 
Although A20 and CYLD have many overlapping targets, no obvious functional 
redundancy exists between these two DUBs. This is presumably due to the distinct 
temporal order of their function during inflammatory responses (Sun, 2008). While 
CYLD blocks spontaneous activation of NF-κB, A20 is induced upon NF-κB activation 
and is crucial to terminate the pathway in a negative feedback loop. Phosphorylation of 
CYLD by IKK has been shown to be required for TRAF2 ubiquitination and activation 
of NF-κB and JNK pathways (Reiley et al., 2005). Therefore, phosphorylation-dependant 
inactivation of CYLD might provide a window for NF-κB activation before signal-
induced termination by A20. Linkage type specificity is another key difference between 
CYLD and A20. In vitro studies suggest that A20 preferentially cleaves K48-linked 
polyubiquitin chains (Komander and Barford, 2008; Lin et al., 2008) while CYLD 
hydrolyses both linear and K63-linked oligomers (Komander et al., 2008, 2009). In cells, 
A20 might depend on ubiquitin-binding protein adaptors such as TAX1BP1 and the 
ABIN-1 to ensure specificity (Mauro et al., 2006; Shembade et al., 2007; De Valck et al., 
1999). 
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In addition to CYLD and A20, other DUBs have been also described to play a role 
in negative regulation of the NF-κB pathway [reviewed in (Sun, 2008)]. For instance, 
Cezanne inhibits TNFα-induced IKK activation by promoting deubiquitination of the 
TNFR- associated RIP1. Similar to A20, Cezanne is rapidly induced in response to TNF-
α, although unlike A20, its DUB activity is essential for mediating the inhibitory functions 
(Enesa et al., 2008; Evans et al., 2003).  Recently, Cezanne was reported to preferentially 
hydrolyse K11-linked ubiquitin oligomers (Bremm et al., 2010); how this function of 
Cezanne might regulate the NF-κB pathway still remains unknown. USP21 is another 
DUB which inhibits TNFα-induced IKK activity by also removing polyubiquitin chains 
from RIP1 (Xu et al., 2010). Clearly, IKK regulating DUBs share many overlapping 
targets; however the linkage type-specificity and the distinct temporal order of activity 
might account for their specific functions. 
 
1.3 FLICE-Like Inhibitory Proteins 
The first members of the FLICE-like inhibitory protein (FLIP) family were 
identified as viral genome products (vFLIPs), following a bioinformatic search conducted 
to recognise death effector domain (DED)-containing proteins that function as apoptosis 
regulators (Thome et al., 1997). Soon after, a consensus sequence from the viral FLIPs 
was used to screen human expressed sequence tags and several human homologues were 
identified, collectively named as cellular FLIPs (cFLIPs)(Irmler et al., 1997). All members 
of the FLIP family harbour two tandem DEDs in their N-terminal region, similar to that 
found in caspase-8 and caspase-10 (Fig 1.3). As suggested by structural properties of 
FLIPs, the initial bioactivity reported was an ability to interact with FADD (Fas-
associated protein with death domain) and inhibit apoptosis induced by multiple death 
receptors (Bertin et al., 1997; Hu et al., 1997a; Irmler et al., 1997; Thome et al., 1997). 
However, since their discovery, many other biological roles have been described for 
different FLIPs. In the following sections, I will review the structure and multi-faceted 
regulatory functions of the cellular and viral FLIPs with a particular emphasis on KSHV 
vFLIP. 
1.3.1 Viral FLIPs 
Viral FLIPs are present in several γ-herpesviruses and the human molluscipoxvirus 
(Figuire 1.3A). The vFLIP-encoding γ-herpesviruses consist of bovine herpesvirus-4 
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(BHV-4), herpesvirus samiri (HSV), equine herpes virus-2 (EHV-2), rhesus monkey 
rhadinovirus (RRV) and the Kaposi’s sarcoma-associated herpesvirus (KSHV). The 
genome of molluscum contagiosum virus (MCV) encodes two distinct vFLIPs: MC159 
and the closely related MC160 (Searles et al., 1999; Thome et al., 1997). Unlike cFLIPs, 
the amino terminal DEDs of different vFLIPs are not identical and contain variable 
amino acid sequences (Figure 1.4). Furthermore, none of the vFLIPs contain a caspase-8-
like domain; instead, the serial DEDs are extended by C-terminal tails of variable lengths. 
During the early stages of a viral infection, death receptor-induced cell death can 
effectively demolish the infected cells. Not surprisingly, viruses have evolved various 
strategies (e.g., expressing vFLIPs) to resist cell death and thereby, facilitate the viral 
propagation and persistence. The ability of vFLIPs to effectively inhibit apoptotic 
pathways not only results in persistent infection, but also transforms the host cells 
(Thome et al., 1997). KSHV vFLIP is a notable example of a viral oncoprotein that plays 
indispensable roles in tumourigensis of the associated virus. 
1.3.1.1 Kaposi’s sarcoma-associated virus 
KSHV (also known as human herpesvirus-8 (HHV-8)) is the causative agent of 
Kaposi’s sarcoma (KS), a neoplasm of lymphatic endothelial cells. KS is the most 
common type of malignancy in HIV patients, although it occurs in other 
immunosuppressive conditions like organ transplant. KSHV is also associated with two B-
cell lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease (MCD) (Mesri et al., 2010). Similar to the life cycle of other 
herpesviruses, KSHV displays both lytic and latent modes of infection. Expression of lytic 
genes (such as vIL-6, vIRFs, vCCLs and vGPCR) have been documented to contribute to 
KSHV oncogenicity by initiating the host signalling cascades involved in secretion of cell 
growth factors. However, KSHV genes pivotal for the viral genomic persistence and 
cellular transformation are mainly found among those expressed during latent infection 
(Wen and Damania, 2010). Indeed, KSHV infection is predominantly latent in the 
associated malignancies. Three KSHV genes are abundantly expressed in the latent mode 
of infection: vCyclin, latency-associated nuclear antigen (LANA) and vFLIP. These genes 
are encoded in one tricistronic transcript driven by a single promoter and collectively 
provide cells with proangiogenic and inflammatory signals, anti-apoptotic abilities as well 
as enhanced proliferative and growth signals [reviewed in (Cesarman, 2014)]. 
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1.3.1.2 KSHV vFLIP 
KSHV vFLIP (also known as K13) is a 188 amino acid protein encoded by ORF71 
and shares 33% sequence homology with the cellular homologues. It is a potent and 
specific activator of the NF-κB pathway (Chaudhary et al., 1999; Matta and Chaudhary, 
2004) but also interferes with several other pathways such as autophagy, MAPK and death 
inducing signalling cascades (See 1.3.3-1.3.6) . Expression of vFLIP induces transcription 
of up to 200 NF-κB target genes, most notably cFLIP which can further enhance evasion 
of death receptor induced apoptosis (Punj et al., 2009). Our group has previously shown 
that NF-κB-mediated secretion of growth factors enables vFLIP to protect cells from 
detachment-induced apoptosis, or anoikis (Efklidou et al., 2008). 
Accumulating evidence support a role for vFLIP in KSHV-associated 
tumourigenesis through constitutive activation of NF-κB (Ballon et al., 2011; Baud and 
Karin, 2009; Chugh et al., 2005; Sun et al., 2003). A recent study on transgenic vFLIP 
knock-in mice indicated that expression of vFLIP in B cells is sufficient to induce B-cell 
malignancies in vivo (Ballon et al., 2011) . Furthermore, vFLIP accelerated the process of 
lymphomagenesis in Myc-transgenic mice which overexpress Myc in lymphoid organs 
(Ahmad et al., 2010). In agreement with these findings, pharmacologic or genetic 
inhibition of vFLIP-induced NF-κB activation leads to apoptosis in PEL cells (Godfrey et 
al., 2005; Guasparri et al., 2004; Keller et al., 2000). Besides anti-apoptotic effects, vFLIP-
mediated NF-κB activation suppresses the lytic reactivation of the KSHV and thereby, 
further contributes to maintenance of latent infection (Ye et al., 2008). 
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Figure 1.3. Viral and cellular FLIP proteins. A) Viral FLIPs are encoded by several γ-
herpesviruses and the human molluscipoxvirus (MCV). Unlike cFLIPs which share a 
common N-terminal sequence of 202aa, tandem DEDs of different vFLIPs are not 
identical and contain variable amino acid sequences. B) From 13 splice variants of the 
cFLAR gene, only three are translated to protein which consist of a long isoform (FLIPL)  
and two short variants (cFLIPS  and cFLIPR). cFLIPL (55kD) is structurally similar to 
procaspase-8 (C) but its C-terminal caspase domain is enzymatically inactive due to lack of  
a crucial catalytic cysteine. The N-terminal DEDs of cFLIPS, but not cFLIPL or vFLIPs, 
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are followed by a unique 19 amino acid sequence which plays an important role in 
ubiquitination of cFLIPS (at the indicated K192 and K195 residues) and its subsequent 
degradation. Upon interaction with caspase-8, cFLIPL can further be cleaved at positions 
D196 or D376 to produce p22- and p43-FLIP fragments, respectively. p22-FLIP is also a 
cleavage product of FLIPS/R. C) Domain organisation of procaspase-8 
 
 
Figure 1.4. Amino acid sequence alignment of the cellular and viral FLIPs. Amino 
acid sequences of the shown FLIP proteins were retrieved from NCBI protein database 
(http://www.ncbi.nlm.nih.gov/protein) and aligned using PRALINE multiple sequence 
alignment software. Residues are colour-coded for the rank of conservation. The 
accession numbers for the protein sequences used for alignment were: cFLIP 
BAB32551.1, KSHV vFLIP AAD46498.1, RRV vFLIP AAF60069.1, HSV vFLIP 
CAC84369.1, EHV vFLIP NP_042671.1, MCV vFLIP 159 NP_044110.1, MCV 
vFLIP160 NP_044111.1. 
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1.3.2 Cellular FLIPs 
In 1997, cellular FLIP proteins were independently identified by several groups and 
therefore, are recognised by other names such as MRIT (Han et al., 1997), Usurpin 
(Rasper et al., 1998), iFLICE (Hu et al., 1997b), FLAME1 (Srinivasula et al., 1997), 
CLARP (Inohara et al., 1997), CASH (Goltsev et al., 1997) and Casper (Shu et al., 1997). 
1.3.2.1 cFLIP isoforms and cleavage products 
Cellular FLIP is encoded by the CFLAR gene (CASP8 and FADD-like apoptosis 
regulator), located on the human chromosome 2q33-34, close to caspase-8 and caspase-10 
genes. Proximity of these genes suggests that cFLIP may have emerged by duplication of 
procaspase-8/10 genes (Han et al., 1997; Inohara et al., 1997; Rasper et al., 1998; 
Srinivasula et al., 1997). To date, up to 13 splice variants of  human cFLIP have been 
identified at mRNA level, three of which are expressed as proteins: Long isoform 
(cFLIPL: 55kDa), short isoform (cFLIPS: 26kDa) and cFLIP Raji (cFLIPR, 24kDa) first 
isolated from human Burkitt’s lymphoma B-cell line, Raji (Golks et al., 2005; Irmler et al., 
1997) (Figure 1.3B). Unlike humans, mice do not express FLIPS and contain only two 
isoforms of FLIPL and FLIPR (Ueffing et al., 2008). 
The CFLAR gene contains 14 exons and the initially transcribed precursor mRNA 
undergoes alternative splicing to generate transcripts for different cFLIP isoforms. 
Inclusion of exon7 which harbours a stop codon, results in translation of cFLIPS, while 
skipping this exon generates FLIPL-encoding mRNA. Translation of a small part of 
intron6 generates the shortest isoform, FLIPR (Djerbi et al., 2001). Recently, a single 
nucleotide polymorphism (SNP) of the 3’ splice consensus of intron6 was identified 
controlling expression of FLIPS or FLIPR. Interestingly, the splice-dead SNP which causes 
the expression of FLIPR is present at higher frequencies in transformed B cell lines and is 
also associated with an increased risk of follicular lymphoma in humans (Ueffing et al., 
2009).  
All cFLIP isoforms share an identical N-terminal sequence of 202 amino acids, 
which includes two DEDs, but have different C-terminal ends. The overall structure of 
cFLIPS is similar to vFLIPs but it contains a unique 19 amino acid C-terminal tail that is 
responsible for its ubiquitination and proteasomal degradation (Poukkula et al., 2005). In 
cFLIPL, the tandem DEDs are followed by a caspase-like domain (CLD; composed of 
p20 and p12) that is similar to the catalytic domain of procaspase-8/10 (Figure 1.3C). 
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However, this domain is catalytically inactive due to substitution of several amino acids 
essential for the caspase activity, including a cysteine in the Gln-Ala-Cys-X-Gly motif and 
a histidine in the His-Gly motif (Budd et al., 2006).  
In addition to the natural isoforms, two N-terminal cleavage products of cellular 
FLIPs have been detected in cells. Caspase-mediated cleavage of the cFLIP at positions 
D376 (on FLIPL) and D196 (on all isoforms), generates the proteolytic fragments p43-
FLIP (43kDa) and p22-FLIP (22kDa), respectively (Figure 1.3B) (Golks et al., 2006; 
Kataoka and Tschopp, 2004; Scaffidi et al., 1999).  
1.3.2.2 Transcriptional and translational control of cFLIPs 
Expression of cFLIP proteins is tightly regulated in normal cells.  This is achieved 
through numerous regulatory mechanisms at the transcriptional, translational and post-
translational levels (Safa et al., 2008). Several transcription factors are known to modulate 
the transcriptional activity of the CFLAR gene. NF-κB, CREB, FoxO, p63, p53, EGR1, 
NFAT, hnRNP K, AR and sp1 are among those which induce cFLIP transcription, while 
c-myc, Foxo3a, c-Fos, IRF5 and sp3 repress it (Shirley and Micheau, 2010). NF-κB 
activation is one the main inducers of cFLIPs; these proteins, in turn, elicit the NF-κB 
pathway, generating a positive feedback loop on stimulated cells (Micheau et al., 2001).  
Little is known about isoform-specific regulation of cFLIP transcription, although 
some scattered reports exist. For instance, the AP-1 complex has been shown to repress 
cFLIPL expression (Li et al., 2007), while E21F, a transcription factor involved in control 
of cell cycle, inhibits the expression of cFLIPS (Salon et al., 2006). Furthermore, an siRNA 
screening aimed at characterising the targets of p63 suggested that this protein upregulates 
cFLIPR transcription, while suppressing that of cFLIPS without altering the transcription 
levels of cFLIPL (Borrelli et al., 2009). 
The short isoform is shown to be regulated at translational level as well. Panner et 
al., demonstrated that in glioblastoma multiforme (GBM) cells, activation of the 
Akt/mTOR/S6K1 pathway results in polyribosomal accumulation of cFLIPS mRNA and 
therefore, increased expression of FLIPS. Inhibition of mTOR or its target S6K1 
supressed translation of cFLIPS, but not cFLIPL, and led to TRAIL-sensitisation of GBM 
cells (Panner et al., 2005). An mTOR-independent pathway has been also described to 
regulate cFLIPS translation. In this pathway, activation of Ral and its effector protein 
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RalBP1, inhibits cdc42-mediated activation of S6K1 and thereby, down-regulates the 
expression of FLIPS (Panner et al., 2006). 
1.3.2.3 Post-translational regulation of cFLIPs 
Cellular FLIPs exhibit a relatively short half-life. This has been indicated by rapid 
depletion of these proteins following treatment of cells with the inhibitor of protein 
synthesis cycloheximide (Kreuz and Siegmund, 2001; Micheau et al., 2001). Vice versa, 
cFLIPs are found to accumulate quickly in response to proteasome inhibitors such as 
MG-132, lactacystin, epoxomicin and bortezomib/Velcade® (Chang et al., 2006; 
Fukazawa et al., 2001; Kim et al., 2002; Perez et al., 2003). Post-translational 
modifications, most notably ubiquitination and phosphorylation, play crucial roles in 
regulating the turnover rate of different cFLIPs. 
cFLIP proteins are predominantly degraded via the ubiquitin-proteasome 
degradation system. cFLIPS is particularly more prone to ubiquitination and displays a 
considerably shorter half-life compared with cFLIPL (Poukkula et al., 2005; Schmitz et al., 
2004). This is largely due to the unique 19 amino acid C-terminal sequence of cFLIPS that 
facilitates its ubiquitination at lysine residues 192 and 195, marking this protein for 
proteasomal degradation (Poukkula et al., 2005); the stability of cFLIPR is similar to 
cFLIPS (Golks et al., 2005; Ueffing et al., 2008). Both proteins have been shown to be 
targeted by the E3 ubiquitin ligase c-Cbl (Kundu et al., 2009; Zhao et al., 2013), although 
the E3 responsible for the ubiquitination of K192/195 residues remains to be identified. 
TNFα-mediated JNK1 (Jun N-terminal Kinase1) activation can enhance cFLIPL 
degradation by inducing the E3 ubiquitin ligase Itch (Chang et al., 2006). The caspase-like 
domain of FLIPL is necessary for interaction with Itch, highlighting once more the 
importance of C-terminal sequences of cFLIP isoforms in determining their stability.  
Phosphorylation events are also central to regulation of cFLIP levels. PKC 
phosphorylates cFLIP proteins at serine193 (Kaunisto et al., 2009). This results in 
decreased ubiquitination of all isoforms, although it only prolongs the half-lives of cFLIPS 
and cFLIPR. Since site-specific mutation of S193 does not affect recruitment of different 
isoforms to the DISC (death inducing signalling complex), PKC-mediated cFLIP 
phosphorylation may regulate apoptotic pathways only via rapid changes in cFLIPS levels 
(Kaunisto et al., 2009). This seems to be different from calcium/calmodulin-dependent 
kinaseII (CaMKII)-mediated phosphorylations of cFLIP proteins (at a residue other than 
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S193) which block DISC recruitment of both short and long isoforms (Yang et al., 2003). 
Recently, serine273 of cFLIPL was shown to be targeted by PI3K/Akt. Phosphorylation 
of cFLIPL-S273 following TNFα-induced macrophage activation resulted in 
ubiquitination and proteasomal degradation of cFLIPL (Shi et al., 2009). This cFLIPL 
ubiquitinaton, however, was not dependent on JNK/Itch. Phosphorylation of cFLIPS is 
found to be crucial for mycobacterium tuberculosis-induced cell death in murine 
macrophages. M.tb-mediated TNF activation induces p38 and Abl, which in turn 
phosphorylate cFLIPS on Ser4 and Tyr211, respectively. This facilitates recognition of 
FLIPS by the E3 ubiquitin ligase c-Cbl, leading to its degradation and initiation of 
apoptosis (Kundu et al., 2009). Taken together, these studies elucidate how the cross-talk 
between phosphorylation and ubiquitination events results in quick isoform-specific 
changes in cFLIP levels. This provides cells with a crucial ability to generate rapid 
responses to cellular distress. 
1.3.3 Regulation of cell death pathways by FLIPs 
Controlling the delicate balance between cell death and survival pathways is 
essential for development and homeostasis of multi-cellular organisms. To achieve this, 
cells have evolved numerous regulatory proteins such as FLIP, which can promote or 
inhibit demolition of cells in a certain set of conditions. Cell death can occur through 
several distinct routes (e.g, apoptosis, necrosis and autophagy-related cell death) and 
remarkably, FLIP proteins have been documented to be involved in regulation of all these 
types of cell demise. 
1.3.3.1 Extrinsic and intrinsic apoptotic pathways 
Apoptosis is a programmed mode of cell death that enables multicellular organisms 
to dispose of unwanted cells with minimum damage to neighbouring cells (Taylor et al., 
2008). Precise regulation of apoptosis is central to the development, differentiation and 
homeostasis of tissues. Apoptotic signalling pathways are classified into two distinct types: 
intrinsic pathways induced by factors such as DNA damage, UV or γ-radiation, 
chemotherapeutic drugs and cytokine deprivation (Figure 1.5, left), and extrinsic pathways 
initiated by death receptors (DR) (Krammer et al., 2007; Lavrik et al., 2005) (Figure 1.5, 
right).  
Proteins of the DR family belong to the TNFR superfamily. To date, eight 
members of this family have been described: TNFR1 (also known as DR1, p55, p60 and 
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CD120a), CD95 (also known as DR2, Fas and APO-1), DR3 (also known as APO-3, 
LARD, TRAMP and WSL1), TNF-related apoptosis inducing ligand receptor1 
(TRAILR1; also known as DR4 and APO-2), TRAILR2 (also known as DR5, KILLER 
and TRICK2), DR6, ectodysplasin A receptor (EDAR) and nerve growth factor receptor 
(NGFR) (Lavrik et al., 2005). DR family are characterised by the presence of a C-terminal 
sequence of 80-100 amino acids, called the death domain (DD) that is responsible for 
transducing the apoptotic signals. Indeed, homotypic DD interactions connect DRs to 
adaptor proteins FADD and TRADD (Guicciardi and Gores, 2009). 
Upon ligation of CD95, TRAILR1 or TRAILR2, a multiprotein complex is formed 
near the plasma membrane known as death-inducing signalling complex (DISC). This 
complex is composed of DR, FADD, cFLIP and precursors of two initiator caspases: 
procaspase-8 and procaspase-10. While FADD and DR interact via DDs, cFLIP or 
procaspase-8/10 are recruited to FADD via the DEDs of each protein. Activation of the 
initiator caspases following DISC formation, results in the induction of effector caspases 
(caspase-3, -6 and -7), which in turn proteolyse a wide array of substrates leading to 
dismantling and packaging of cells into apoptotic bodies (Figure 1.5, right). 
In the intrinsic pathway, also known as the mitochondrial pathway, death signals are 
initiated by mitochondrial membrane permeabilisation (MMP) (Martinou and Green, 
2001). Anti-apoptotic members of the Bcl-2 family (such as Bcl-2, Bcl-XL, BCL-W and 
MCL1), preserve the integrity of outer mitochondrial membrane by inhibiting the 
oligomerisation of proapoptotic Bcl-2 members, BAX and BAK. Upon arrival of a death 
signal, antiapoptotic Bcl-2 proteins are inhibited by Bcl-2 homology3(BH3)-only proteins 
(eg., BID, BAD, BIM and BMF) (Kuwana et al., 2005; Letai et al., 2002). This leads to 
formation of BAX-BAK oligomers within the outer membrane that allows for efflux of 
intermembrane space proteins such as cytochrome C, SMAC/DIABLO and AIF 
(apoptosis-inducing factor). Once released form mitochondria, cytochrome C mediates 
assembly of a caspase activation complex known as the apoptosome. This complex 
consists of about seven molecules of apoptotic protease-activating protein-1 (APAF1) and 
the same number of initiator procapspase-9. Similar to events followed by DISC 
assembly, activation of caspase-9 within the apoptosome induces a cascade of effector 
caspases that culminates in cell death (Taylor et al., 2008) (Figure 1.5, left). In some 
conditions, extrinsic death signals can activate the intrinsic pathway through caspase-8 
mediated cleavage of the BH3-only family member, BID (BH-3 interacting domain death 
agonist). Truncated BID (tBID) can then promote release of intermembrane space 
proteins resulting in apoptosome formation and cellular demolition (Korsmeyer et al., 
2000). 
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Figure 1.5. Extrinsic and intrinsic cell death pathways. Extrinsic apoptotic pathway 
(right) commences by engagement of death receptors (DRs) with their cognate ligands 
which then leads to recruitment of adaptor proteins (e.g, FADD and TRADD) and 
formation of DISC, consisting of DR, FADD, procaspase-8/10 and cFLIP isoforms. 
Autoprocessing and activation of the initiator procaspase-8/10, promotes the activation 
of downstream caspases, such as caspase-3, 6 and 7, for the execution of apoptosis. The 
extrinsic pathway is mainly under the control of cFLIP family which fine-tune the activity 
of initiator caspases at the DISC. In the intrinsic pathway (left) various stimuli such as UV 
or chemotherapeutic agents which provoke cell stress and damage activate one or more 
members of the BH3-only proteins. This in turn induces the assembly of BAK-BAX 
oligomers within mitochondrial outer membranes, leading to release of intermembrane 
proteins such as cytochrome C which promotes the assembly of apoptosome. Activation 
of caspase-9 within this complex then propagates a cascade of caspase activation, similar 
to final steps of the extrinsic pathway. Caspase-8-mediated cleavage of BID to generate 
tBID can link the extrinsic pathway to the mitochondrial cell death cascade; cFLIP can 
also inhibit this step. 
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Deregulation of cell death pathways resulting from insufficient or excessive 
apoptosis form the basis of multiple human disease such as neurodegenerative disorders, 
autoimmunity and cancer (Green and Evan, 2002; Vaux and Flavell, 2000). Therefore, 
apoptotic pathways are tightly controlled at multiple levels. For instance, members of the 
cIAP family, including NIAP, XIAP and cIAP1/2 have been shown to directly inhibit 
caspase-3,-7 and -9 (Liston et al., 1996). As mentioned above, proteins of the Bcl-2 family 
modulate the mitochondrial death programs. At the DISC level, apoptotic signals are 
regulated by FLIP proteins that facilitate or inhibit the activation of casapase-8. 
Nonetheless, DISC formation does not always result in cell death but it can be also 
directed to switch on several survival and proliferative pathways like NF-κB or MAPK. 
Remarkably, a collective body of research shows that FLIPs also play crucial roles in 
regulation of the DR-induced non-apoptotic pathways (Oztürk et al., 2012).  
1.3.3.2 Roles of FLIPs in apoptosis 
Procaspase-8 activation, which is pivotal for DR-induced apoptosis, occurs through 
an “induced proximity” mechanism where DR-mediated homo-dimerisation of 
procaspase-8 leads to its self-cleavage and release of fully active catalytic subunits (p10 
and p18) (Chang et al., 2003). Similar to procaspase-8, FLIPs are recruited to DISC-
associated FADD via homotypic DED interactions. Hence, the anti-apoptotic function of 
FLIP proteins relies on their ability to restrain FADD-mediated homo-dimerisation and 
activation of procaspase-8 molecules (Krueger et al., 2001b).  
Although viral FLIPs, cFLIPR and cFLIPS have been well-established as potent 
inhibitors of procaspase-8 activation (Golks et al., 2005; Krueger et al., 2001a; Thome et 
al., 1997), function of cFLIPL has been inconsistently reported to be either pro-apoptotic 
(Goltsev et al., 1997; Han et al., 1997; Inohara et al., 1997; Shu et al., 1997) or anti-
apoptotic (Irmler et al., 1997; Rasper et al., 1998; Srinivasula et al., 1997). The pro-
apoptotic role of cFLIPL is supported by the phenotype of cFLIP null mice which 
resembles that of mice lacking caspase-8 or FADD. These mice die at embryonic day 10.5 
with impaired heart, vascular and haematopoietic development, suggesting a function for 
cFLIPL that is similar to FADD or caspase-8 (Yeh et al., 2000). Furthermore, expression 
of cFLIPL at physiological levels is suggested to mediate apoptosis by formation of 
catalytically active cFLIPL/caspase-8 heterodimers (Chang et al., 2002; Micheau et al., 
2002). Nevertheless, the pro-apoptotic role of cFLIPL disagrees with the observation that 
cFLIPL-specific knockdown cells or MEFs lacking cFLIP are highly susceptible to DR-
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induced cell death compared with WT cells (Sharp et al., 2005; Yeh et al., 2000). In 
addition, ectopic expression of cFLIPL at high levels is found to inhibit procaspase-8 
activation via competing for FADD binding (Scaffidi et al., 1999).  
Despite these contradictory reports, several studies have now elucidated that 
depending on its expression levels cFLIPL can either promote or inhibit apoptosis (Chang 
et al., 2002; Fricker et al., 2010; Neumann et al., 2010). A recent study by Fricker et al., 
analysed the relationship between amounts of cFLIPL and the regulation of CD95-
induced cell death, using mathematical modelling combined with quantitative western 
blotting. The authors demonstrated that cFLIPL blocks apoptosis when highly 
overexpressed, whereas its moderate expression can promote cell death when 
accompanied with strong stimulation of CD95 or in the presence of high levels of 
cFLIPS/R (Fricker et al., 2010). Therefore, the cFLIPL role at the DISC is not only dose-
dependent but also may rely on other factors such as signal strength and the levels of 
other cFLIP isoforms.   
Biochemical assays as well as crystal structure studies on vFLIP MC159 propose 
that viral and cellular FLIPs may use different mechanisms to inhibit caspase-8 activation. 
The homotypic interactions between FADD-DED and procaspase-8-DED2 or cFLIP-
DED2 are mediated through a highly conserved hydrophobic patch (Berglund et al., 2000; 
Carrington et al., 2006; Eberstadt et al., 1998). In pull-down experiments, cFLIP competes 
away procaspase-8 in binding to FADD. In contrast, MC159 cannot compete procaspase-
8 away and binds to FADD-DED through an extensive area outside the hydrophobic 
patch interface (Yang et al., 2005). Therefore, MC159 (and perhaps other vFLIPs) may 
disrupt DISC assembly by preventing FADD-DED self-association rather than inhibiting 
procapase-8 binding (Yu and Shi, 2008). Overexpression of isolated FADD-DED or 
tandem DEDs of procaspase-8 results in self-assembly to produce long cytoplasmic 
filaments (also known as death effector filaments) which can induce apoptosis 
independent of death receptors (Siegel et al., 1998). Unlike these proapoptotic DEDs, 
which are found highly aggregated in vitro, isolated tandem DEDs from MC159 or EHV-2 
vFLIP E8 do not form filaments in cell culture and appear as monomers in vitro (Li et al., 
2006a; Yang et al., 2005). Indeed, these viral DEDs can effectively block self-assembly of 
DEDs from FADD or procaspase-8 to form death filaments (Siegel et al., 1998). Whether 
other viral FLIPs use the same DISC-inhibition strategy still remains unanswered. 
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1.3.3.3 Roles of FLIPs in necroptosis 
Regulated necrosis, referred to as necroptosis, is an alternative form of cell death 
that occurs when caspase-8 activity is inhibited and it depends on kinase activity of RIP1 
and RIP3 (Cho et al., 2009; He et al., 2009; Zhang et al., 2009a). The embryonic lethality 
observed in FADD −/− and CASP-8−/− mice can be rescued by additional deletion of the 
kinases RIP1 or RIP3, indicating that FADD and caspase-8 inhibit the RIP1/3-mediated 
cell death during embryonic development (Kaiser et al., 2011; Oberst et al., 2011; Zhang 
et al., 2011). 
Although necroptosis has evolved as an immune defence mechanism against 
intracellular infections, it has been also implicated in causation of several pathologies such 
as ischemia–reperfusion injury, neurological and myocardial disease (Linkermann and 
Green, 2014). Necroptotic signalling cascades can be initiated by stimulation of DRs, 
TLRs, genotoxic drugs and some viral and bacterial pathogens (e.g. human simplex virus-
type1 and vaccinia virus) (Vanlangenakker et al., 2012). Similar to their role in apoptosis, 
cFLIP proteins can regulate necroptosis in an isoform-specific manner. 
Evidence for modulation of necroptosis by FLIP proteins (and a connection 
between apoptosis and necroptosis) comes from the detection of a cytoplasmic complex, 
termed the ripoptosome, induced by treatments of human tumour cells that deplete or 
inhibit cIAP proteins (Feoktistova et al., 2011; Tenev et al., 2011a). This depletion leads to 
the formation of a RIP1/FADD/procaspase-8 complex. cIAPs inhibit formation of this 
complex by ubiquitinating RIP1 that leads to ubiquitin-mediated recruitment of several 
kinases required for  NF-κB activation (Bertrand et al., 2008; Varfolomeev et al., 2008). 
CYLD-mediated deubiquitination of RIP1, on the other hand, enables the kinase activity 
of RIP1 and necrosome assembly (Wang et al., 2008). In the absence of FLIP proteins, 
procaspase-8 molecules homodimerise in ripoptosome, promoting cell death by 
apoptosis. Recruitment of cFLIPL to this complex leads to partial caspase-8 activation, not 
enough to induce apoptosis, but sufficient to cleave RIP kinases and disassemble the 
ripoptosome, resulting in cell survival (Boatright et al., 2004; Oberst et al., 2011; Pop et 
al., 2011). cFLIPS, on the other hand, blocks caspase-8 activation and facilitates cell death 
through necroptosis (Feoktistova et al., 2011) (Figure 1.6). Similarly, vFLIP MC159 shifts 
the outcome of ripoptosome toward necroptosis (Feoktistova et al., 2012). Roles of other 
viral FLIPs, however, have yet to be examined. 
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Figure 1.6. FLIP proteins regulate the activity of the ripoptosome complex. Under 
baseline conditions, a small proportion of RIP1 is persistently modified to active 
conformation. This modified RIP1, also called open conformation, is targeted for Ub-
mediated degradation by cIAPs. Upon depletion of cIAPs by genotoxic stress, 
accumulation of modified RIP1 promotes formation of a ripoptosome signalling complex 
which consists of RIP1, FADD, caspase-8/10 and cFLIP isoforms. Different 
compositions of the caspase-8 and cFLIP isoforms bring about different levels of 
ripoptosome-associated caspase-8 activity and therefore, lead to different cell death 
responses.  Procaspase-8 dimerisation within the complex forms active caspase-8 and 
results in cell death via apoptosis. However, cFLIPL within the ripoptosome decreases the 
caspase-8 activity to levels which are not sufficient for its apoptotic function but still can 
inactivate the modified RIP1 and therefore, cause ripoptosme disassembly. In the 
presence of cFLIPS, procaspase-8 remains non-functional and so, active RIP1 
accumulation which is followed by the recruitment of RIP3 brings about cell death via 
necroptosis [Reproduced from (Feoktistova et al., 2011) with a permission from the 
author].  
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1.3.4 Regulation of autophagy pathways by FLIPs 
Autophagy is a homeostatic process in which cytosolic materials such as proteins, 
organelles and pathogens are engulfed into double-membraned vesicles, termed the 
autophagosome, and then delivered to lysosome for degradation. Depending on the 
cellular conditions, the processed constituents can then be disposed of or recycled if 
needed. The latter provides cells with a mechanism of adaptation to starvation (Ryter et 
al., 2013). Autophagy can be also induced by factors such as hypoxia, and endoplasmic 
reticulum stress as well as exposure to a wide range of chemical and physical agents. 
Although autophagy is primarily a cytoprotective pathway, its uncontrolled upregulation 
can lead to cell death (Shintani and Klionsky, 2004). Too much or too little autophagy has 
been implicated in several human pathologies including neurodegeneration, myopathies, 
cancer, heart and liver disease (Mizushima et al., 2008). 
The core autophagic machinery comprises of the well-conserved family of 
autophagy-related (Atg) proteins. Molecular regulation of autophagy pathway occurs at 
three steps: (i) initiation, (ii) nucleation of an isolation membrane and (iii) elongation and 
completion of autophagosomes. Activation of ULK1 complex (ULK1, Atg13 and 
FIP200), which on resting conditions is inhibited by mTOR complex1, triggers the 
autophagy cascade. Next, the classIII PI3K complex (Beclin 1, hVps34, Atg14) mediates 
nucleation of autophagosomal membranes. The elongation and closure of the 
autophagosomal vesicles is dependent on the Atg5/Atg12/Atg16 complex and the 
ubiquitin-like protein, LC3. Unlike the first complex which dissociates from 
autophagosome once it is fully formed, LC3-phosphatidyl ethanolamine conjugates (aka 
LC-II) remain attached to vesicles.  Attachment of phosphatidyl ethanolamine molecules 
to LC3 is mediated by Atg4 cysteine protease, Atg3 E2-like enzyme and Atg7 E1-like 
enzyme (Pyo et al., 2012).   
A screen conducted to identify KSHV proteins that could inhibit autophagy-
mediated cell death, pulled out vFLIP.  KSHV vFLIP, HVS vFLIP, MC159L, cFLIPL and 
cFLIPS all inhibit autophagy. The FLIP proteins interact with the Atg3, preventing LC3 
conjugation to phosphatidyl ethanolamine  and attachment to membranes for autophagic 
vesicle expansion (Lee et al., 2009) (Figure 1.7). 
During KSHV latency, deregulation of cell proliferation by vCyclin elicits DNA 
damage responses which, if unchecked, can promote autophagy and oncogene-induced 
senescence (OIS) (Koopal et al., 2007; Verschuren et al., 2002). By countering the v-
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cyclin-induced autophagy, vFLIP plays an indispensable role in prevention of OIS, 
permitting the expansion of abnormal cells (Leidal et al., 2012).  
KSHV vFLIP mutants deficient in NEMO- or FADD-binding are capable of 
blocking autophagy (Lee et al., 2009; Leidal et al., 2012). Hence, the anti-autophagic role 
of vFLIP appears to be mediated by a unique motif, independent of its ability to induce 
NF-κB or block apoptosis. Indeed, Atg3-binding region of KSHV vFLIP was mapped to 
DED1 α2 helix (aa 20-29) and DED2 α4 helix (aa 128-139). Introducing peptides derived 
from these motifs can effectively block Atg3-vFLIP interaction without interrupting that 
of Atg3-LC3, leading to growth inhibition and autophagy-mediated cell death (Lee et al., 
2009). 
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Figure 1.7. Cellular and viral FLIPs block autophagy. Autophagy is a homeostatic 
mechanism which is activated in response to various conditions such as absence of the 
amino acids, growth factors or oxygen. During starvation, mTORC1 that represses 
autophagy in normal conditions is inhibited which in turn causes ULK1 complex (ULK1, 
Atg13, FIP200) activation. Autophagy initiation is also dependent on other complex 
(Beclin 1, hVps34, Atg14) crucial for nucleation of autophagosomal membranes. The 
nucleation complex is activated through JNK1-mediated phosphorylation and subsequent 
inactivation of its inhibitory protein Bcl-2. The elongation and closure of the 
autophagosomal vesicles is dependent on the Atg5/Atg12/Atg16 complex and LC3. 
Unlike the first complex which dissociates from autophagosome once it is fully formed, 
LC3-phosphatidyl ethanolamine (PE) conjugates remain attached to vesicles.  Attachment 
of PE molecules to LC3 is mediated by Atg3 E2-like enzyme and Atg7 E1-like enzyme.  
Cellular and viral FLIPs have been shown to supress autophagy by preventing the Atg3-
LC3 interaction. 
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1.3.5 Regulation of NF-κB pathways by FLIPs 
The ability of cFLIP proteins to activate NF-κB was initially demonstrated using 
overexpression experiments (Chaudhary et al., 2000; Hu et al., 2000). Later on, cFLIPL 
was found to mediate NF-κB activation following CD95 stimulation through a 
mechanism involving the recruitment of RIP1, TRAF1 and TRAF2 (Kataoka et al., 2000). 
This pathway is believed to depend on processing of cFLIPL to the p43 fragment as non-
cleavable mutant of cFLIPL does not induce it (Kataoka and Tschopp, 2004; Matsuda et 
al., 2014; Neumann et al., 2010). p43-FLIP has been found associated with NEMO after 
CD95 signalling (Neumann et al., 2010). One study reported that p22-FLIP, another 
cleavage product of cFLIPL/S/R can also directly interact with NEMO and activate IKK. 
p22-FLIP seems to be primarily important in NF-κB induction required for lymphocyte 
activation and DC maturation (Golks et al., 2006).  
Akin to its role in apoptosis, the expression level of cFLIPL is found to be a major 
determinant of its function as inhibitor or activator of DR-induced NF-κB signalling. 
Neumann et al showed that cFLIPL mediates CD95-induced NF-κB activation when 
expressed at moderate levels. On the other hand, high concentrations of cFLIPL can 
occupy the DISC, preventing the procaspase-8 activation, p43-FLIP production and NF-
κB activation (Neumann et al., 2010). This is in accordance with a number of other 
studies that propose cFLIPL downregulates CD95-induced NF-κB activity (Imamura et 
al., 2004; Kavuri et al., 2011; Kreuz et al., 2004). The reported inhibitory function of 
cFLIPS in TCR-induced NF-κB activation might be also explained by its capacity to 
effectively block procaspase-8 activation and the resultant generation of cFLIP cleavage 
products.  
Regulatory roles of cFLIP isoforms have been also controversially discussed in 
regard with TRAIL-induced NF-κB activation (Kavuri et al., 2011; Song et al., 2007; 
Wachter et al., 2004). While both positive and negative roles have been ascribed to cFLIPs 
in this context, a recent study argued against involvement of these proteins in TRAIL-
induced NF-κB signalling. Instead, FADD and caspase-8 were shown to mediate TRAIL-
induced signalling to IKK (Grunert et al., 2012). 
Among FLIP proteins, KSHV vFLIP is the most well-known inducer of NF-κB 
(Chaudhary et al., 1999; Chugh et al., 2005; Liu et al., 2002; Sun et al., 2003, 2006). Our 
group demonstrated direct, stable interaction between KSHV vFLIP and NEMO which 
leads to constitutive IKK complex activation (Field et al., 2003). Initially, it was suggested 
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that KSHV vFLIP binds to TRAF2 via a putative TRAF-binding motif and that this 
facilitates IKK activation by vFLIP (Guasparri et al., 2006). In contrast, later reports 
demonstrated that vFLIP could directly bind and activate NEMO independent of TRAF2 
or TRAF3 (Matta et al., 2007). In KSHV-infected B cell lines, the IKK subunits alpha, 
beta and gamma, together with HSP90, are the only detectable proteins complexed with 
vFLIP; also NEMO immunoprecipitation depletes all detectable vFLIP from cell lysate 
(Field et al., 2003). KSHV vFLIP can also activate the alternative NF-κB pathway by 
upregulating the expression of p100 and its processing to p52. Non-canonical NF-κB 
induction by vFLIP is unique in that it does not require NIK and occurs through direct 
interaction between p100, vFLIP and IKK (Matta and Chaudhary, 2004). 
Both viral FLIPs from MCV (MC159 and MC160) block TNF-induced NF-κB 
signalling; MC159 has been shown to do this by binding to NEMO (Nichols and Shisler, 
2006; Randall et al., 2012). On the other hand, MC160 is not detectable in association 
with any of IKK subunits. However, expression of MC160 leads to substantial decrease in 
levels of IKKα/β and interactions between these subunits, suggesting that MC160 may 
exert its inhibitory function by dissociating the IKK complex (Nichols and Shisler, 2006). 
The vFLIPs from RRV and HSV do not activate NF-κB, in contrast to vFLIP form EHV 
(Chaudhary et al., 1999; Lee et al., 2009; Ritthipichai et al., 2012). The interaction of these 
viral FLIPs with NEMO has yet to be studied. 
Detailed mechanisms of NF-κB activation by KSHV and cellular FLIPs will be 
discussed in chapters 3-5. 
1.3.6 Regulation of MAPK pathways by FLIPs 
The MAPK signalling network is involved in fundamental cellular processes such as 
growth, proliferation, differentiation and apoptosis. This pathway is built upon a three-tier 
kinase module where a MAPK becomes activated through phosphorylation by a MAPKK 
which, in turn, is induced by an upstream MAPKKK (Dhillon et al., 2007). Six distinct 
groups of MAPKs have been described so far in mammalian cells: extracellular signal-
regulated kinase (ERK)1/2, ERK3/4, ERK5, ERK7/8, c-Jun N-terminal kinase 
(JNK)1/2/3 as well as the p38 isoforms α/β/γ [reviewed in (Arthur and Ley, 2013)]. 
While ERK1/2 are predominantly activated by growth factors, JNK and p38 kinases are 
induced in response to stress stimuli and cytokines (Pearson et al., 2001). 
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cFLIPL, cFLIPS  and p43-FLIP can all activate ERK1/2 via recruitment of the 
upstream MAPK3, Raf-1 which activates MAPK2 MEKK and then ERK (Kataoka et al., 
2000; Koenig et al., 2014). In activated T cells, high levels of cFLIP leads to simultaneous 
activation of NF-κB and ERK, promoting IL-2 secretion and T-cell proliferation 
(Kataoka et al., 2000). Nevertheless, a recent study reported that high expressions of 
cFLIP proteins can inhibit CD95-induced ERK activation, through blocking the 
procaspase-8 processing (Kober et al., 2011). It is possible that, like their role in apoptosis, 
cFLIPs differentially regulate ERK in cell-, pathway- and signal strength-dependent 
manner.  
Unlike ERK signalling, p38 and JNK appear to be preferentially inhibited by cFLIP 
isoforms. Gene silencing of cFLIP isoforms in keratinocytes enhances CD95- and 
TRAIL-induced p38 and JNK activation without affecting NF-κB activation (Kavuri et 
al., 2011). In addition, cFLIP−/− B-cells highly activate p38 and JNK signalling in response 
to LPS, while neither NF-κB nor ERK1/2 signalling is altered in these cells (Zhang et al., 
2009b). Following TNFα activation, cFLIPL, but not cFLIPS, directly binds to MKK7, an 
activator of JNK (Nakajima et al., 2006). This stimulus-dependant binding inhibits the 
activation and interactions of MKK7 with its upstream kinases such as MEKK1, ASK1 
(apoptosis-signal-regulating kinase1), and TAK1. As mentioned previously, cFLIPL is also 
targeted for degradation by JNK-induced E3 ubiquitin ligase Itch (Chang et al., 2006). 
Therefore, cFLIPL appears to operate as a molecular rheostat in TNFα-induced JNK 
signalling. While prolonged induction of JNK, which leads to cell death, is blocked by 
cFLIPL, its degradation by Itch prevents full blockade of the pathway.  
KSHV vFLIP was initially reported to activate JNK/AP-1 pathway in a TRAF2 
dependent fashion, eventually leading to high expressions of cIL-6 (An et al., 2003). 
However, later studies failed to detect vFLIP-mediated  JNK/AP-1 activation in either 
PEL or non-PEL cells (Sun et al., 2006; Ye et al., 2008). In marked contrast, vFLIP was 
demonstrated to suppress AP-1 activity -which is required for lytic KSHV replication- 
through NF-κB activation. This function of vFLIP is speculated to be central  for 
maintaining the latent KSHV infection (Ye et al., 2008). 
1.3.7 FLIPs as promising targets for anti-cancer therapies 
Enhanced cFLIP expression has been observed in a wide variety of cancers 
including melanoma (Yang et al., 2007), glioblastoma (Panner et al., 2009), colorectal 
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(Longley et al., 2006; Wilson et al., 2007), pancreatic (Haag et al., 2011; Kauh et al., 2010), 
ovarian (El-Gazzar et al., 2010; Park et al., 2009), prostate (Zhang et al., 2007) and gastric 
carcinomas (McLornan et al., 2010). Importantly, the higher levels of cFLIP correlate with 
more aggressive tumours (Korkolopoulou et al., 2004; Ullenhag et al., 2007; Valente et al., 
2006; Valnet-Rabier et al., 2005; Wang et al., 2007a). In fact, cFLIP has been considered 
as a prognosis marker which may contribute to characterisation of patients at higher risks 
(Bagnoli et al., 2010). In support of this notion, increased amounts of cFLIPL were 
identified as an independent maker of adverse clinical outcome in several malignancies 
such as ovarian, colon and endometrial carcinomas as well as Burkitt’s lymphoma (Bagnoli 
et al., 2009; Safa et al., 2008).   
Abnormal upregulation of cFLIP proteins renders cancer cells resistant to not only 
CD95 (Mezzanzanica et al., 2004) and TRAIL-induced cell death (Geserick et al., 2008; Li 
et al., 2007) but also to chemotherapeutic drugs (Rogers et al., 2007). Resistance to 
TRAIL-induced apoptosis is particularly important as this type of cell death is found to be 
highly selective for the killing of neoplastic cells rather than normal ones (Walczak et al., 
1999). This is shown to be due to an impaired expression of decoy receptors in cancer 
cells (Pan et al., 1997; Sheridan et al., 1997). Alike cFLIPs, vFLIPs play crucial roles in 
apoptosis evasion and therefore, oncogenicity of the associated viruses. Thus, targeting 
FLIP proteins appears as an attractive anti-cancer therapy, especially if combined with 
conventional approaches such as TRAIL treatment and chemotherapy. Sensitising 
malignant cells to apoptosis by inhibiting FLIPs may also allow for administering lower 
doses of chemotherapeutic agents, decreasing the drug-induced systemic toxicity in cancer 
patients (Safa and Pollok, 2011). 
Several strategic interventions have been utilised to inhibit FLIP variants which include (i) 
usage of compounds inhibiting transcription or translation of these proteins (ii) 
oligonucleotide- or RNAi-mediated silencing of FLIPs and (iii) targeting FLIPs for 
degradation. These therapeutic strategies and advantages and disadvantages of each 
method have been extensively reviewed in (Safa and Pollok, 2011; Shirley and Micheau, 
2010).  
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1.4 HTLV-1 Tax: a functional analogue of the KSHV vFLIP 
1.4.1 HTLV-1 biology 
Human T-cell lymphotropic virus type 1 (HTLV-1) was discovered in Japan where 
it shows a high prevalence, about 10% of the population are infected (Yoshida, 2005). 
The virus was isolated and sequenced by the Gallo lab at the National Cancer Institute in 
the US and was the first human retrovirus to be identified (Poiesz et al., 1980). In Japan it 
is mainly transmitted neonatally by breastfeeding (Matsuoka and Jeang, 2007), and 
although it mainly infects T-cells, it enters cells by binding to a widely expressed glucose 
transporter GLUT-1 (Manel et al., 2003).  
HTLV-1 causes an aggressive T-cell leukaemia, adult T-cell leukaemia (ATL), and is 
also associated with a progressive motor neuron disease known as HTLV-1 associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) (Osame et al., 1987; Yoshida, 2005). 
ATL occurs with a long latency, up to 60 years, after infection with HTLV-1 (Matsuoka, 
2003). Early in the disease infected T-cells are driven to proliferate by upregulation of the 
IL-2 receptor and secretion of IL-2 (Ballard et al., 1988; Wano et al., 1988). Then 
oligoclonal expansion of infected cells occurs. Finally, the aggressive leukemia develops, at 
this stage the cells have ceased to be dependent on autocrine IL-2; the transformed 
phenotype is dependent on secondary mutations, at least some caused by insertional 
mutagenesis induced by the viral genome (Grassmann et al., 2005). HTLV-1 is a complex 
retrovirus than encodes additional proteins along with those required for viral replication 
(Matsuoka and Jeang, 2007). The Rex protein is required for nuclear export of unspliced 
RNA, analogous to the Rev protein of HIV (Rimsky et al., 1988).  
1.4.2 HTLV-1 Tax 
The Tax protein is responsible for the stimulation of T cell proliferation by HTLV-
1.  Tax activates the NF-κB pathway (Ballard et al., 1988) and expression of Tax in T cells 
is sufficient to up-regulate both the IL-2 and its receptor, and drive cells to proliferate 
(Grassmann et al., 1989; Wano et al., 1988). Tax also upregulates HTLV-1 viral gene 
expression via recruitment of CREB to the LTR, enhancing viral replication (Yin and 
Gaynor, 1996; Zhao and Giam, 1992). Indeed Tax is a polyfunctional protein, interactions 
with a variety of host cellular proteins have been reported [reviewed in (Boxus et al., 
2008)]. Later in infection Tax expression is lost and the HTLV-1 HBZ protein, encoded 
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by an antisense transcript, drives transformation; HBZ is also a transcriptional regulator 
with many opposite effects to Tax (Satou et al., 2006). 
Tax is of particular relevance to this study because, like some vFLIP proteins, it 
binds directly to NEMO to activate IKK (Chu et al., 1999; Harhaj and Sun, 1999; Jin et 
al., 1999), explaining its ability to constitutively activate NF-κB pathway leading to 
upregulation of NF-κB-dependent genes. Nevertheless, how the Tax–IKK physical 
association leads to IKK activation is incompletely understood. Two regions of NEMO, 
distinct from that recognised by KSHV vFLIP, have been reported to be necessary for 
Tax activation of IKK (See 3.1.2) (Xiao and Sun, 2000; Xiao et al., 2000). Tax also 
activates the alternative NF-κB pathway in a similar manner to vFLIP, by enhancing p100 
processing, dependent on IKKα and NEMO, but not NIK (Xiao et al., 2001b). 
Therefore, these proteins from unrelated viruses, which share no amino acid homology, 
represent a remarkable example of convergent evolution in the manner in which they 
activate the NF-κB pathway. 
1.5 Aims of the thesis 
Leading on from previous projects in our laboratory that demonstrated the 
necessity and dynamics of the vFLIP-NEMO interaction, I set out to achieve the 
following goals: 
1) To identify the regions of NEMO required for activation of IKK by KSHV 
vFLIP, cellular FLIPs and HTLV-1 Tax 
2) To determine how IKK is activated by KSHV vFLIP, cFLIPs and Tax 
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2. MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Molecular buffers and bacterial media 
All buffers and bacterial media were prepared in double distilled H2O (ddH2O). 
Table 2.1. Buffers and bacterial media. 
Buffer/media  pH Composition 
Phosphate-buffered saline (PBS) 7.4 137 mM NaCl 
  2 mM KCl 
  10 mM sodium hydrogen phosphate 
(dibasic) 
  2 mM potassium hydrogen phosphate 
(dibasic) 
Tris-EDTA (TE) 8.0 10 mM Tris-HCl 
  1 mM EDTA 
Tris-acetate EDTA (TAE) 7.8 40 mM Tris-HCl 
  1 mM EDTA 
  20 mM sodium acetate 
Elution buffer (EB) 8.5 10 mM Tris-HCl 
Luria Bertani broth 7.5 1% bacto-tryptone 
  0.5% bacto-yeast extract 
  10% NaCl 
Luria Bertani agar 7.5 LB broth plus bacto-agar 15g/L 
Transformation buffer (TFB)-I 5.5 30 mM potassium acetate 
  100 mM rubidium chloride 
  10 mM calcium chloride 
  50 mM magnesium chloride 
  15% glycerol 
  acetic acid to desired pH 
TFB-II 6.5 10 mM MOPS 
  75 mM calcium chloride 
  10 mM rhubidium chloride 
  15% glycerol 
  KOH to desired pH 
6x gel loading buffer 6.8 0.25% bromophenol blue 
  0.25% xylene cyanol FF 
  30% glycerol in water 
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2.1.2 Antibodies 
Table 2.2. Primary antibodies used for immunoblotting and immunoprecipitation. 
Target Clone Manufacturer Species/Isotype Dilution 
Atg3  CST Rabbit, Polyclonal 1:1000 
Caspase-8 C-20 Santa Cruz Goat, Polyclonal 1:1000 
cFLIP† 
NF6 
Enzo Life 
Sciences 
Mouse, IgG1 1:2000 
CYLD  Sigma Rabbit, Polyclonal 1:1000 
FADD 1/FADD BD Mouse, IgG1 1:1000 
FLAG epitope M2 Sigma Mouse, IgG1 1:2000 
GAPDH 
14C10 CST 
Rabbit, 
Monoclonal 
1:4000 
GST B-14 Santa Cruz Mouse, IgG1 1:1000 
HA epitope 
Y-11 Santa Cruz 
Rabbit, 
Monoclonal 
1:1000 
HOIL-1  Walczack lab Mouse, IgG2a 1:1000 
HOIP  Sigma Rabbit, Polyclonal 1:2000 
IKKαβ H470 Santa Cruz Rabbit, Polyclonal 1:1000 
MEKK3 40/MEKK3 BD Mouse, IgG1 1:1000 
NEMO FL-419 Santa Cruz Rabbit, Polyclonal 1:3000 
pIKKα(S176/180)/ 
β(S177/181)  
16A6 CST 
Rabbit, 
Monoclonal 
1:1000 
pIKKα(S176)/β(S177) 
C84E11 CST 
Rabbit, 
Monoclonal 
1:1000 
pIκBα (S32) 
14D4 CST 
Rabbit, 
Monoclonal 
1:1000 
pIκBα (S32/36) 12C2 CST Mouse, IgG1 1:700 
RIP1 38/RIP1 BD Mouse, IgG2a 1:1000 
SHARPIN  Walczak lab Mouse, IgG1 1:1000 
TAK1 M-579 Santa Cruz Rabbit, Polyclonal 1:1000 
vFLIP 6/14 Collins lab Rat, Monoclonal 1:300 
Manufacturers: BD, Beckton Dickenson Transduction Laboratories, CST, Cell 
Signalling Technology. 
† The anti-cFLIP(NF6) antibody has been raised against amino acids 1-194 of 
human cFLIP and therefore, recognises all of its isoforms and proteolytic fragments. 
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Table 2.3. HRP-conjugated secondary antibodies used for immunoblotting. 
Target Host Manufacturer Dilution 
Goat IgG Rabbit Dako 1:2000 
Mouse IgG Sheep GE Healthcare 1:10000 
Mouse IgG (ligh chain-specific) Mouse Jackson Immunoresearch 1:20000 
Rabbit IgG Pig Dako 1:3000 
Rabbit IgG (Fc-specific) Goat Jackson Immunoresearch 1:20000 
Rabbit IgG (ligh chain-specific) Mouse Jackson Immunoresearch 1:20000 
Rat IgG Rabbit Dako 1:1000 
Fc: Fragment crystallisable region of an antibody. 
2.1.3 Primers 
Table 2.4. Primers used for amplifying cDNAs of genes of interest. 
Amplicon Target 
Vector 
Primer name Primer sequence (5'→3') 
cFLIPL pDual & 
pCDNA3 
BglII-cFLIP-FW agatctgccaccatgtctgctgaagtcatccat 
 cFLIPL-NotI-RS gcggccgcttatgtgtaggagaggataagtttctttc 
cFLIPS pDual & BglII-cFLIP-FW agatctgccaccatgtctgctgaagtcatccat 
 pCDNA3 cFLIPS-NotI-RS gcggccgctcacatggaacaatttccaagaattt 
p22-FLIP pDual & BglII-cFLIP-FW agatctgccaccatgtctgctgaagtcatccat 
 pCDNA3 p22-NotI-RS ggggcggccgctcaatccttgagac 
CYLD pDual BamHI-CYLD-FW ggatccgccaccatgagttcaggcttatggagccaagaa
aaag 
  CYLD-NotI-RS gcggccgcttatttgtacaaactcattgttggactctgg 
FADD pCAN BamHI-FADD-FW ggatccgacccgttcctggtgctgctgc 
  FADD-NotI-RS gcggccgctcaggacgcttcggaggtagatg 
RIP1 pDual AsiSI-RIP1-FW gcgatcgcgccaccatgcaaccagacatgtccttgaatg 
  RIP1-NotI-RS gcggccgcttagttctggctgacgtaaatcaagctgctc 
HA-RIP1 pCDNA3 KpnI-HA RIP1-FW ggtaccgccaccatgtacccatacgacgtcccagactac
gctggtcaaccagacatgtccttgaatgtca 
  RIP1-NotI-RS gcggccgcttagttctggctgacgtaaatcaagctgctc 
IκBα(1-54) pGEX-
2T 
BamHI-IκBα-FW ggatccgccatgttccaggcg 
  IκBα∆54-EcoRI-RS gaattctcagaggcggatctcctg 
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Luciferase pDual BamHI-Luc-FW ggatccaccgccatggaagacgccaaaaacataaagaa
agg 
  Luc-NotI-RS gcgggcgcttacaatttggactttccgcccttcttggcc 
NEMO 
∆254 
pDual AscI-SFFV-FW ggcgcgccagtcctccgacagactg 
  SalI-NEMO∆254-RS gtcgactcaccgctcactgcccaccacgctgctcttg 
NEMO 
∆271 
pDual AscI-SFFV-FW ggcgcgccagtcctccgacagactg 
  SalI-NEMO∆271-RS gtcgactctagtcactcggcctgctggagctgctg 
vFLIP pDual & BamHI-vFLIP-FW ggatccgccaccatggccacttacgag 
 pCDNA3 vFLIP-NotI-RS gcggccgcctatggtgtatggcgatagtg 
 
Table 2.5. Primers used for site-directed mutagenesis 
Mutation Primer Sequence (5'→3') 
cFLIP A56L FW: tcggggacttgttggaactgctctac 
 RS: gtagagcagttccaacaagtccccga 
cFLIP K192/K195RR FW: gaatgttctccaagcagcaatccaaagaagtctcagagatccttcaaataacttcagg 
 RS: cctgaagttatttgaaggatctctgagacttctttggattgctgcttggagaacattc 
cFLIP F114/L115AA FW: tgtgcgagggatattaggtctttgatagctgcaagcaaggacactatagggtctc 
 RS: gagaccctatagtgtccttgcttgcagctatcaaagacctaatatccctcgcaca 
IKKβ S177/S181AA FW: gctggatcagggcgctctttgcacagcattcgtggggac 
 RS: gctggatcagggcgctctttgcacagcattcgtggggac 
IKKβ S177/S181EE FW: aggagctggatcagggcgaactttgcacagaattcgtggggaccctgc 
 RS: gcagggtccccacgaattctgtgcaaagttcgccctgatccagctcct 
RIP1 E620/D622AA FW: gaaattgaccatgactatgcgcgagctggactgaaagaaaaggtt 
 RS: aaccttttctttcagtccagctcgcgcatagtcatggtcaatttc 
RIP1 G595/K596AA FW: cccaatcagggaaaatctggcagcgcactggaaaaactgtgccc 
 RS: gggcacagtttttccagtgcgctgccagattttccctgattggg 
RIP1 K377R FW: cccagcctgcagagtagactccaagacgaag 
 RS: cttcgtcttggagtctactctgcaggctggg 
vFLIP D102/E104RR FW: cactgttctccacgtacgcgggcggctgtgtgcgaggg 
 RS: ccctcgcacacagccgcccgcgtacgtggagaacagtg 
vFLIP E104R FW: ccacgtagacgggcggctgtgtgcgagg 
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 RS: cctcgcacacagccgcccgtctacgtgg 
vFLIP F115/L116AA FW: tgtgcgagggatattaggtctttgatagctgcaagcaaggacactatagggtctc 
 RS: gagaccctatagtgtccttgcttgcagctatcaaagacctaatatccctcgcaca 
vFLIP R12E BamHI-vFLIP R12E- FW: ggatccgccaccatggccacttacgaggttct 
ctgtgaggtggcggagaaactgggcacgga 
 
Table 2.6. Sequencing primers 
Primer  Sequence  
SFFV FW cgagctctataaaagagctca 
pDual seq RS taaagcagcgtatccacatagcgtaaaagga 
pSIREN shRNAFW atttcttgggtagtttgcag 
pSIREN shRNA RS gggctgctaaagcgcatgc 
 
2.1.4 Plasmids used in this study 
Table 2.7. Mammalian and bacterial expression vectors used in this project. 
Plasmid Origin 
pDual (SFFV) NEMO WT (Ub) mCherry Akira Shimuzu, Collins lab 
pDual (SFFV) NEMO F312A (Ub) mCherry Akira Shimuzu, Collins lab 
pDual (SFFV) NEMO F238/D242RR (Ub) mCherry Akira Shimuzu, Collins lab 
pDual (SFFV) NEMO D242V (Ub) mCherry this study 
pDual (SFFV) NEMO ∆271 (Ub) mCherry this study 
pDual (SFFV) NEMO ∆254 (Ub) mCherry this study 
pDual (SFFV) vFLIP (Ub) GFP Akira Shimuzu, Collins lab 
pDual (SFFV) FLAG-Tax (Ub) GFP Akira Shimuzu, Collins lab 
pDual (SFFV) cFLIPL (Ub) GFP this study 
pDual (SFFV) cFLIPS (Ub) GFP this study 
pDual (SFFV) p22-FLIP (Ub) GFP this study 
pDual (SFFV) CYLD (Ub) GFP this study 
pDual (SFFV) RIP1 WT (PGK) GFP this study 
pDual (SFFV) RIP1 WT (PGK) GFP this study 
pDual (SFFV) RIP1 K377R (PGK) GFP this study 
pDual (SFFV) RIP1 G595/K596AA (PGK) GFP this study 
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pDual (SFFV) RIP1 E620/D622AA (PGK) GFP this study 
pDual (SFFV) empty (Ub) GFP David Escors, UCL 
pSIN (SFFV) GFP David Escors, UCL 
pSIN (CMV) NF-κB luciferase this study 
pSIN (CMV) NF-κB mCherry this study 
pHIV-SIREN GFP David Escors, UCL 
pHIV-SIREN PuroR Greg Towers, UCL 
pHIV-SIREN HygroR this study 
pGL. IgK this study 
pGL. H2DK this study 
pRL.TK David Guiliano, UEL 
pNF-κB-H2DK-luciferase Inna Lavrik, DKFZ, Germany 
pCDNA3 empty Pablo Rodriguez, UCL 
pCDNA3 vFLIP this study 
pCDNA3 His-vFLIP this study 
pCDNA3 FLAG-vFLIP this study 
pCDNA3 vFLIP A57L this study 
pCDNA3 vFLIP F115/L116AA this study 
pCDNA3 vFLIP R12E this study 
pCDNA3 vFLIP R12E/E104R this study 
pCDNA3 vFLIP D102R/E104R this study 
pCDNA3 p22-FLIP WT this study 
pCDNA3 p22-FLIP A56L this study 
pCDNA3 p22-FLIP F114/L115AA this study 
pCDNA3 p22-FLIP K192/195RR this study 
pCDNA3 cFLIPS WT this study 
pCDNA3 cFLIPS A56L this study 
pCDNA3 cFLIPS F114/L115AA this study 
pCDNA3 cFLIPS K192/195RR this study 
pCDNA3 cFLIPL WT this study 
pCDNA3.1 FLAG-cFLIPL WT Pascal Meier, ICR 
pCDNA3 cFLIPL A56L this study 
pCDNA3 cFLIPL F114/L115AA this study 
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pCDNA3 cFLIPS K192/195RR this study 
pCDNA3 cFLIP D196E/D376N Inna Lavrik, DKFZ, Germany 
pCDNA3 FLAG-Tax this study 
pCDNA3 Myc-NEMO WT this study 
pCDNA3 MycNEMO D242V this study 
pCDNA3 Myc NEMO F312A this study 
pCDNA3 Myc-NEMO F238/D242RR this study 
pCDNA3 HA-IKKα WT this study 
pCDNA3 HA-IKKα S176/S180AA this study 
pCDNA3 HA-IKKα S176/S180EE this study 
pCDNA3 HA-IKKβ WT this study 
pCDNA3 HA-IKKβ S177/S181AA this study 
pCDNA3 HA-IKKβ S177/S181EE this study 
pCDNA3.1 His-V5-HOIP  Henning Walczak, UCL 
pCDNA3.1 FADD Henning Walczak, UCL 
pCDNA3 HA-FADD this study 
pCDNA3 HA-RIP1 this study 
pGEX-2T IκBα (1-54) this study 
pGEX IκBα (1-73) S32/S36AA Neil Perkins, Newcastle 
University 
 
2.2 Molecular biology 
2.2.1 Polymerase chain reaction (PCR) 
To amplify DNA fragments for subcloning into an expression vector, PCR 
reactions were performed using the high fidelity Phusion® DNA polymerase (NEB), as 
described in Table 2.8. Phusion DNA Polymerase possesses 3´→5´ proof-reading activity 
and generates blunt end products which, following purification, can be ligated into 
pJET1.2/blunt cloning vector.  
For colony screen PCRs, we used the goTaq® Green Master Mix (Promega, 
Madison, WI). The colony PCR is a convenient method to screen for the absence or 
presence of a plasmid DNA insert directly from the transformed E.coli colonies. This 
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method can also be used to determine the insert orientation following blunt-end DNA 
ligations. Table 2.9 summarises the reagents used for the PCRs with goTaq polymerase.  
Table 2.8. Phusion polymerase reaction mixtures  
Component 
Stock 
Concentration 
Volume 
added 
Final 
concentration 
Nuclease-free water - to 50 µl  
Phusion HF† or GC† 
buffer 
x5 10 µl x1 
dNTPs 10 mM 1µl 200 µM 
Forward Primer 10 µM 2.5 µl 0.5 µM 
Reverse Primer 10 µM 2.5 µl 0.5 µM 
DNA template 100 ng 1 µl 100 ng 
Phusion DNA 
polymerase 
2 units/µl 0.5 µl 1 unit/50 µl PCR 
Total volume  50 µl  
†: As recommended by the manufacturer, HF buffer was used as the default buffer 
for high fidelity amplification, while GC buffer was used in PCRs with GC-rich template 
or those which did not work with HF. 
Table 2.9. goTaq polymerase reaction mixtures 
Component 
Stock 
Concentration 
Volume added 
Final 
concentration 
Nuclease-free water - to 25 µl - 
GoTaq Green Master 
Mix 
x2 12.5 µl x1 
Forward Primer 10 µM 2.5 µl 1 µM 
Revers Primer 10 µM 2.5 µl 1 µM 
DNA template  
A small amount of 
E.coli colony 
 
Total volume  25 µl  
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Reactions were run in a Hybraid thermal cycler using parameters listed in Table 2.10 
and Table 2.11. 
Table 2.10. Cycling parameters for Phusion polymerase reactions 
Cycle step Cycles Temperature Time 
Initial Activation 1 98 oC 30 seconds 
Denaturation 
25-30 
98 oC 5-10 seconds 
Annealing 
~ 5oC below Tm of 
primers 
10-30 seconds 
Extension 72 oC 15-30 seconds/kb 
Final Extension 1 72 oC 5-10 min 
Hold 1 4 oC ∞ 
 
Table 2.11. Cycling parameters for goTaq polymerase reactions 
Cycle step Cycles Temperature Time 
Initial Activation 1 95 oC 2 min 
Denaturation 
25-30 
95 oC 30 seconds 
Annealing 
~ 5 oC below Tm of 
primers 
30 seconds 
Extension 72 oC 1 min/kb 
Final Extension 1 72 oC 5-10 min 
Hold 1 4 oC ∞ 
 
2.2.2 Site-directed mutagenesis 
Mutations were introduced using either QuickChange® XL II Mutagenesis Kit 
(Agilent Technologies) according to the manufacturer’s instructions, or by overlap 
extension PCR method (OE-PCR). Both methods are based on amplification of the 
unmutated template DNA using complementary primer pairs both harbouring the desired 
mutation in their middle part (one forward and one reverse primer, here referred to as 
sense and antisense).  
The QuickChange XL-II mutagenesis relies on a single PCR reaction using 
mutation-containing primers and a plasmid DNA as template. Extension of the 
oligonucleotide primers by Pfu HF DNA polymerase generates a mutated plasmid 
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containing staggered nicks. DNA isolated from most strains of E.coli is dam methylated 
and therefore, susceptible to digestion with the restriction enzyme DpnI. Hence, treatment 
of the PCR mixture with DpnI results in digestion of the parental unmutated DNA; 
however, the mutated plasmid produced by the PCR is unmethylated and so, is preserved. 
The mutated plasmid can then be transformed into competent cells and amplified within 
bacteria. 
In OE-PCRs, three PCR reactions are performed to generate a DNA fragment with 
the desired mutation. For this method, apart from the mutation-harbouring internal 
primers, two primers (FW: forward and RS: reverse) one for each end of the final product 
are required. First, two PCR reactions using FW+antisense and sense+RS oligos were 
performed to generate two overlapping DNA segments containing the mutation of 
interest at their 3'- and 5'-terminal part, respectively. Finally, a third PCR was carried out 
to adjoin the two segments into a full-length product using FW and RS primers and 
products of the initial PCRs as template. These PCR products were then cloned into 
pJET1.2/blunt cloning vector. Presence of the mutation (and also absence of undesired 
sequence alterations) was verified by DNA sequencing, before subcloning the mutated 
genes into expression vectors. 
The primers used for site-direct mutagenesis were designed using the online 
QuickChange® Primer Design program; they are listed in Table 2.5. 
2.2.3 Restriction digestions 
All restriction enzymes and their optimal buffers were purchased from Promega 
(Madison, WI) or New England Biolabs (NEB; Ipswich, MA). Digestion reactions for 
DNA analysis were normally performed at 37 oC for at least two hours, in a total volume 
of 10 µl (1 µl DNA, 0.5 µl of each enzyme, 1 µl of 10x buffer and 7 µl water). For 
isolation of plasmid backbone or inserts for ligation, reactions were carried out in a final 
volume of 30 µl (3 µl DNA, 1 µl of each enzyme, 3 µl of 10x buffer and 23 µl water). The 
incubation time was reduced to 30 min when using High-Fidelity restriction enzymes. 
To generate blunt-end DNA fragments from those with sticky-ends, the DNA was 
incubated with Klenow DNA polymerase at 37 oC for 30 minutes in a 30 µl reaction 
consisting of: 20µl gel-purified sticky end DNA, 1µl dNTP, 1 µl Klenow (NEB), 5µl 
water and 3 µl of x10 reaction buffer (10mM Tris-HCl, pH7.9, 50mM NaCl, 10mM MgCl2 
and 1mM DTT). The Klenow is a proteolytic fragment of E.coli DNA polymerase which 
75 
 
retains polymerisation and 3'→5' exonuclease activity, but has lost 5'→3' exonuclease 
activity. Hence, it fills in 5' overhangs and chews back 3' overhangs, generating a blunt-
end DNA fragment (Jacobsen et al., 1974). 
2.2.4 DNA ligations 
For ligation of DNA fragments, Rapid DNA Ligation Kit® (Thermo Scientific) was 
used. Ligation reactions were carried at room temperature for 5-10 minutes, in a total 
volume of 20 µl using 1 µl T4 DNA ligase (5 U/µl) and 4 µl of 5x Rapid ligation buffer. 
Next, 2µl of the reaction mixture was used for transformation of the competent cells. 
To minimise self-ligation of DNA fragments in reactions where both insert and 
vector were blunt-ended, we treated the backbone vector with calf intestinal alkaline 
phosphatase (CIAP) prior to ligation. This enzyme dephosphorylates 5'-ends of the 
vector, preventing them from binding to hydroxyl groups of the 3'-ends and therefore, 
minimising the re-circulation of the cut vectors. The dephosphorylation reactions were 
performed using 1µl of CIAP (1 U/µl, Promega) at 37 oC for 15 min, followed by further 
15 min incubation at 56 oC to heat-inactivate the enzyme. 
2.2.5 Annealing DNA oligonucleotides for subcloning into a plasmid 
In order to introduce a short stretch of DNA into a plasmid, we designed 
overlapping oligonucleotides that once assembled could be directly cloned into the 
overhangs generated by restriction digest of the destination vector. For annealing the 
oligonucleotides, 2.5 µl of each (reverse and forward) form a 100 µM stock were mixed 
and diluted in 50 µl of annealing buffer (10mM Tris pH 8.0, 50mM NaCl and 1mM 
EDTA). The mixture was incubated at 95 oC for 5 min and then, allowed to cool down to 
room temperature on the bench for approximately 45 min. The annealed oligonucleotides 
were diluted 10 times using nuclease-free water. Finally, the annealed oligonucleotides 
were mixed with cut vector in ratios between 3:1 to 6:1, in a standard ligation reaction as 
described in section 2.2.4. 
2.2.6 Agarose gel electrophoresis and recovery of DNA 
Agarose gel electrophoreses were performed to separate, characterise and purify the 
DNA samples. DNA fragments were electrophoresed in 1% agarose gels (Invitrogen, 
Carlsbad, CA) containing 5 µg/ml ethidium bromide (Dutscher Scientific, Essex, UK), 
using TAE buffer as running buffer. Prior to loading, DNA samples were mixed with x6 
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TriTrack DNA loading dye (Thermo Scientific) and then, were run alongside 1kb Plus 
DNA ladder (Invitrogen, Carlsbad, CA) for the estimation of band sizes. Gels were finally 
visualised under UV illumination and analysed using the GeneSnap image acquisition 
software (SYNGENE, NJ, USA). 
For DNA purification after electrophoresis, the bands of interest were excised form 
the gel and purified using Qiaquick Gel Extraction kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. 
2.2.7 Preparation, transformation and growth of competent bacteria 
For the generation of competent cells, we used the rhubidium chloride method. 
Briefly, XL10 gold E.coli (Agilent were streaked onto an LB-agar plate containing 
Tetracycline (10 µg/ml) and incubated overnight at 37 oC. A single colony was then 
picked and cultured overnight in 10 ml of LB medium with Tetracycline (10 µg/ml). 
Next, 100 ml of LB medium without antibiotics was inoculated with 1 ml of overnight 
culture and grown at 37 oC for approximately 90-120 min, until an OD600 of 0.5-0.6 was 
achieved. The bacterial suspension was then cooled on ice for 10 min and harvested at 
3000 RPM and 4 °C for 10 min. The pellet was gently suspended in 50 ml of TFB-I 
buffer (See table 2.1) and left on ice for 5 min. Following this incubation, cells were spun 
down again as explained above, re-suspend in 4 ml of ice-cold TBF-II buffer and left on 
ice for additional 15 min. Finally, aliquots of 100 µl were prepared and stored at -80 oC 
until use. 
For transformation, vials of competent bacteria were thawed on ice and inoculated 
with 100-500 ng of plasmid DNA or 2-5 µl of ligation reaction. After incubation on ice 
for 20 minutes, the bacteria were heat-shocked for 15 seconds at 42 oC (or 2 minutes at 37 
ºC) and put back on ice for an additional 2 minutes. The transformed cells were then 
streaked onto LB-agar plates containing selection antibiotics (Ampicillin 50 µg/ml, or 
Kanamycin 30 µg/ml) and grown overnight at 37oC. 
2.2.8 DNA purification and quantification 
Single colonies of transformed bacteria were picked from LB agar plates and grown 
overnight at 37 ºC, in 4 ml (minipreps) or 100 ml (midipreps) of LB broth supplemented 
with appropriate selection antibiotics (usually Ampicillin 50 µg/ml). Plasmid DNA was 
purified using QiaPrep Spin Miniprep or Plasmid Midiprep kits (Qiagen) following the 
77 
 
manufacturer’s protocol. The purified DNA was normally eluted in EB buffer or 
nuclease-free water and quantified using NanoDrop® 3300 spectrophotometer (Thermo 
Scientific, Wilmington, DE). 
2.2.9 Extraction of cellular RNA and cDNA synthesis 
The cDNAs encoding human IKKα and IKKβ, were amplified from cDNA 
synthesised from Jurkat T cells. To do this, we first isolated total cellular RNA using 
RNeasy mini kit (Qiagen) according to the manufacturer’s instructions. Next, mRNA was 
reverse transcribed to cDNA using the qScript® II cDNA SuperMix (Quanta 
BioSciences). Reverse transcription-PCR reaction mixtures and parameters are shown 
below in Table 2.12. Finally, 2 µl of the cDNA/RNA sample was used as template to 
amplify IKKα and IKKβ cDNAs by means of a standard PCR reaction. 
Table 2.12. RT-PCR reaction mixtures (top) and thermocycler parameters (bottom). 
Component Volume added 
qScript cDNA SuperMix 4 µl 
RNA template 1 µg (whatever the volume) 
Nuclease-free water to 20 µl 
Total volume 20 µl 
 
Cycle Temperature Time 
Annealing 25oC 5 min 
Elongation 42oC 30 min 
Denaturation 85oC 5 min 
Hold 4oC ∞ 
 
2.2.10  DNA sequencing  
DNA sequences were verified, using standard or customised primers, at the 
University College London or Beckman Coulter sequencing services. The list of 
customised primers is given in Table 2.6. 
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2.3 Tissue culture 
HEK293T cells were used for viral packaging, lentivector titrations and also testing 
of the transgene expression of cloned plasmids. They are highly transfectable cells derived 
from human embryonic kidney cells which stably expresses the large T antigen from 
simian virus 40. The expression of T antigen contributes to episomal maintenance and 
increased replication of vectors containing SV40 origin/promoter (DuBridge et al., 1987; 
Pear et al., 1993). This makes HEK293T ideal target cells for viral preparations, gene 
expression and protein production. 
All adherent growing cell lines including HEK293T, HEK293 and mouse 
embryonic fibroblasts (MEF) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM)(Sigma), supplemented with 10% foetal bovine serum (FBS)(Gibco, Paisley, 
UK), 2 mM L-glutamine (Gibco), 100 U/ml Penicillin and 100 µg/ml Streptomycin 
(Gibco). These cells were grown at 37 oC in a 10% CO2 incubator and passaged every 2-3 
days, using Trypsin/EDTA (Sigma). The wild-type and MEKK3 KO MEFs were kindly 
provided by Prof. Philip Cohen (University of Dundee, Scotland). 
Jurkat SVT35 cells and the 70Z/3 Pre-B cell line were cultured in Roswell Park 
Memorial Institute (RPMI) medium, supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/ml Penicillin, 100 µg/ml Streptomycin and 50 µM 2-Mercaptoethanol (Gibco). 
These cells were grown in a 5% CO2 incubator and passaged 1:10 (70Z/3) or 1:5 (Jurkat) 
every 3 days. The 70Z/3 and Jurkat SVT35 cells as well as their respective NEMO-
deficient derivatives, 1.3E2 (Yamaoka et al., 1998) and JM4.5.2 cell (Harhaj et al., 2000), 
were kind gifts of Prof. Alain Isräel (Pasteur institute, Paris, France). 
All cell lines were frozen in FBS containing 10% dimethyl sulfoxide (DMSO) at a 
density of 4-8 x106 cells/ml. Cell counting was performed either manually by use of a 
Neubauer chamber slide, or by using the Muse® cell analyser (Millipore).  
2.4  Lentivectors 
2.4.1 Lentiviral transfer plasmids 
In this study, the pDual promoter lentivector backbone which has been previously 
described by our group (Arce et al., 2009; Rowe et al., 2009), was used. This construct 
incorporates two expression cassettes controlled by the spleen focus-forming virus 
(SFFV) and ubiquitin (Ub) promoters (Figure 2.1A). The SFFV promoter drives the 
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expression of a target gene (e.g, vFLIP or NEMO) while the Ub promoter initiates the 
expression of a fluorescent protein (emerald green fluorescent protein (eGFP) or 
mCherry). 
The cDNA template of transgenes were amplified using reverse and forward 
primers with incorporated 5' BamHI and Kozak sequences (forward) and 3' NotI site 
(reverse), and then were subcloned into BamHI-NotI restriction sites under the control of 
the SFFV promoter. If the BamHI site was present within the gene of interest, the BglII 
site was used which gives compatible cohesive ends. If this was not applicable either, a 
pDual vector encoding AsiSI and NotI insertion sites (provided by Dr. Gary Britton), was 
used. Sequences of primers used for amplification of the transgenes have been listed in 
Table 2.4. 
cDNA sources 
cDNA templates were from the following sources: p22-FLIP and non-cleavable 
cFLIPL (Prof. Inna Lavrik, DKFZ, Germany), WT cFLIPL (Prof. Pascal Meier, ICR), 
RIP1 and FADD (Prof. Henning Walczak, UCL), CYLD (Addgene plasmid depositary), 
mCherry and firefly luciferase (Dr. David Escors). E.coli expressing plasmids encoding 
human cFLIPS cDNA (Clone ID: IHS1380-212917810) was obtained from Open 
Bioystems (Thermo Scientific). Human IKKα and IKKβ cDNAs were isolated from a 
cDNA pool synthesised from Jurkat cells. 
2.4.2 Vector production 
Lentivectors (LV) were generated by a 3-plasmid transient co-transfection of 
HEK293T cells using a transfer vector, a 2nd generation HIV-derived packaging plasmid 
(p8.91) and a plasmid expressing vesicular stomatitis virus-glycoprotein (VSV-G) envelope 
(pMD.G). The p8.91 and pMD.G vectors were obtained from Plasmid factory (Bielefeld, 
Germany) and have been described previously (Demaison et al., 2002) (Figure 2.1B and 
C). 
One day prior to transfection, 107 HEK293T cells were seeded in 15 cm2 dishes to 
reach a cell confluency of 70-80% the following day. Cells were then transfected using the 
FuGENE® HD transfection reagent (Promega) with the following mixture of 
components (per plate): 
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Table 2.13. Components of transfection mixture for LV production (amounts for a 15 
cm plate) 
Reagent Quantity 
LV transfer plasmid 3.75 µg 
p8.91 2.5 µg 
pMD.G 2.5 µg 
FugeneHD 45 µl 
Opti-MEM (Gibco) 500 µl 
 
The mix was incubated at room temperature for 20 minutes and then added 
dropwise to cells in fresh DMEM. Twenty-four hours later the medium was changed and 
subsequently, three collections were made at day 2, 3 and 4 post-transfection. 
Supernatants containing lentiviral particles were then passed through 0.45 µm filters and 
concentrated 200-fold by ultra-centrifugation (20,000 RPM, at 4 oC for 2 hours) in a 
Sorvall centrifuge (Beckman Coulter). Viral pellets were then resuspended in ice-cold 
whole medium, incubated on ice for 1-2 hours and finally, aliquoted and stored at -80 oC, 
until use. 
2.4.3 Viral titrations 
Titration of LVs expressing a fluorescent protein (usually GFP or mCherry) was 
performed using flow cytometry technique, while for those lacking a fluorescent protein 
gene, quantitative PCR (qPCR) method was used. 
2.4.3.1 LV titrations by flow cytometry 
2x105 HEK293T cells were seeded in 24-well plates in 0.5 ml of DMEM, three to 
four hours before transduction. Cells were then transduced with serial dilutions (1 in 5, 
25, 125, 625 and 3125) of the prepared lentiviral particles. Twenty-four hours later, plate 
wells were topped up with an additional ml of medium. Three days following 
transduction, cells were harvested, washed in PBS twice, pelleted in FACS tubes (1,500 
RPM, at 4oC for 5 min) and resuspended in 300 µl of PBS. Subsequently, the percentage 
of fluorescent protein-expressing cells was quantified by flow cytometry using LSR-
Fortessa® cell analyser (BD Biosciences) and BD Diva software. Dilutions which resulted 
in 10-30% transduction rate –which fall within the linear range of the titration graph- were 
used to calculate virus titrations using the following formula: 
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2.4.3.2 LV titrations by qPCR 
This titration method calculates the number of integrated vector copies per cell. 
2x105 of HEK3293T cells were plated out in 24-well plates and transduced with 2-5 µl of 
LV. Three days post-infection, genomic DNA was extracted using DNeasy® Blood and 
Tissue kit (Qiagen) and quantified by Nanodrop. Standards containing 101 to105 copies of 
pHV per µl were prepared. We used primers and fluorescent Taqman probe which 
recognise the HIV leader sequence. Reactions were performed in duplicates using 
Realplex Eppendorf mastercycler. The PCR program included an initial step of 90 oC for 
10 min, followed by 40 cycles of 90 oC for 1 min and 60 oC for 10 min. Finally, the 
number of cells was estimated from extracted gDNA concentration and then, based on 
the standard curve values, number of integrant copies per cell was calculated. The 
oligonucleotide sequences and the amount of reagents used for each reaction have been 
summarised in the following table.  
Table 2.14. Components of qPCR reaction for titration of lentivectors. 
Reagent Quantity/rxn Sequence 
FW primer (GT248) 0.5 µl 5’ tgtgtgcccgtctgttgtgt 3’ 
RS primer (GT 249) 0.5 µl 5’ gagtcctgcgtcgagagagc 3’ 
Strong stop probe 0.25 µl FAM 5’cagtggcgcccgaacaggga3’ TAMRA 
Quantitect Master 
Mix 
12.5 µl  
ddH2O 8.25 µl  
Sample (Std or 
unkown) 
2 µl  
Total 25 µl  
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2.4.4 Cell transductions 
Unless otherwise stated in the figures, cells were infected with lentiviral vectors at the 
following multiplicity of infection (MOI): HEK293/293T (10), Jurkat cells (20), MEFs 
(50) and 70Z/3 cells (100). At least 24 hours were allowed for the transgene expression 
before performing the functional assays. 
 
Figure 2.1. Lentiviral constructs. A) pDual vector. B) 2nd generation packaging plasmid. 
C) Envelope-expressing vector. D) pGIPZ. E) pHIV-SIREN. CMV: cytomegalovirus, 
cPPT: central polypurine tract, HygroR: hygromycin resistance gene, IRES: internal 
ribosome entry site, LTR: long terminal repeat, PuroR: puromycin resistance gene, RRE: 
rev response element, SFFV: spleen focus-forming virus, tGFP: turbo GFP, Ub: 
ubiquitin. VSV-G: vesicular stomatitis virus-glycoprotein, WPRE: woodchuck hepatitis 
virus post-transcriptional regulatory element, Ψ: packaging signal. 
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2.5  Generation of stable knock-down cell lines 
Short hairpin RNA (shRNA)-expressing lentivectors were produced using pGIPZ 
lentiviral plasmids (UCL Open Biosystems shRNA library). Alternatively, custom shRNA-
encoding sequences were designed and cloned into pHIV-SIREN lentivector backbone 
(modified from pSIREN RetroQ, Clonetech).  
2.5.1 pGIPZ 
pGIPZ plasmids contain CMV promoter driving the transcription of turboGFP 
marker gene which is followed by an IRES (Internal Ribosome Entry Site), Puromycin 
resistance gene and  an shRNA-encoding sequence within a microRNA30 context (Figure 
2.1D). HEK293T cells were transduced with shRNA lentivectors (normally 5-7 targeting 
viruses for each protein) at an MOI of 50 and 48 hours later, Puromycin was added to 
medium at 1µg/ml concentration to select infected cells. A non-silencing and a GAPDH-
targeting lentivectors were produced and tested alongside gene-specific shRNAs as 
negative and positive controls, respectively. Finally, the knockdown of protein expression 
was analysed by immunoblotting. 
2.5.2 pHIV-SIREN 
If pGIPZ constructs did not result in a successful knockdown or a different 
selection marker was needed, customised shRNA expressing oligonucleotide pairs were 
designed using Clonetech’s online shRNA target finder and shRNA designer softwares 
and then, subcloned into the pHIV-SIREN backbone. Upon hybridisation, 
oligonucleotides designed by this software produce 5' EcoRI and 3' BamHI sticky ends 
which can be then ligated into the compatible sites within the destination vector.  
The pHIV-SIREN is a bicistronic lentiviral construct designed to express a shRNA 
using the human U6 promoter and a selection marker gene (GFP, or Puromycin, or 
Hygromycin) driven by the phosphoglycerate kinase (PGK) promoter (Figure 2.1E). 
Selection of cells with HygromycinB (HygroGold®, Source Biosciences) was performed 
for two weeks at a concentration of 200 µg/ml. Cells transduced with GFP-expressing 
LVs were isolated by fluorescence-activated cell sorter (FACS). 
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2.5.3 shRNA sequences 
Table 2.15. shRNA-targeted sequences. 
Targeted Gene Ref Seq shRNA# Clone number Sequence (5'→3')  
Atg3 (Hs) NM_022488.4 1 V2LHS_201190 cattgaccatattcatcaa ● 
  2 V2LHS_14033 ggacttatatgtttatgca ● 
  3 V2LHS_11836 cagccttacttgtttaata  
  4 V3LHS_319838 aagctgtcattccaacaat  
  5 V3LHS_319835 tggaaaataaggacaatat  
Caspase-8 (Hs) NM_001228.4 1 V2LHS_112731 gtcatcctgggagaaggaa  
  2 V2LHS_112733 cctactttcacactaagaa  
  3 V2LHS_112730 gagctgctcttccgaatta  
  4 V3LHS_320399 gggtggttattgaaagtaa ● 
  5 V3LHS_398368 tgcacagtagagcaaatct ● 
  6 V3LHS_398369 gcaacaaggatgacaagaa  
FADD (Hs) NM_003824.3 1 V2LHS_16975 caggacgaattgagataat ● 
  2 V2LHS_16973 cgggatctcgtatctttaa  
  3 V3LHS_388202 ccgatgtcatggaactcag  
  4 V3LHS_412699 tgcaattctacagtttctt  
  5 V3LHS_388204 aggctggctcgtcagctca  
  6 V3LHS_388203 tgaccgagctcaagttcct  
  7 V3LHS_412698 aagatcttgtctccactaa ● 
HOIL-1 (Hs) NM_006462.4  pHIV-SIREN ccacaacactcatctgtcaaa ● 
HOIP (Hs) NM_017999.4 1 V3LHS-399213 agctgctgtgctatgttcc ● 
  2 V3LHS-399214 agcacggaggtgatgtgtc  
  3 V3LHS-399210 tggcgtggtgtcaagttta  
  4 V3LHS-399212 tgccgagtgatagagcaga  
MEKK3 (Hs) NM_203351.1 1 pHIV-SIREN cctggatatgagaccatga ● 
  2 pHIV-SIREN gagtgacgtcagaatcaag  
  3 V2LHS_1970 gcattgaactcaatcatga  
  4 V2LHS_151699 caaatgtcatgctgcctta  
  5 V2LHS_151695 ctgaccatcttcatggagt ● 
  6 V3LHS_329522 tcggtgaaagaccagttga  
  7 V3LHS_329524 agacacaggtcactcaaat  
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  8 V3LHS_329521 accaagatgatcttgataa  
  9 V3LHS_329520 agaatcaagttcgagcaca  
RIP1 (Hs) NM_003804.3 1 V2LHS_241668 cagttgataatgtgcataa  
  2 V2LHS_17422 accaacagatgaatctata  
  3 V3LHS_638037 agagtaaactccaagacga ● 
  4 V3LHS_638038 acagagaagtcggatgtgt  
  5 V3LHS_638034 agctgctaagtaccaagct  
  6 V3LHS_638036 tgggcgatatttgcaaata  
  7 V3LHS_645251 tgaagtggacgcctcactt  
  8 V3LHS_638040 accactagtctgacggata ● 
  9 V3LHS_340514 gcgagatggactgaaagaa  
SHARPIN (Hs)  1 pHIV-SIREN gtgttctcagagctcggtttc  
  2 pHIV-SIREN ctgtccttcctgcaccttcat ● 
  3 pHIV-SIREN tggaaacttgacggagaga  
TAK1 (Hs) NM_003188.3 1 V2LHS-153758 cagatgagccattacagta  
  2 V2LHS-201931 cctttggagttgtttgcaa ● 
  3 V2LHS-201612 cgcccttcaatggaggaaa  
  4 V2LHS-202210 cgtgtgaaccatcctaata ● 
  5 V3LHS-370925 agagtgaatctggacgttt  
  6 V3LHS-370924 agcttttagatgaaaacaa  
  7 V3LHS-370923 aggtagtaattacagtgaa ● 
TAK1 (Mm) NM_172688.3 1 pHIV-SIREN cctgaacttcgaagagatc  
  2 pHIV-SIREN cgaagagatcgactacaag  
  3 pHIV-SIREN ctgagaggaaggctttcat  
  4 pHIV-SIREN gcctgaatccagtatgtct ● 
GAPDH (Hs) NM_0012897
45.1 
  ccctcatttcctggtatgacaa ● 
non-silencing    atctcgcttgggcgagagtaa ● 
Hs: Homo sapiens, Mm: Mus musculus, RefSeq#: Reference sequence number  
● indicates the shRNAs resulting in the highest knockdown efficiency.  
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2.6  Western blotting 
Cells were washed twice with ice-cold PBS and then lysed by adding PBS-T lysis 
buffer (PBS containing 1% Triton X100 and 5% Glycerol, supplemented with complete 
protease inhibitor cocktail (Roche Diagnostics)) and incubating on ice for 10-15 min. 
After this, whole cell lysates were clarified by centrifugation at 13,000 RPM, 4 oC for 20 
minutes. The supernatants were transferred to new tubes and quantified for total protein 
concentration using bicinchoninic acid (BCA) colorimetric assay (Pierce® BCA protein 
assay kit, Thermo Scientific, Rockford, IL). After adjusting samples for equal protein 
concentrations, they were mixed with 4x Laemmli sample buffer and boiled at 95 oC for 5 
minutes.  
30-50 µg of the prepared samples were subjected to electrophoresis in a 4% SDS-
polyacrylamide stacking gel, followed by an 8-12% SDS-polyacrylamide separating gel at 
120 Volts for 2 hours. The separated proteins were transferred to polyvinylidene 
difluoride (PVDF) membrane using semi-dry transfer system and subsequently blocked 
with 5% skimmed milk in PBS-T (PBS with 0.1% Tween20) for an hour. Next, it was 
incubated overnight at 4 oC with appropriate dilution of a primary antibody in PBS-T 
containing 5% BSA and 0.1% Na3N. The membrane was washed in PBS-T five times for 
5 minutes and incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibody in PBS-T with 5% non-fat milk for an hour at room temperature. After 
thoroughly washing the membrane as stated above, it was incubated with LumiGLO® 
ECL (Cell Signalling Technology) for a minute and then, drained and exposed to 
Hyperfilm ECL (Amersham). 
For reprobing with another antibody, membrane was incubated with stripping 
buffer for up to 45 minutes at 55 oC to denature both primary and secondary antibodies. 
This was followed by multiple washing steps with dH2O and PBS-T. Membrane was then 
blocked for one hour and the immunoblotting procedure was continued as explained 
above. The buffers and antibodies used for immunoblotting have been summarised in 
Table 2.14 and Table 2.2, respectively. 
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Table 2.16. Western blot buffers and gel reagents 
Buffer/gel Composition 
Laemmli sample buffer 50 mM Tris, pH6.8 
 10% Glycerol 
 2% SDS 
 5% 2-Mercapthoethanol 
 0.2 mg/ml Brumophenol blue 
 0.1 M DTT 
Running buffer 25 mM Tris, pH8.5 
 200 mM Glycine 
 0.1% SDS 
Transfer buffer 100 mM Tris, pH6.8 
 200 mM Glycine 
 20% Methanol 
Stripping buffer 62.5 mM Tris-HCl, pH6.8 
 2% SDS 
 100 mM 2-Mercaptoethanol 
4% stacking polyacrylamide gel 125 mM Tris-HCl, pH6.8 
 4% Acrylamide/bis 
 10% SDS 
 0.1% TEMED 
 1% Ammonium persulphate (APS) 
10% separating polyacrylamide gel 125 mM Tris-HCl, pH8.8 
 10% Acrylamide/bis 
 10% SDS 
 0.1% TEMED 
 1% APS 
 
2.7  Immunoprecipitation 
After washing twice with ice-cold PBS, cells were lysed with PBS-E lysis buffer 
(PBS containing 1% TritonX100, 2 µM EDTA and complete Protease inhibitor cocktail) 
and incubated on ice for 15 minutes. The cell lysate were clarified as mentioned above and 
pre-cleared by incubating with beads for an hour at 4 oC. The pre-cleared lysate was 
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incubated with 1:100 dilutions of the desired antibody (test or isotype-matched control) 
plus 20 µl of ProteinA or G slurry beads at 4 oC for 2 hours while rotating. Next, beads 
were pelleted by centrifugation at 2,000 RPM for 2 min and washed twice with the high 
salt wash buffer (recipe in Table 2.17) followed by two additional washes with the PBS-E 
solution. Immune complexes were dissociated by adding 20 µl of 2x Laemmli buffer and 
boiling at 95 oC for 5 minutes. Finally, co-immunoprecipitation results were analysed by 
western blotting. 
2.8  In vitro IKK kinase assay 
Cytoplasmic extracts were prepared using kinase lysis buffer (see Table 2.17) and 
quantified for protein concentration using BCA method. 500-1000 µg of lysates were 
incubated with 20 µl Protein A sepharose beads and 1 µg anti-NEMO (sc-8330, Santa 
Cruz) for at least 2 hours at 4 oC. Beads were then washed in 0.5 ml of high salt wash 
buffer three times, 5 minutes each, followed by two more washes with kinase wash buffer. 
After removing all the residual wash buffer, 40 µl kinase reaction buffer plus 2 µg GST-
IκBα (1-54) and 0.5 µl p32γ-ATP was added to each sample and tubes were immediately 
incubated at 30 oC for 30 min. Reactions were stopped by adding 15µl 4x Lammeli buffer 
and incubating the tubes at 95 oC for 5 min. The samples were separated by 10% SDS-
PAGE which was then dried out on a filter paper and exposed to a storage phosphor 
screen (GE Healthcare) for 15-30 minutes. To visualise the radiolabelled bands, the 
storage phosphor screen was scanned using Typhoon PhosphorImager (GE Healthcare) 
and the intensity of bands were quantified by ImageQuant TL 7.0 software (GE 
Healthcare).  
Table 2.17. Composition of kinase assay buffers. 
Buffer Composition 
Kinase lysis buffer 20 mM Tris-HCl, pH7.5 
 150 mM NaCl 
 1% Triton X-100 
 5% Glycerol 
 1 mM PMSF 
 Protease inhibitor cocktail 
High salt wash buffer 25 mM Tris-HCl, pH7.6  
 500 mM NaCl  
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 1 mM EGTA 
 1 mM DTT  
 1% Triton X-100 
 5% Glycerol 
 1 mM Na3VO4 
 10 mM β-glycerophosphate 
 5 mM NaF 
 1 mM PMSF 
Kinase wash buffer 20 mM HEPES, pH7.6 
 50 mM NaCl 
 20 mM β-glycerophosphate 
 0.5 mM DTT 
 1 mM PMSF 
Kinase reaction buffer 20 mM HEPES, pH7.6 
 50 mM NaCl 
 10 mM MgCl2 
 2 mM DTT 
 20 µM ATP 
 0.1 mM Na3VO4 
 
2.8.1 Expression and purification of GST-IκBα(1-54) 
First, IκBα(1-54) was PCR-amplified using the primers FW: 
5'ggatccgccatgttccaggcg3' and RS: 5'gaattctcagaggcggatctcctg3', containing BamHI and 
EcoRI restriction sites (underlined), respectively. The PCR product was cloned into 
pJET1.2, sequence-verified and then digested and subcloned into the pGEX-2T vector 
(kindly provided by Dr. Pablo Rodriguez, UCL Cancer Institute).  
Next, BL21 bacteria (NEB) were transformed with pGEX-2T-IκBα, streaked onto 
ampicillin LB-agar plates and grown overnight. A single colony was picked and grown at 
37 °C in 100mL LB-broth containing 50 µg/ml ampicillin and 2% glucose until an 
absorbance of 0.4 to 0.5 at 600nm was reached. The bacterial culture was then induced by 
addition of 2mM isopropyl-β-thiogalactopyranoside (IPTG) for 3 hours at 37 °C. To act 
as a negative control, 5 ml of culture was be removed before induction and grown along 
with the induced culture. After incubation time, cultures were harvested by centrifugation 
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at 4,000 RPM for 10 minutes. The pelleted bacteria were then resuspended in B-PER 
Bacterial Protein Extraction Reagent (Pierce, ThermoSceintific), at 4 ml per gram of 
bacterial pellet, to lyse and release the GST fusion protein. Subsequently, the lysates were 
ultra-centrifuged at 20,000 RMP for 20 min at 4 oC to remove the bacterial debris. The 
supernatant was removed for purification with the pellet being resuspended in PBS for 
SDS-PAGE analysis after protein purification. 
The supernatant was transferred to a 1 ml Glutathione Spin Column (Pierce) and 
the GST-IκBα was purified following the manufacturer’s instructions (the protocol states 
that 3 fractions of eluted protein are produced with a possible 10 mg of protein being 
purified). Following the elution of the GST-IκBα from the spin column, the elution 
fractions, lysate, lysate supernatant and flow-through samples were subjected to SDS-
PAGE and coomassie stained to determine the presence of the protein (Figure 2.2) After 
confirming the presence of GST-fusion proteins,  the samples were dialysed to remove 
glutathione and other sample contaminants, using the 10 kDa molecular weight cut-off 
Vivaspin® columns (Millipore) and a dialysis buffer (20mM Tris-HCl, pH8.0, 100mM 
NaCl, 0.2mM EDTA, 10mM β-glycero-3-phosphate and 10% glycerol). Finally, the 
protein samples were adjusted to a concentration of 1 µg/µl and stored at -80 oC until use. 
 
Figure 2.2. Expression and purification of the GST-IκBα. 
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2.9  In vitro IκBα phosphorylation assay 
Resting HEK293T cells were lysed in HTX lysis buffer (10mM HEPES pH7.4, 
10mM MgCl2, 1mM MnCl2, 0.1mM EGTA, 0.5% Triton X100) supplemented with 
complete protease inhibitor cocktail (Roche) and the S100 fractions were prepared by 
sequential centrifugation at 1,000 and 100,000g for 5 and 45 minutes, respectively. The 
cleared lysates were then incubated with recombinant FLIP and ATP generating system 
(10x stock: 10mM ATP, 20mM HEPES pH7.2, 10mM MgCl2, 350mM creatinine 
phosphate and 500 µg/ml creatinine kinase ) for 10 min at 37 oC. The reactions were 
terminated by adding 5x Laemmli buffer and boiling at 95 oC. Eventually, rec-FLIP-
induced IKK activation rate was detected by immunoblotting for downstream indicators 
such as pIkBα and pIKKα/β. Levels of total IKKα/β served as control for equal protein 
loading. 
2.9.1 Purification and expression of recombinant vFLIP, p22-FLIP and GB1-
p22FLIP 
Recombinant vFLIP was overexpressed and purified as described in Bagnéris et al 
(Bagnéris et al., 2008). For the production of recombinant p22-FLIP (and GB1-p22-
FLIP), cFLIPS was first PCR amplified from a human thymus cDNA library (Clontech) 
using the primers 5'ttgctagcatgtctgctgaagtc3' and 5'ttctcgagtcacatggaacaatttc3' containing 
NheI and XhoI restriction sites respectively (underlined). Following digestion, the product 
was then ligated into the pETM442 vector (described in (Bagnéris et al., 2008)) to provide 
an N-terminal 6His-NusA tobacco etch virus (TEV) protease cleavable solubility tag to 
aid expression and purification. The resulting pETM442-cFLIPS vector was then used as 
the template for production of pETM442-p22-FLIP which was generated by the 
introduction of a stop codon at D196 using the primers 
5'tccaaaagagtctcaagtagccttcaaataacttcaggat3' and 
5'atcctgaagttatttgaaggctacttgagactcttttgga3'. GB1-p22-FLIP was produced by subcloning 
p22-FLIP into the EcoRI and XhoI restriction sites of a modified pET15b vector (kind gift 
from Prof Paul Driscoll, NIMR) to produce pET15-GB1-p22-FLIP (containing a 6His-
GB1 solubility tag). The original pET15b vector was modified by inclusion of the coding 
sequence for the 56 amino acid B1 domain of E.coli protein G (GB1) 5’ to the multiple 
cloning site (MCS), the addition of an EcoRI restriction site directly 3’ to GB1 and 
removal of the MCS EcoRI site. This enabled subcloning of p22-FLIP 3’ to GB1 into the 
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new EcoRI and existing XhoI sites. pETM442-p22-FLIP and pET15-GB1-p22-FLIP were 
then transformed into BL21(DE3) star® cells (Invitrogen).  
The cultures were then inoculated into LB medium containing ampicillin (100 
µg/ml) at a ratio of 1:100 and grown to an OD600 of between 0.6-0.8. They were 
subsequently induced with 1mM IPTG and the temperature reduced to 16°C overnight. 
Cells were harvested by centrifugation and the pellets either frozen at -80°C or re-
suspended in a buffer comprising 25mM Tris-HCl pH 8.5, 200mM NaCl (buffer A) 
supplemented with an EDTA free protease inhibitor complex tablet (Roche) and DNase I 
(10 µg/ml). The purification protocols used for p22-FLIP and GB1-p22-FLIP were near 
identical. Resuspended pellets from 8L cultures of both proteins were sonicated on ice 
and the lysates clarified by centrifugation (46,000g for 1 hour). Supernatants were 
subsequently filtered through a 0.45 µm filter prior to loading on HisTrap FF columns 
(GE Healthcare) pre-equilibrated with buffer A. These were then washed with buffer B 
(A and 20mM imidazole) and eluted with buffer C (A and 500mM imidazole). For p22-
FLIP, the 6His-NusA tag originating from the pETM442-p22-FLIP construct was 
removed by incubating 6His-NusA-p22-FLIP with TEV protease overnight while 
dialysing in buffer A (to remove the imidazole) and the solution reapplied to a 5ml 
HisTrap FF column pre-equilibrated in buffer A. p22-FLIP was eluted from the column 
using buffer A and 40mM imidazole. Fractions having greater than 95% purity as judged 
by SDS-PAGE gels were subsequently pooled and frozen at -80°C. Following elution 
from the 5ml HisTrap column, GB1-p22-FLIP appeared to be over 95% pure. To 
improve stability, however, GB1-p22-FLIP was subsequently dialysed into a buffer 
containing 5mM L-arginine, 300mM NaCl, 5mM TCEP and 25mM Imidazole prior to 
concentration using a 6ml, 10 kDa molecular weight cut-off Vivaspin concentrator 
(Millipore) and storage at -80 °C. 
2.10 Immune complex dephosphorylation 
Immunoprecipitated complexes were dephosphorylated using the Lambda protein 
phosphatase (LPP). This is an Mn2+-dependent phosphatase with activity towards 
phosphorylated serine, threonine and tyrosine residues (Zhuo et al., 1993). Reactions were 
performed at 30 oC for 30 minutes, in a final volume of 50 µl using varying amounts of 
LPP (NEB) and Protein MetalloPhosphatase reaction buffer (50mM HEPES pH7.5, 10 
mM NaCl, 2 mM DTT, 0.01% Brij35 and 1 mM MnCl2). Subsequently, the reactions were 
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terminated by adding 25 mM Na3VO4  (Gordon, 1991) and 20 mM NaF, followed by 
cooling the samples on ice.  
2.11  Luciferase gene reporter assays 
Depending on the transfectability of the tested cell types, NF-κB luciferase assays 
were performed either by transfections or by viral transductions. 70Z/3, MEFs and Jurkat 
cells were mainly transduced while for HEK293 and HEK293T cells both transductions 
and transfections were utilised. 
2.11.1 NF-κB reporter luciferase assays by transfection 
One day prior to transfection, 2x105 of HEK293 or 105 of HEK293T cells were 
seeded in 24-well plates in total volume of 500 µl. Then, cells were transfected with 400 
ng of NF-κB luciferase plasmid (pGL.IgK or pGL H2DK), 100 ng of pRL.TK as internal 
control and 500 ng of pCDNA3 vectors encoding a transactivator gene. Twenty-four 
hours later the medium was removed, cells were resuspended in 100 µl of medium and 
transferred into an optical bottom 96-well plate. Luciferase activity was then measured 
using Dual-Glo® luciferase assay kit (Promega, Madison, WI). First, NF-κB-induced firefly 
luciferase activity was quantified by adding 50 µl of Dual-Glo luciferase reagent, this 
signal then was quenched by adding 50 µl of Stop and Glo reagent which also produces 
stabilised signal from Renilla luciferase. Firefly luciferase activity levels were normalised to 
that of Renilla which is driven by thymidine kinase promoter of herpes simplex virus and 
serves as transfection efficiency control. 
2.11.2 NF-κB reporter luciferase assays by transduction 
HEK293/293T, Jurkat, MEFs and 70Z/3 cells were transduced with NF-κB 
luciferase lentivectors at MOIs of 10, 50, 100 and 500, respectively to generate the stable 
NF-κB-reporter cell lines. These cells were passaged at least 2-3 times before performing 
assays. Next, to assess NF-κB activity, 5x104 cells were seeded in optical bottom 96-well 
plate and transduced with test lentivectors at MOIs of 10, 20, 50 and 100 for 
HEK293/293T, Jurkat, MEFs and 70Z/3 cells, respectively. Forty-eight hours later, 50 µl 
BrightGlo® luciferase substrate (Promega) was added to each well and NF-κB-induced 
luminescence was detected using Varioskan Flash multimode reader (Thermo Scientific). 
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2.12 Statistical analysis 
Statistical differences between two groups were analysed by the two-tailed unpaired 
student’s t -test using the GraphPad Prism v4.03 software package (Graphpad Sotware, La 
Jolla, CA). The calculated P-values are given in the figures. All experiments were 
performed in triplicates, on at least three independent occasions (unless otherwise stated). 
The quantitative data are presented as mean±SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
 
 
CHAPTER  
3 
 
3. The Role of NEMO in IKK Activation by 
KSHV vFLIP and Cellular FLIPs 
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3.1 Introduction 
Constitutive activation of NF-κB signalling is linked to cancer development and 
progression by providing an inflammatory environment for tumour cells and conferring 
resistance to apoptosis (DiDonato et al., 2012). The oncoproteins KSHV vFLIP and 
HTLV-1 Tax stably bind to NEMO and constitutively activate the IKK complex, 
contributing to the neoplastic character of the associated viruses. Cellular FLIPs, which 
share a high degree of sequence homology with KSHV vFLIP (Figure 1.4), are also strong 
inducers of the NF-κB cascade (Hu et al., 2000). These proteins become upregulated in a 
variety of malignancies and are promising targets for cancer therapies (Shirley and 
Micheau, 2010). Much is known about the role of cFLIPs in the regulation of cell death 
pathways; however, how they activate NF-κB remains elusive. Potential similarities to 
vFLIP-induced activation have been suggested, but not investigated.  
The crystal structure of the vFLIP-NEMO complex has been solved and multiple 
lines of evidence exist that indicate the necessity of binding to NEMO for the vFLIP-
mediated induction of IKK (Bagnéris et al., 2008; Field et al., 2003; Liu et al., 2002). It is 
not clear how this interaction leads to activation. In this chapter, we aimed to explore the 
role of NEMO in FLIP-induced IKK activation with a particular emphasis on the 
ubiquitin binding function of NEMO. The UBAN domain of NEMO is indispensable for 
cytokine-induced IKK activation and has been shown to undergo conformational changes 
upon binding to linear ubiquitin oligomers (Bloor et al., 2008; Rahighi et al., 2009). Our 
initial working hypothesis was that vFLIP binding to NEMO may cause similar 
conformational changes, leading to changes in proximity or conformation of the catalytic 
IKKα and IKKβ, in favour of the activation. Therefore, we first set out to determine 
whether FLIP proteins required ubiquitination and the ubiquitin binding activities of the 
NEMO to stimulate IKK, or whether binding to NEMO was sufficient to bypass these 
processes. 
In the following sections, I provide a brief description of the key IKK-dependent 
functions of the NEMO and also, a summary of the current knowledge on the interaction 
of NEMO with vFLIP, Tax and cellular FLIPs. 
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3.1.1 Molecular control of IKKs by NEMO 
3.1.1.1 NEMO mediates the Ub-dependent activation of IKK 
Activation of the canonical NF-κB pathway is contingent upon non-degradative 
polyubiquitination. NEMO plays a crucial role in ubiquitin-mediated activation of the 
IKK complex as it specifically recognises polyubiquitin chains through its UBAN domain 
and also, becomes ubiquitinated itself (Tokunaga et al., 2009; Wu et al., 2006a).  Cells 
expressing NEMO mutants defective in Ub-binding exhibit impaired activation of 
IKKα/β in response to IL-1 and TNFα (Ea et al., 2006; Windheim et al., 2008; Wu et al., 
2006a). Importantly, similar mutations of the UBAN domain of NEMO are found in 
patients afflicted with EDA-ID and IP, emphasising the essential role of this domain in 
vivo (Hubeau et al., 2011; Smahi et al., 2000). 
Initially it was thought that the UBAN specifically binds to K63-linked ubiquitin 
chains (Wu et al., 2006a); later studies, however, demonstrated that it displays 100-fold 
higher affinity for linearly-linked ubiquitin chains (Rahighi et al., 2009; Xu et al., 2011). 
Consistent with these findings, full-length NEMO mutants engineered to selectively bind 
to K63-linked polyubiquitin only weakly activate NF-κB (Kensche et al., 2012). One 
further study, however, demonstrated that despite the much higher preference of NEMO 
C-terminus for linear ubiquitin oligomers, its immobilisation – which may be reminiscent 
of cellular IKK oligomerisation - enhances its affinity towards K63 linkages (Hadian et al., 
2011). Therefore, in cells, both types of these linkages may function in a certain spatio-
temporal order to achieve the maximal levels of NF-κB activation. 
As previously mentioned, activation of the IKKs seems to occur through an 
induced proximity which results from dense organisation of the signalling components or 
structural changes induced by binding of adapter proteins. NEMO-mediated ubiquitin 
binding has been proposed to participate in both processes. 
Upon receptor-mediated activation of the NF-κB, K63-linked ubiquitin chains 
synthesised by E3 ligases such as TRAF2/5 and cIAP1/2 (in TNFα signalling), and 
TRAF6 (in IL-1 signalling), provide a recruitment platform for TAB2/TAK1 and 
NEMO/IKK complex. These K63 ubiquitin chains also recruit LUBAC (Emmerich et 
al., 2013) to generate linear polyubiquitin oligomers on the NEMO and other substrates 
such as RIP1 (Gerlach et al., 2011), resulting in further stabilisation of the signalling 
complex. UBAN-mediated attachment to ubiquitin chains is suspected to enable NEMO 
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to facilitate co-localisation of IKKs with TAK1, leading to phosphorylation and activation 
of the IKKα/β (Clark et al., 2013).  
Alternatively, binding of NEMO to ubiquitin have been suggested to cause IKK 
activation via other mechanisms. Crystal structure studies by Rahighi et al., showed that 
binding of linear di-ubiquitin molecules to the UBAN domain, induces an straightening of 
this coil-coiled region (Rahighi et al., 2009). It was proposed that this conformational 
change may then transmit to the N-terminal regions of NEMO, resulting in the re-
orientation of the catalytic IKKs, favouring activation by autophosphorylation. Relevant 
to this notion, site-specific mutations can be introduced to NEMO (such as K270A in 
murine NEMO) which overcome the need for ubiquitin binding and constitutively 
activate IKK in the absence of any proinflammatory stimuli (Bloor et al., 2008). Such 
mutations may mimic the conformational alterations induced by the binding of the 
ubiquitin oligomers. That said, whether structural changes to NEMO translate to 
allosteric effects on IKKα/β, remains to be demonstrated. 
3.1.1.2 Post-translational modifications of NEMO fine-tune the IKK activity 
In addition to ubiquitination, other post-translational modifications such as 
phosphorylation and SUMOylation, also play crucial roles in modulating the function of 
NEMO (Perkins, 2006). Following NF-κB stimulation, IKKβ phosphorylates NEMO at 
several amino acids, located near the N-terminus and the C-terminus (Carter et al., 2003; 
Palkowitsch et al., 2008; Prajapati and Gaynor, 2002). Notably, phosphorylation of 
serine68 of NEMO, which resides within the IKKα/β-binding domain, disrupts the 
NEMO dimerisation and NEMO-IKKβ interaction (Palkowitsch et al., 2008). 
Accumulating evidence suggest that this modification together with the simultaneous 
authophosphorylation of IKKβ at its C-terminal NBD (Delhase, 1999; Schomer-Miller et 
al., 2006), serve as an intrinsic regulatory mechanism preventing hyperactivation of the 
IKKα/β following stimulation. 
SUMOylation of NEMO is another important post-translational modification, 
found to be critical for its role in the nuclear-initiated NF-κB activation (Miyamoto, 2011). 
In cells, a subset of NEMO exists as an unbound form that shuttles between nucleus and 
cytoplasm. This form of NEMO appears to be essential for connecting the nuclear DNA 
damage events to cytoplasmic activation of IKK. Upon genotoxic stress, nuclear NEMO 
becomes SUMOylated by the SUMO E3 ligase, PIASy (protein inhibitor of activated 
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STAT y) at the lysines 277 and 309 (Huang et al., 2003; Mabb et al., 2006; Stilmann et al., 
2009). This marks NEMO for cIAP1-mediated monoubiquitination at the same lysine 
residues, leading to its nuclear export and subsequent activation of TAK1, IKK and NF-
κB, in a manner that requires ELKS (Huang et al., 2003; Wu et al., 2006b). Interestingly, 
SUMO-fused mutants of NEMO localise in the nucleus, indicating the importance of 
SUMOylation in determining the subcellular localisation of NEMO (McCool and 
Miyamoto, 2012). Taken together, these findings underscore the significance of the post-
translational modifications of NEMO in producing a highly regulated and signal-specific 
NF-κB signalling. 
3.1.1.3 NEMO ensures the substrate-specificity of the IKKβ 
Most studies on NEMO have focused on its well-known role in the activation of 
IKKα/β.  Nevertheless, a recent study showed that constitutively active IKKβ fails to 
activate NF-κB in the absence of NEMO, suggesting that NEMO may have additional 
roles (Schröfelbauer et al., 2012). Further investigations by Schrofelbauer et al., revealed 
that NEMO directs the substrate-specificity of IKKβ towards IκBα, through its ZF 
domain. Not surprisingly, various in-frame deletions and point mutations of the ZF 
domain are associated with the disease, EDA-ID (Cordier et al., 2008).  
IKKα and IKKβ are pleiotropic enzymes which target a broad spectrum of NF-κB-
related (e.g. IκBs, p65, and p105) and NF-κB-unrelated substrates (e.g. β-catenin, FOXO3 
and p53) (Hinz and Scheidereit, 2014). Mutations of NEMO that fail to recruit IκBα, 
result in an increased phosphorylation of p65 and p105 (Schröfelbauer et al., 2012). This 
raises the possibility that NEMO may use distinct regions to target the activity of catalytic 
IKKs to other substrates. In support of this notion, panr2 mice that harbour a L153P 
mutation in NEMO exhibit severe defects in phosphorylation of p65 and p105, despite 
normal phosphorylation and degradation of IκBα (Siggs et al., 2010). Taken together, 
these findings indicate that NEMO is necessary not only for the activation of the IKK 
complex but also to ensure the substrate-selectivity of the enzymatic subunits. 
3.1.1.4 NEMO serves as a docking site for various IKK-regulating proteins 
Activation of IKK is a transient event which depends on dynamic regulatory 
processes to produce an optimal signal. The balance towards activation or deactivation is 
determined by selective recruitment of the upstream co-factors to the IKK complex 
machinery. In this regard, the elongated coiled-coil structure of NEMO provides a 
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docking platform for numerous regulatory proteins. Tables 3.1 gives a summary of such 
proteins which directly or through an adapter protein, interact with NEMO and modulate 
IKK activity.  
Apart from the functions mentioned here, NEMO regulates a plethora of other 
NF-κB dependent (e.g. interferon production) and NF-κB independent mechanisms 
which have been reviewed in (Clark et al., 2013). 
Table 3.1. NEMO-interacting proteins. 
Interactor Interaction region Function Reference 
A20 aa 95-218 inh (Zhang et al., 2000) 
ABIN1 aa 50-100 inh (Mauro et al., 2006) 
ABIN2 aa 174-306 inh (Liu et al., 2004) 
ActI/CIKS aa 1-150 inh (Li et al., 2000; Mauro et al., 2003; 
Qian et al., 2004) 
ATM n.d act (Wu et al., 2006b) 
CARMA1,3 n.d act (Stilo et al., 2004) 
CBP n.d inh (Verma et al., 2004) 
CSN3 aa 297-419 inh (Hong et al., 2001; Rual et al., 2005) 
CYLD ZF inh (Kovalenko et al., 2003; Saito et al., 
2004; Trompouki et al., 2003) 
EHV2 vCLAP aa 300-419 act (Poyet et al., 2001) 
ELKS n.d act (Ducut Sigala et al., 2004) 
HIF-2α aa 50-358 act (Bracken et al., 2005) 
HSP70 aa 25-320 inh (Ran et al., 2004) 
Htt aa 1-134 act (Khoshnan et al., 2004) 
NLRX1 UBAN inh (Xia et al., 2011) 
p47 K63 and linear Ub 
chains bound to 
NEMO 
inh (Shibata et al., 2012) 
PAN1 n.d inh (Bruey et al., 2004) 
PARP1 aa 1-126 act (Stilmann et al., 2009) 
PIASy aa 1-120 act (Huang et al., 2003; Mabb et al., 2006) 
PIDD n.d act (Janssens et al., 2005) 
PP2A aa 121-179 act (Kray et al., 2005) 
PP2Cβ n.d inh (Prajapati et al., 2004) 
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RIP1 UBAN act (Wu et al., 2006a; Zhang et al., 2000) 
SRC3 n.d act (Amazit et al., 2007) 
TANK aa 200-250 (mNEMO) act (Bonif et al., 2006; Chariot et al., 
2002) 
TFG LZ act (Miranda et al., 2006) 
TRAF1/2 n.d act (Devin et al., 2001; Henn et al., 2007) 
TRUSS n.d act (Soond et al., 2003) 
Ubiquitin UBAN act (Bloor et al., 2008; Ea et al., 2006; Wu 
et al., 2006a) 
ZNF216 n.d act (Huang et al., 2004a) 
n.d: not determined, inh: inhibition, act: activation, mNEMO: murine NEMO. 
3.1.2 Interactions of the Tax, vFLIP and cFLIPs with NEMO 
It is now well-established that the persistent activation of the canonical IKKs by 
Tax and vFLIP requires stable assembly with NEMO (Chu et al., 1999; Field et al., 2003; 
Harhaj and Sun, 1999). Although the mechanism by which these interactions lead to NF-
κB activation is still a matter of mystery (See 5.1 for the suggested mechanisms). Using co-
immunoprecipitation assays, Tax has been shown to interact with two distinct but highly 
homologous motifs in NEMO: one in the N-terminus (aa 100-140) and the other, near 
the C-terminus (aa 312-340) (Figure 3.1A) (Xiao et al., 2000). The region of Tax 
responsible for binding to NEMO is localised to a leucine rich repeat (LRR) motif, 
containing amino acid residues 105-141. Site-specific mutations of the LRR domain which 
disrupt binding to NEMO, such as those in the Tax M22 mutant (T130A, L131S), 
abrogate Tax-induced IKK activation. Strikingly, in-frame fusion of the M22 to NEMO 
restores its NF-κB activating function, further emphasising the necessity of interaction 
with NEMO for Tax-mediated IKK activation (Xiao and Sun, 2000; Xiao et al., 2000).  
vFLIP, despite employing a similar mode of IKK activation which depends on 
physical interaction with NEMO, appears to target a different region of NEMO. Studies 
conducted in our laboratory have mapped the vFLIP-binding region of NEMO to its 
HLX-2 domain (residues 192-252) (Bagnéris et al., 2008; Field et al., 2003). Subsequent 
crystal structure studies determined that this region of NEMO forms a parallel 
intermolecular coiled -coil recognised by two vFLIP molecules that interact through their 
respective DED1 motifs (Fig 3.1B and C) (Bagnéris et al., 2008). Interactions of the 
NEMO helices with DED1 is facilitated by the presence of two deep adjacent clefts, of 
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which, cleft1 mediates the majority of the interprotein contacts (Fig 3.1C). Mutating the 
key amino acids of the cleft1-HLX2 interface (e.g. A57L in vFLIP and D242R in NEMO) 
results in complete abolition of the complex formation.   
While some homologues of the KSHV vFLIP (e.g. p22-cFLIP) are similarly potent 
activators of the IKK, others fail to stimulate this complex (e.g. MC159L). This raises the 
possibility that the ability of FLIPs to activate IKK may depend on the conservation of 
structural properties affecting the FLIP-NEMO interface. In support of this concept, 
structural alignment of the KSHV vFLIP and MC159L suggested that the sequence 
differences in the latter, result in obscuring cleft2 and complete closure of cleft1, thereby 
abrogating the NEMO binding (Figure 3.1D). In the case of p22-FLIP, however, there 
are no amino acid substitutions that would lead to major steric clashes and hence drastic 
remodelling of cleft1 and cleft2. Therefore, FLIP-mediated activation of the canonical 
NF-κB pathway may strongly rely on the preservation of the NEMO contacts mediated 
by clefts of the DED1 motif (Figure 3.1D)(Bagnéris et al., 2008). 
Among cFLIP variants, the proteolytic fragments p43-FLIP and p22-FLIP, have 
been reported to directly interact with NEMO (Golks et al., 2006; Neumann et al., 2010). 
p43-FLIP is generated by procapase-8 cleavage of the cFLIPL at the DISC following 
CD95 stimulation (Neumann et al., 2010), however, p22-FLIP can be catalysed from all 
isoforms (cFLIPL/S/R) and differs form p43-FLIP in that it can be also produced in non-
apoptotic cells. Therefore, p22-FLIP is believed to be the final cleavage product of cFLIP 
proteins, serving as the mediator of NF-κB activation, in a manner similar to that of 
KSHV vFLIP (Bagnéris et al., 2008; Golks et al., 2006). Nevertheless, there exists no 
experimental data demonstrating whether p22-FLIP (or any other cFLIP variant) targets 
the same vFLIP-binding region of the NEMO and whether this possible interaction is 
necessary for cFLIP-induced IKK activation.  
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Figure 3.1. Structure of NEMO and its complexes. A) Domain organisation of 
the NEMO and its interaction sites with IKKα/β, vFLIP, ubiquitin and Tax. CC: colied 
coil, HLX: helical domain, LZ: leucine zipper, ZF: zinc finger. B) Crystal structures of 
NEMO fragments. Three-dimensional structure of the full-length NEMO is not available 
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yet; however, the crystal structures of several NEMO fragments have been resolved. 
These include: N-terminal kinase binding domain of NEMO in complex with IKKβ 
(Rushe et al., 2008), HLX2 in complex with KSHV vFLIP (Bagnéris et al., 2008), CC2-LZ 
fragment in complex with linear di-ubiquitin (Rahighi et al., 2009) and ZF domain 
(Cordier et al., 2008). C) The KSHV vFLIP-NEMO interface. Left panel: KSHV vFLIP 
depicted as green surface contains two adjacent vertical clefts in its DED1 motif. Cleft1 
and cleft2, highlighted in magenta and yellow, respectively, are found to form a 
complementary binding surface for NEMO helices. Right panel: two vFLIP molecules are 
seen in complex with a central region of two parallel alpha helices of NEMO. Both clefts 
of the vFLIP are pivotal to the recognition of the NEMO dimer, although, the majority of 
interprotein contacts are mediated by cleft1. D) Structural comparisons of KSHV vFLIP, 
MC159 vFLIP and p22-FLIP. Analysis of the electrostatic potential surfaces of these 
proteins shows that the cleft1 and cleft2 are absent in MC159 vFLIP. However, homology 
model of p22-FLIP suggests that two binding clefts are conserved in this protein and that 
the analogous interactions to those observed with KSHV vFLIP are possible with 
NEMO. Reproduced from (Zheng et al., 2011) and (Bagnéris et al., 2008) with a 
permission from the publishers. 
 
 
3.2 Aims of the chapter 
• Identify the domains of NEMO that are required for IKK activation by vFLIP 
and cellular FLIPs  
• Examine whether cellular FLIPs physically interact with NEMO and if they do, 
which region of the NEMO is targeted 
• Examine the importance of linear ubiquitination in FLIP-induced activation of 
IKK 
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3.3 Results 
3.3.1 Generation of a NF-κB reporter luciferase assay system 
In order to establish a cell-based NF-κB activation assay, we generated a lentiviral 
vector (LV) that allows for NF-κB-dependent transcription of the firefly luciferase under 
the control of the minimal CMV promoter and four repeats of an NF-κB binding site 
(Figure 3.2A). First, to test the specificity of the system, we transduced cells with the 
lentivectors encoding GFP, or vFLIP, or NF-κB luciferase with and without vFLIP or 
GFP (each MOI=10). Forty-eight hours later, cells were lysed and activity of the firefly 
luciferase was measured using Bright-Glo detection system. As shown in Figure 3.2B, the 
IKK activator vFLIP robustly induced expression of luciferase by more than 100-fold 
increase (compared to unstimulated cells), whereas the GFP control failed to induce any 
luciferase activity. Next, to examine the sensitivity of our reporter system, we transduced 
HEK293T cells with increasing MOIs (0.5, 1, 2, 4, 8, 16 and 32) of both NF-κB luciferase 
and vFLIP lentivectors. Figure 3.3C and D show that the levels of luciferase activity 
correlated well with MOIs of the vFLIP LV, except in the condition where MOI of 32 
was used for the NF-κB luciferase LV. Since the transductions of vFLIP and NF-κB 
luciferase were performed simultaneously, this could be due to a competition in viral entry 
between the two LVs at high MOIs. In all the luciferase experiments discussed later, I first 
transduced cells with NF-κB luciferase LV to produce a reporter cell line and then, 
activation assays were performed after at least two cell passages. 
Collectively, the data presented in Figure 3.2 show that our LV-based NF-κB 
activation assay is highly sensitive and specific. An important advantage of this LV-based 
system is that it allows for genetic engineering of poorly transfectable cells (e.g. MEFs) 
that cannot be assessed using conventional reporter assays based on transient transfection. 
Furthermore, working with stable reporter cells can circumvent the problem with 
variations in transfection efficiency that may mask the NF-κB-dependent signal. 
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Figure 3.2. Generation of a cell-based NF-κB reporter luciferase assay. A) 
Schematic representation of the lentiviral construct (pSIN NF-κB Luc) used for the NF-
κB reporter luciferase assays. CMV MP: minimal promoter of cytomegalovirus, cPPT: 
central polypurine tract, LTR: long terminal repeat, NF-κB RE: NF-κB response element, 
RRE: rev response element, SIN: self-inactivating, WPRE: woodchuck post-transcription 
regulatory element. B) NF-κB reporter luciferase assay to check the specificity of the 
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system. HEK293T cells, seeded in 96-well plates (2x104/well) were transduced with 
lentiviral vectors encoding GFP, or vFLIP, or NF-κB luciferase with and without GFP or 
vFLIP. The NF-κB dependent luciferase activity was measured 48 hours post-
transduction. C) NF-κB reporter luciferase assay to check the sensitivity of the system. 
The same number of HEK293T cells, as described in (B), were transduced with LVs 
encoding NF-κB reporter luciferase and vFLIP over a broad range of MOI (0.5, 1, 2, 4, 8, 
16, 32) for each lentivector. Cells were lysed 48 hours following transduction and the 
luciferase activities were measured using Bright GLO luminescence detection kit 
(Promega). The results are represented as RLU (relative luminesce units). D) as in (C), but 
the results have been represented as normalised fold change values, calculated by dividing 
of the RLU of activated cells to RLU of the control cells. 
 
3.3.2 Unlike vFLIP and Tax, cellular FLIPs require Ub-binding function of 
NEMO to activate NF-κB signalling 
To determine which functions of NEMO were necessary for IKK activation by the 
FLIP proteins, we used the NEMO null cell line 1.3E2 - a derivative of the mouse preB 
cell line 70Z/3- harbouring an NF-κB responsive luciferase gene. These cells were 
reconstituted with wild-type  NEMO, a point mutant which does not bind linear ubiquitin 
(F312A, (Rahighi et al., 2009)), or a F238R/D242R mutant suggested by structural studies 
to disrupt vFLIP binding (Bagnéris et al., 2008). To do this, we used lentiviral vectors 
expressing wild type or mutant NEMO together with an mCherry fluorescent protein (See 
Figure 2.1A). Cells were transduced so that approximately 50% were mCherry positive. 
We then isolated cell clones, expanded those that were mCherry positive and performed 
immunoblotting to establish that the transduced cells expressed NEMO (Figure 3.3A). 
Cells were then infected with a second lentiviral vector expressing cFLIP variants (p22-
FLIP, FLIPS, FLIPL), or vFLIP, or Tax together with eGFP. After 48 hrs eGFP was 
monitored and cells with transduction rates over 80% were used to measure luciferase 
activity.  
Figure 3.3C shows that both vFLIP and Tax could activate IKK in the absence of 
its ubiquitin binding function, unlike the control Toll-like receptor agonist 
lipopolysaccharide (Figure 3.3B). In contrast, cFLIPL, cFLIPS, and their proteolytic 
product p22-FLIP all require the ubiquitin binding function of NEMO to activate IKK 
(Figure 3.3D). To our surprise, all cFLIP variants were able to activate vFLIP-binding 
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deficient NEMO, suggesting that cellular FLIPs either target different motifs of NEMO, 
or bind to it indirectly, or function at some upstream step (Figure 3.3D). Activation of 
F238/D242RR mutant by Tax, which binds to distinct regions of NEMO, and also LPS 
further showed that this mutation specifically inhibits vFLIP and does not impair other 
activatory mechanisms (Figure 3.3C). 
As previously mentioned, the Ala57 residue of vFLIP plays an important role in 
binding to NEMO and an A57L mutation reportedly impairs NF-κB inducing activity of 
the protein. The LAE sequence harbouring this alanine is conserved in both KSHV and 
cellular FLIPs (marked with * in Figure 3.4A). To test if this residue was also important 
for the function of cFLIPs, I generated equivalent A56L mutants of all three isoforms and 
performed an NF-κB activation assay on 293T cells. The mutation resulted in almost 
complete inactivation of all FLIPs (Figure 3.4C). However, western blot analysis showed 
low levels of protein expression for vFLIP, p22-FLIP and FLIPS, indicating that this 
mutation renders the proteins unstable (Figure 3.4B). This observation makes the relevant 
results inconclusive; nevertheless, similar protein levels in the case of WT and mutant 
FLIPL suggests that the conserved L57 residue may play a role in NF-κB induction by 
cFLIP variants.  
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Figure 3.3. Mutational studies on NEMO reveal differential NF-κB activation 
mechanisms for the KSHV vFLIP and cellular FLIP isoforms. A) Immunoblot 
showing the expression of NEMO in 1.3E2 cells, 70Z/3 cells and 1.3E2 cells 
reconstituted with wild-type or mutant NEMO. The blot was re-probed for GAPDH to 
ensure even protein loading. B) To generate stable NF-κB reporter cell lines, cells were 
transduced with lentiviral vectors encoding NF-κB responsive luciferase gene (MOI=500). 
The transduced cells were passaged multiple times prior to NF-κB luciferase assays. 
Subsequently, the luciferase reporter assays were performed 6 hours after stimulation with 
LPS (10 µg/ml) or C) 48 hours following transduction with lentivectors encoding vFLIP, 
Tax (MOI=50) and D) cFLIP variants (MOI=100).  Data are representative of three 
independent experiments performed in triplicates. Error bars indicate SD of the mean 
values. 
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Figure 3.4. NF-κB activation by A57L vFLIP and A56L cFLIP isoforms.  A) 
Sequence alignment of the KSHV vFLIP and cFLIP. Amino acid sequences of the 
proteins were retrieved from NCBI protein database and aligned using PRALINE 
multiple sequence alignment software. Accession numbers of the KSHV vFLIP and 
cFLIPS are AAD46498.1 and NP_001120656.1, respectively. Amino acid residues of 
vFLIP predicted by structural studies to be important for vFLIP-NEMO interaction have 
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been shown inside yellow circles. The equivalent conserved residues of cFLIP are 
depicted inside blue circles. Ala57 of KSHV vFLIP (indicated by *) which is essential for 
binding to NEMO and its adjacent amino acids (56-58, LAE) are highly conserved in 
cellular FLIPs. B) HEK293T were seeded in 24-well plates cells (2x105/well) 24 hours 
prior to transfection. Each well was transfected with 400 ng NF-κB firefly luciferase 
plasmid (pGL.IgK), 100ng Renilla luciferase plasmid (pRL.TK) as internal control and 
300ng of pCDNA3 vectors encoding WT, or A57L vFLIP, or A56L cFLIP isoforms. NF-
κB induction levels were measured after 24 hours using Dual-GLO kit (Promega). B) 
Western blot showing the expression of the WT and mutants versions of the vFLIP and 
cFLIP variants. The mutations severely lower the stability of both viral and cellular FLIPs. 
Quantitative data are representative of three independent experiments, performed in 
triplicates. 
3.3.3 cFLIPs generate an active IKK without stable interaction with NEMO  
Activation of the vFLIP-binding deficient NEMO by cFLIPs suggested that these 
proteins may target a distinct domain of NEMO or function upstream of this protein. 
Therefore, we next sought to determine whether cFLIP isoforms associate with NEMO 
and generate a constitutively active IKK. To do this, we transfected HEK293T cells with 
expression plasmids for FLIPS, FLIPL, a non-cleavable version of cFLIPL (cFLIPL 
D196E/D376N) and p22-FLIP as well as vFLIP as a positive control for IKK direct 
interaction. We then immunoprecipitated the IKK complex using an anti-NEMO 
antibody and measured its ability to phosphorylate recombinant IκB. As can be seen in 
Figure 3.5 panel A, in each case the cFLIP isoforms generated an activated IKK. The 
level of activation was comparable or greater than that generated by vFLIP, though less 
than the transient activation observed following TNFα treatment.  
We then examined whether the cFLIP isoforms were found associated with the 
activated kinase and found no evidence for the presence of cFLIP isoforms in the IKK 
immune-precipitates, though vFLIP was clearly present as revealed by both anti-NEMO 
and anti-FLIP immunoprecipitations (Figure 3.5B). This is in contrast to the previous 
reports that showed p22-FLIP and p43-FLIP fragments stably associated with IKK 
(Golks et al., 2006; Neumann et al., 2010). Clearly, differences in the experimental 
conditions could explain these differing results; however, our data demonstrate that the 
cFLIP isoforms can generate an active IKK without remaining physically associated with 
the IKK complex. 
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Figure 3.5. Cellular FLIPs constitutively activate IKK complex without stable 
association with NEMO. A) In vitro kinase assays to determine the activation of IKK. 
HEK293T cells seeded in 6-well plates (5x105 cells/well) were transfected with pCDNA3 
vectors encoding p22FLIP, FLIPS, FLIPL, non-cleavable FLIPL, vFLIP or Tax. Forty-
eight hours later, whole cell lysates were extracted and subjected to immunoprecipitation 
(IP) with anti-NEMO or immunoblotting (IB) with the indicated antibodies. In vitro kinase 
assay was then performed on immuno-isolated IKK complexes using GST-IκBα (1-54) 
and γ32P-ATP as substrates. Extract of cells treated with TNFα (10ng/ml) for 5 min was 
used as a positive control. Relative band intensity of phosphorylated GST-IκB was 
quantified by ImageQuant TL Plus7.0 and normalised to the corresponding 
immunoprecipitated IKKα/β levels. B) cFLIP variants are not found in complex with 
NEMO. HEK293T cells seeded in 15 cm2 dishes were transfected with pCDNA3 
constucts, using FuGene HD transfection reagent. Cells were lysed 48 hrs later and the 
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extracts were immunoprecipitated with 2 µg of antibodies against NEMO, cFLIP and 
vFLIP, or their isotype-matched controls. The immunoprecipitates were subject to 10% 
SDS-PAGE and were analysed by western blotting. Data shown are representative of at 
least four independent repeats. * indicates the position of p43-FLIP bands. cF: cFLIP, I: 
isotype control, N: NEMO, ns: non-specific, vF: vFLIP. 
3.3.4 cFLIPL requires LUBAC to activate IKK 
As cFLIP isoforms required the ubiquitin binding function of NEMO to activate 
IKK (Figure 3.3), we examined the effect of ubiquitination pathways on their action. 
Linear ubiquitin chain binding to NEMO is crucial for IKK activation by TNFα and these 
are generated by the trimeric LUBAC, composed of HOIL-1, HOIP and SHARPIN (Iwai 
et al., 2014). We therefore generated HEK293 cells that were stably transduced with 
lentiviral vectors containing short hairpin RNAs targeting HOIL-1, HOIP and SHARPIN 
(Figure 3.6A). Cells transduced with scramble non-targeting shRNA served as control. As 
previously reported LUBAC was required for IKK activation by TNFα (Figure 3.6B) but 
was dispensable for activation by vFLIP (Tolani et al., 2014) and Tax (Figure 3.6C). A 
clear blockade of cFLIPL and nc-cFLIPL induced activation of IKK was observed in the 
LUBAC knock-down cells. However, cFLIPS and p22-FLIP were unaffected by LUBAC 
knock-down (Figure 3.6C). 
Lack of inhibition in the LUBAC KD cells, led us to hypothesise that cFLIPS and 
p22-FLIP may specifically require binding of K63-linked ubiquitin chains to NEMO. 
CYLD is a deubiquitinase (Komander et al., 2009) which can remove ubiquitin chains 
with K63 as well as linear linkages and has been shown to target several components of 
IKK signalling such as NEMO, RIP1, TRAF2 and TRAF6, resulting in inhibition of NF-
κB signalling (See 1.2.3.3). Therefore, we overexpressed CYLD in our scramble and 
LUBAC KD HEK293 cells (Figure 3.7A). Upregulation of CYLD caused a significant 
decrease in TNFα-induced NF-κB activation in LUBAC KD cells, but not control cells 
(Figure 3.7B). As seen in Figure 3.7C, cFLIPL was once again inhibited in the CYLD 
overexpressed cells, while p22-FLIP, cFLIPS and vFLIP were unaffected. Nevertheless, in 
the case of cFLIPS-induced activation, a statistically significant but not considerable 
decrease could be detected in the CYLD transduced/LUBAC KD cells when compared 
to control cells. The lack of requirement for ubiquitin signalling by cFLIPS and p22-FLIP 
required further investigation as the ubiquitin binding function of NEMO was clearly 
required. This conundrum will be addressed and discussed later in this thesis. 
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Figure 3.6. Effects of knocking down LUBAC on the NF-κB activation ability of 
the Tax, vFLIP and cellular FLIPs. A) HEK293 cells were transduced with lentiviral 
vectors encoding either scramble control shRNA (scr) or shRNAs targeting HOIL-1, 
HOIP and SHARPIN, sequentially. Generation of LUBAC KD cells was confirmed with 
western blotting against each component of the complex and the housekeeping protein, 
GAPDH. ns; non-specific B) TNFα-induced NF-κB activation which was measured 6 
hours after stimulation at 10 ng/ml concentration is inhibited in LUBAC KD cells. C) 
Subconfluent monolayers of scramble and LUBAC KD HEK293 cells seeded in 24 well-
plates (2x105/well) were co-transfected with an NF-κB−firefly Luc reporter construct 
(300ng/well) and a Renilla Luc reporter vector (normalisation control,100ng/well) along 
with an empty or transactivator expressing pCDNA3 vectors (500ng/well). The luciferase 
reporter assay was performed 24 hrs post-transfection as described in “section 2.11.1”. 
Values shown are the mean±SD of fold changes in the luciferase activity, from one 
representative experiment out of three, performed in triplicates; ** denotes p<0.01 and 
***, p<0.001.  
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Figure 3.7. Only cFLIPL is inhibited in CYLD-overexpressing HEK293 cells. A) 
Immunoblot showing the expression of the ectopically expressed CYLD in scramble KD 
and LUBAC KD HEK293 cells. Cells transduced with GFP-encoding lentivectors were 
used as control. B) Effects of CYLD overexpression on NF-κB activation levels induced 
by TNFα or C) cFLIPs, vFLIP and Tax were measured using NF-κB reporter luciferase 
assay, as described in Figure 3.6. Results shown are representative of three independent 
experiments, performed in triplicates. Mean values were compared by two-tailed unpaired 
Student’s t-test; ns: not statistically significant, * p<0.05, ** p<0.01 and *** p<0.001. 
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3.3.5 The UBAN domain of NEMO is dispensable for vFLIP activation of IKK 
The C-terminal ubiquitin binding region of NEMO ends right before the vFLIP-
binding site and one of the two Tax-binding regions of NEMO, resides within the N-
terminal region far from the UBAN domain (Figure 3.1A). Given that vFLIP and Tax did 
not require ubiquitin binding function of NEMO, we sought to examine whether the 
absence of the UBAN domain would have any impact on the capacity of these 
oncoproteins to activate the canonical IKK signalling. To do this, we generated C-
terminally truncated mutants of NEMO which terminated at positions Glu271 (∆271) and 
Arg254 (∆254) (Figure 3.8A). While the first of these two, lacks the essential 
ubiquitination and ubiquitin-binding residues, the whole putative UBAN domain (CC2-
LZ) is deleted in the second one. NEMO deficient 1.3E2 cells were reconstituted with 
WT or truncated mutants of NEMO (Figure 3.8B) and analysed using the NF-κB 
luciferase reporter assay.  
As shown in Figure 3.8D, both vFLIP and Tax induced near WT levels of 
activation in cells expressing the truncated NEMO mutants. In sharp contrast, neither 
LPS (Figure 3.8C) nor any of the cFLIP variants (Figure 3.8E) were able to stimulate IKK 
in the absence of the UBAN domain. Taking advantage of a NEMO deficient Jurkat cell 
line, known as JM4.5.2 cells we tried to reproduce these findings and showed that, 
similarly, vFLIP could fully activate ∆271 or ∆254 NEMO reconstituted Jurkat cells 
(Figure 3.8G). The same findings were evident in the case of Tax (Figure 3.8H). In 
keeping with these results, subsequent immunoprecipitation studies showed that the 
interaction of vFLIP with NEMO remains intact in the absence the UBAN domain, in 
contrast to the F238/D242RR point mutation which results in complete disruption of the 
complex (Figure 3.9). Surprisingly, we failed to detect significant activation of NF-κB by 
any of the cFLIP isoforms in the Jurkat cells, indicating that these proteins may induce 
IKK in a cell type-specific manner (Figure 3.8I).  
In conclusion, our findings confirm that the N-terminal region of NEMO is alone 
sufficient for activation of IKK by vFLIP and its functional analogue, Tax. These results 
are consistent with those of Tolani et al who report a similar result with vFLIP inducing a 
NEMO-estrogen receptor fusion protein in which NEMO was truncated at Gly251 
(Tolani et al., 2014).  
 
117 
 
 
 
 
118 
 
 
Figure 3.8. The UBAN domain of NEMO is dispensable for IKK activation by 
vFLIP and Tax. A) Schematic representation of the NEMO mutants truncated to 
include amino acids 1-271 (NEMO ∆271) or amino acids 1-254 (NEMO ∆254). B) 
Immunoblot showing the expression of NEMO in 1.3E2 cells reconstituted with either 
NEMO full-length, or NEMO ∆271, or NEMO ∆254. C)  Cells were transduced with 
NF-κB luciferase LV (MOI=500) to generate stable NF-κB reporter cell lines. 
Subsequently, the luciferase reporter assays were performed 6 hours after stimulation with 
LPS (10 µg/ml) or D) 48 hours following transduction with lentivectors encoding vFLIP, 
Tax (MOI=50) and E) cFLIP variants (MOI=100).  F) Western blot analysis of NEMO 
expression in Jurkat cells and JM.4.5.2 cells stably expressing WT or UBAN-deficient 
mutants of NEMO. G) Stable NF-κB sensor cell lines were produced by transducing cells 
with NF-κB luciferase encoding LVs (MOI=50). NF-κB dependent luciferase activates 
were measured 48 hours after transduction with LVs expressing vFLIP and H) Tax 
(MOI=20), or I) cFLIP variants (MOI=50). Data are representative of three independent 
experiments performed in triplicates. Error bars indicate SD of the mean values. 
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Figure 3.9. vFLIP binds to UBAN-deficient mutant of NEMO.  JM4.5.2, Jurkat and 
JM.4.5.2 cells stably expressing NEMO WT, NEMO F238/D242RR, or NEMO ∆271 
were transduced with vFLIP-encoding LVs (MOI=20). Cells were lysed 72 hours later 
and the extracts (300 µg/sample) were immunoprecipitated with 0.5 µg of anti-NEMO 
antibody or an isotype-matched control. The immunoprecipitates were subject to 12% 
SDS-PAGE and were analysed by western blotting against the indicated antibodies. Data 
shown are representative of two independent repeats. I: isotype-matched control, N: 
NEMO. 
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3.4 Discussion 
NEMO functions as the signal integration hub of the canonical IKK signalling. By 
direct binding to this regulatory subunit, KSHV vFLIP and Tax persistently activate NF-
κB signalling; however, how this interaction results in signal transmission to activate the 
catalytic subunits IKKα and IKKβ, is not clear. Due to structural similarities between 
vFLIP and cFLIP isoforms, these proteins have been suggested to adopt a similar 
mechanism of IKK activation.  
 Here it is shown that in fact all cFLIP variants can constitutively activate IKK, but 
unlike vFLIP and Tax, none of them physically associate with the NEMO. These results 
disagree with two previous studies, both originating from the same group, showing an 
stable interaction of  p22-FLIP and p43-FLIP fragments with NEMO (Golks et al., 2006; 
Neumann et al., 2010). It is worth mentioning that those experiments have been mainly 
performed under conditions of overexpressing both cFLIP and IKK; except one 
experiment which showed a weak interaction of endogenous p43-FLIP and NEMO 
following CD95 stimulation (Neumann et al., 2010). Therefore, it is possible that the 
detected cFLIP constitutes a small subset of the protein interacting indirectly with 
NEMO within a complex or it is only an artefact of protein overexpression. Related to 
the latter possibility, including isotype-matched controls in our co-immunoprecipiation 
studies showed that the interactions detected after long exposures of membranes to X-ray 
films, were of non-specific nature. Although differences in experimental settings may 
explain for these discrepancies, our findings indicate that cFLIPs are able to generate an 
active IKK without stable interaction with the NEMO subunit.  
Importantly, we also show that cellular FLIPs differ from KSHV vFLIP in that they 
depend on the ubiquitin function of NEMO. Interestingly, different isoforms were found 
to require distinct ubiquitination pathways. By shRNA-mediated knock-down of LUBAC 
complex, we could demonstrate that linear ubiquitin chains are indispensable for activity 
of the cFLIPL, but not p22-FLIP or cFLIPS. It has been shown that cFLIPL, but not 
cFLIPS, interacts with and requires TRAF2 to activate NF-κB (Kataoka and Tschopp, 
2004; Kataoka et al., 2000). A recent study described that, in IL-1 signalling, LUBAC 
becomes recruited to IKK signalling machinery through K63-linked polyubiquitin 
catalysed by upstream E3 ligases (Emmerich et al., 2013). It is possible that TRAF2 
mediates the LUBAC-dependent activation of IKK by the long isoform of cFLIP.  
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Our findings that p22-FLIP and cFLIPS do not need LUBAC to activate NF-κB 
implied that these proteins must require another type of non-degradative polyubiuquitin -
most likely K63-linked Ub oligomers- as the LUBAC is the only E3 ubiquitin ligase 
known to generate linear chains. Moreover, F312A mutation of the NEMO - which 
disrupts the IKK activation by cFLIPs - is shown to block binding to K63-linked 
ubiquitin chains (Ea et al., 2006). To investigate whether p22FLIP and cFLIPS specifically 
required K63-linked polyubiquitin binding to NEMO, we overexpressed CYLD which is 
known to cleave ubiquitin chains with K63-linkges from a number of IKK signalling 
components including NEMO. Surprisingly, we failed to suppress the activity of the short 
cFLIP forms by overexpression of CYLD. One possible reason for this could be that the 
K63-ubiquinated protein used by these cFLIP variants is not a substrate of CYLD. 
Alternatively, binding to NEMO may render the ubiquitinated intermediate protein 
inaccessible to deubiquitination by the CYLD. In support of this concept, it was recently 
shown that in TNF-R signalling, binding to NEMO protects ubiquitinated RIP1 from 
CYLD-mediated deubiquitination, resulting in prevention of the initiation of necroptotic 
pathways (O’Donnell et al., 2012).   
Although, we have clearly shown that ubiquitin binding function of NEMO is 
essential for the activity of cFLIP isoforms, it remains to be determined which 
ubiquitinatd proteins mediate this process. cFLIP isoforms are found to be a target of 
ubiquitination, themselves. Ubiquitination of cFLIPS at lysines 192 and 195 has been 
described to be responsible for the rapid turnover this isoform (Poukkula et al., 2005). 
Hence, it is tempting to speculate that cFLIP isoforms may undergo other types of non-
degradative polyubiquitination, leading to a transient interaction with UBAN domain of 
NEMO or recruitment of intermediate signalling components. In an attempt to 
investigate this possibility, we generated K192/K195RR mutants of cFLIP isoforms and 
compared their activity with wild-type forms (Figure 3.10A). The mutations resulted in a 
partial decrease, but not complete loss of activity for both cFLIP long and short but led to 
a marked increase in the activity of p22-FLIP variant (Figure 3.10B), making the relevant 
results difficult to interpret. Obviously, a systemic approach to test this concept would 
require a series of site-directed mutagenesis to engineer Arg replacements at each of the 
cFLIP lysines. Moreover, given the availability of specific antibodies against distinct 
polyubiquitin linkages, cFLIP proteins can be immuno-isolated and directly probed for 
the possibility of ubiquitination by non-degradative Ub oligomers.  
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In this study, we have provided evidence indicating that ubiquitination and 
ubiquitin-binding function of NEMO are dispensable for vFLIP-induced mechanism of 
IKK activation. Moreover, we demonstrated that the absence of UBAN domain does not 
have any adverse impact on the NEMO binding ability of the vFLIP. These findings agree 
with a recent study by the Chaudhary lab which showed that the vFLIP-mediated NF-κB 
activities are not impaired in cells derived from mice lacking TRAF6, HOIL-1 genes or 
cpdm mice which harbour a mutation in the SHARPIN gene (Matta et al., 2012). Our 
results are also compatible with those of Tolani et al – published at the time of writing 
this thesis- who reported that N-terminal 251 residues of NEMO are sufficient to support 
vFLIP-induced stimulation of NF-κB (Tolani et al., 2014).  
It has to be noted that although these experiments show the lack of requirement for 
UBAN domain by the vFLIP, they do not completely rule out any involvement of the C-
terminal region in vFLIP-induced transcriptional activities of the NF-κB. Hence, one 
could speculate that the C-terminal region of NEMO contributes to controlling the 
magnitude and duration of the vFLIP-induced responses or plays a role in modulating the 
expression of a subset of NF-κB responsive genes.  
Clearly, vFLIP and Tax bind to distinct regions of NEMO and share no obvious 
sequence homology. Nevertheless, our data indicate that Tax has similarly evolved to 
stimulate NEMO without involvement of the ubiquitination or ubiquitin binding of 
NEMO. This is in agreement with the study showing Tax can activate of IKK in cells 
expressing a truncated NEMO mutant containing aa1-255 (Xiao and Sun, 2000). 
Together, these observations raise the possibility that binding to vFLIP and Tax may 
mimic ubiquitin-induced conformational changes on NEMO that lead to IKK activation. 
However, it has been shown that Tax fused to IKKα and β, can activate NF-κB pathway 
in the absence of NEMO (Xiao and Sun, 2000). Similarly, in frame fusion of NEMO to 
Tax mutants defective in NEMO-binding, is sufficient to activate IKK (Xiao et al., 2000). 
Therefore, given that Tax can self-dimerise (Fryrear et al., 2009; Jin and Jeang, 1997; Tie 
et al., 1996), it is logical to suppose that it may use NEMO as a scaffold to bring the 
IKKα/β subunits into close proximity, leading to activation by cross-phophorylation. This 
model can be also considered for vFLIP since dimeric interactions between vFLIP 
molecules are present within vFLIP-NEMO signalosome (see chapter5). Alternatively, 
these oncoproteins may function by directly recruiting upstream IKK-activating kinase. 
This model of activation will be addressed in the next chapters. 
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In summary, the study presented here shows that Tax, vFLIP and cellular FLIPs 
require distinct regions of NEMO to induce IKK. While Tax and vFLIP activate the NF-
κB pathway independently of the ubiquitin-mediated signalling induced by cytokines, all 
cFLIP variants require ubiquitin-binding function of NEMO for their activation of IKK. 
These findings provide a basis for further identification of the IKK signalling components 
and mechanisms utilised by KSHV vFLIP and different isoforms of cFLIP.   
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Figure 3.10. Effect of the K192/195RR mutations on the NF-κB inducing ability of 
the cFLIP variants. A) Western blot comparing the expression levels of the WT and 
K192/K195RR mutants of cFLIP isoforms. B) HEK293T cells were seeded in 24-well 
plates (2x105 cells well) 16 hours prior to transfections. Subsequently, each well was 
transfected with 400ng NF-κB firefly luciferase plasmid (pGL.IgK), 100ng Renilla 
luciferase plasmid (pRL.TK) as internal control and 300 ng of pCDNA3 vectors encoding 
WT, or muatnt versions of the cFLIP isoforms. NF-κB induction levels were measured 
after 24 hours using the Promega Dual-GLO luciferase assay system. Results shown are 
representative of two independent experiments, performed in triplicates. Error bars 
indicate SD of the mean values which were compared by two-tailed unpaired Student’s t-
test; ns: not statistically significant, * p<0.05 and *** p<0.001. 
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CHAPTER 
4 
 
4. The Role of Signalling Intermediates 
Upstream of IKK in NF-κB Signalling by 
KSHV vFLIP and Cellular FLIPs 
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4.1 Introduction 
In the previous chapter of this thesis, we established that the ubiquitination and 
ubiquitin binding function of the NEMO are essential requirements for the cFLIP-
induced NF-κB activation. Furthermore, it was demonstrated that cellular FLIPs, unlike 
the KSHV vFLIP, do not stably associate with the NEMO subunit of the IKK complex. 
Together, these findings suggested a possible mechanism whereby cellular FLIPs act 
indirectly on the IKK complex via intermediate signalling components. Such intermediate 
adaptors may recruit E3 ligases required for NEMO ubiquitination, or connect the IKK 
complex to upstream IKK-Ks, or serve as ubiquitination substrates which bind to the 
UBAN domain of NEMO. In this chapter, we sought to investigate which adaptor 
proteins were required for IKK activation by cFLIPs and whether these components were 
also important for the activity of vFLIP and Tax. Due to reasons outlined below, the 
targets chosen to study were Atg3, RIP1, caspase-8 and FADD as well as the IKK-
activating kinases TAK1 and MEKK3. 
4.1.1 Caspase-8, FADD and RIP1 
Cellular FLIPs appear in complex with FADD, caspase-8 and RIP1 within several 
death receptor-induced signalling cascades: a cytoplasmic complex containing cFLIPL, 
RIP1, FADD, caspase-8 and TRADD is induced by TNFR signalling (Micheau and 
Tschopp, 2003); a complex containing RIP1, FADD, caspase-8 and NEMO has been 
detected after TRAIL triggering (Varfolomeev et al., 2005) and a 
cFLIP/RIP1/FADD/caspase-8 complex has been found after Fas signalling (Lavrik et 
al., 2008). Moreover, inhibition or depletion of the cIAPs in tumour cells leads to 
assembly of the cytoplasmic ripoptosome complex which contains FADD, caspase-8, 
RIP1 and cellular FLIPs (Feoktistova et al., 2011; Tenev et al., 2011a). Individual 
overexpressions of RIP1, caspase-8 or FADD, all result in strong activation of the NF-κB 
pathway and there is evidence showing an interaction between these proteins and IKK 
complex (Biton and Ashkenazi, 2011; Chaudhary et al., 2000; Poyet et al., 2000; Zhang et 
al., 2000). Therefore, we hypothesised that when overexpressed, cFLIP proteins may 
require a similar multi-protein complex to induce the NF-κB signalling.  Consistent with 
this idea, it has been shown that recruitment of cFLIP to the TRAIL-induced DISC 
complex, results in the translocation of DISC components from lipid rafts to non-rafts, 
further recruitment of the RIP1 and switching the outcome of DISC signals from 
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caspase-initiated apoptosis to activation of the ERK and NF-κB pathways (Song et al., 
2007). 
4.1.2 Atg3 
Cellular FLIPs and KSHV vFLIP have been also shown to directly bind to the 
autophagy pathway protein, Atg3.  This association blocks autophagosome biogenesis 
through preventing the Atg3-LC3 interaction, required for processing of LC3 to its active 
form, LC3-II (See 1.3.4). The Atg3-interacting regions of KSHV vFLIP have been 
localised to DED1 α2 helix (aa 20-29) and DED2 α4 helix (aa 128-139), which are distinct 
from motifs responsible for binding to NEMO and TRAFs (Field et al., 2003; Guasparri 
et al., 2006; Lee et al., 2009). FLIP mutants defective in binding to FADD, TRAFs or 
NEMO are capable of blocking rapamycin-induced autophagy as efficiently as the WT 
versions (Lee et al., 2009). Therefore, it has been concluded that authophagy-inhibiting 
ability of FLIP proteins must be separable from their anti-apoptotic or NF-κB inducing 
activities. Nevertheless, deletion of Atg3-binding regions of the KSHV vFLIP, completely 
abrogates both its NF-κB activation and anti-apoptotic capacity (Lee et al., 2009). These 
results raise the possibly that interaction with Atg3 may play a role in FLIP-induced 
activation of IKK. 
4.1.3 TAK1 and MEKK3 
Alongside ubiquitination events, phosphorylation of the catalytic IKKs by IKK-
phosphorylating kinases is another major step in the activation of the NF-κB pathway. 
Two members of the MAPK family, TAK1 and MEKK3, are the most prominent of 
IKK-Ks that, alone or together, play pivotal roles in the inflammatory stimuli-induced 
IKK signalling (See 1.2.1). Although several studies have examined the function of these 
IKK-Ks in the Tax-induced pathway (Gohda et al., 2007; Suzuki et al., 2007; Wu and Sun, 
2007), it remains to be determined whether they play a role in the activation of IKK by 
vFLIP and cFLIP variants. 
4.2 Aims of the chapter 
• Determine the role of Atg3, FADD, caspase-8 and RIP1 in FLIP-induced 
activation of IKK 
• Examine whether the activation of IKKs by vFLIP and cFLIP isoforms depends 
on upstream MAP3Ks, TAK1 and MEKK3. 
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4.3 Results 
4.3.1 cFLIPS and p22-FLIP activate IKK via a FADD-RIP1  complex 
To further probe the mechanism of action of cellular FLIPs we generated 
HEK293T cells that were knocked-down for the molecules reported to be present in 
complexes with cFLIP isoforms or vFLIP. As previously mentioned, Atg3 has been 
reported to interact directly with vFLIP and cFLIPs (Lee et al., 2009), FADD interacts 
with cFLIP isoforms (reviewed in (Krueger et al., 2001)), and RIP1 interacts with FADD 
(Park et al., 2013). In order to identify shRNAs that would efficiently down-regulate the 
expression of these candidate proteins, at least five different target-specific LVs were 
generated for each gene, using shRNA-encoding lentiviral plasmids obtained from UCL 
Open Biosystem RNAi library. Subsequently, HEK293T cells were transduced with the 
LVs at an MOI of 50 and analysed by western blotting for expression levels of the 
targeted proteins, using GAPDH levels as internal control. Cells infected with LVs 
encoding scramble shRNA served as negative control. From each set, two shRNAs that 
yielded most efficient silencing were used to produce stably knocked-down cell lines for 
the experiments (Figure 4.1 A). The list of sequences targeted by each shRNA has been 
given in Table 2.15.   
As Figure 4.1C shows, FADD and RIP1 were both required for cFLIPS and p22-
FLIP activation of IKK, while Atg3 and caspase-8 were dispensable. On the other hand, 
none of the silenced proteins appeared to play a role in NF-κB activation by TNFα, 
cFLIPL, vFLIP or Tax (Figure 4.1B and C). Our findings agree with those of the 
Chaudhary lab showing that vFLIP, despite physically binding to RIP1, does not require it 
for the activation of IKK (Liu et al., 2002; Matta and Chaudhary, 2004).  
A hydrophobic stretch of amino acids in the DED2 motif of the murine cFLIPR has 
been identified as critical for its interaction with FADD, and hence, its DISC recruitment 
and anti-apoptotic function (Figure 4.2A) (Ueffing et al., 2008). Interestingly, this 
hydrophobic patch - which contains residues F119, L120, L146, L148 and L154 on its 
surface - is highly conserved in both KSHV vFLIP and human cFLIP isoforms (Figure 
4.2B). We mutated the critical amino acids in this hydrophobic stretch (Figure 4.2C), 
which resulted in blocking IKK activation by cFLIPS and p22-FLIP and also cFLIPL, but 
not vFLIP (Figure 4.3D). We then demonstrated that this mutation prevented interaction 
of the cFLIP isoforms with FADD, while FADD and RIP1 were present in these cells as 
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a pre-assembled complex (Figure 4.3). These data provide an explanation for the lack of 
inhibition of cFLIPS and p22-FLIP by CYLD, as ubiquitinated RIP1 bound to IKK has 
been reported to be protected from deubiquitination (O’Donnell et al., 2012). While 
mutation of the putative FADD binding domain in cFLIPL prevented activation of IKK 
(Figure 4.2C), cFLIPL did not require FADD or RIP1 for its action (Figure 4.1C), 
suggesting that this region interacts with a different effector to trigger LUBAC activity. 
This effector may be TRAF2, which has been reported to interact with the N-terminal 
region of cFLIPL, and to be required for NF-κB activation (Kataoka and Tschopp, 2004). 
Our finding that RIP1 was not required for cFLIPL activation differs from the report of 
its role in TCR-triggered NF-κB activation, where RIP1 was required (Kataoka et al., 
2000).  
FADD and cFLIP isoforms interact via their DEDs; while FADD-RIP1 interaction 
is mediated through their respective DDs. Therefore, considering our findings, one could 
speculate that FADD functions as an adaptor protein connecting p22-FLIP or FLIPS to 
RIP1 which, following its ubiquitination, can bind to the IKK complex, facilitating its 
activation. To test this hypothesis, I generated lentiviral constructs encoding WT RIP1, or 
a point mutant of RIP1 reported to block its polyubiquitination (K377R)(Ea et al., 2006), 
or RIP1 mutants suggested to be deficient in FADD-binding (G595/K596AA and 
E620/D622AA)(Park et al., 2013). These LVs were then used to reconstitute a RIP1−/− 
MEF cell line (data not shown) for further studies. However, cFLIP did not induce NF-
κB activation in these cells and other RIP1 deficient cell lines were not available, so I was 
unable to perform further experiments.  
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Figure 4.1. FADD and RIP1 are required for NF-κB activation by cFLIPS and p22-
FLIP. A) Stable gene knockdown of Atg3, caspase-8, FADD and RIP1 in HEK293T 
cells was validated by western blotting. From five independent shRNAs used to silence 
each protein, two that yielded most efficient knockdowns were chosen for the 
experiments. Immunoblots were re-probed for GAPDH levels to ensure equal protein 
loading. B) Control and knockdown cells were transduced with NF-κB Luc lentivectors 
(MOI=10) to develop stable NF-κB reporter cell lines. Luciferase reporter assays were 
performed 6 hours following stimulation with TNFα (10ng/ml) or C) 48 hours after 
transduction with LVs encoding cFLIP variants (MOI=50), vFLIP and Tax (MOI=10). 
Values shown are the mean±SD of the relative luciferase activity from five independent 
experiments; numbers represent the absolute activation fold. 
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Figure 4.2. A hydrophobic stretch of amino acids on the surface of DED2 is 
indispensable for NF-κB activation by cellular FLIP isoforms, but not KSHV 
vFLIP. A) Electrostatic surface representation of the murine cFLIPR. Left panel: 
hydrophobic and charged motifs on the surface of DED1 and DED2. Motifs coloured in 
red and magenta are hydrophilic, and motifs shown in yellow and gold are hydrophilic. 
Right panel: The hydrophobic amino acids present on the surface of DED2 (highlighted 
in yellow). The hydrophilic regions are shown in green (reproduced form (Ueffing et al., 
2008)). B) Sequence alignment of the murine cFLIPR, human cFLIP and KSHV vFLIP. 
The amino acids which form the hydrophobic patch of the DED2 in murine cFLIPR 
(F114, L115, L146, L148 and L154) are fully conserved in both KSHV vFLIP and human 
cFLIP. Sequence alignment was performed by PRALINE software. C) Immunoblot 
showing the expression of F114/L115AA cFLIP mutant, F115/L116AA vFLIP mutant 
and their WT versions in HEK293T cells. D) Subconfluent monolayers HEK293T cells 
seeded in 24-well plates (2x105/well) were co-transfected with an NF-κB firefly Luc 
reporter construct (300ng/well) and a Renilla Luc reporter vector (normalisation 
control,100 ng/well) together with empty or transactivator expressing pCDNA3 vectors 
(500 ng/well). The luciferase reporter assay was performed 24 hours post-transfection 
using Dual-Glo luciferase assay system. 
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Figure 4.3. Unlike KSHV vFLIP, cellular FLIPs associate with a pre-assembled 
FADD-RIP1 complex. HEK293T cells, seeded in 6-well plates (5x105/well) were 
transfected with 1 µg of HA-FADD vector together with 1 µg of pCDNA3 constructs 
expressing WT or mutant versions of the p22-FLIP, cFLIPS, cFLIPL and vFLIP. Forty-
eight hours later, cell lysates were extracted and immunoprecipitated with 0.5 µg of anti-
HA or an isotype-matched control antibody. Cell lysates and the immunoprecipitates were 
then analysed by western blotting with the indicated antibodies. * indicates the position of 
p43-FLIP bands. Results shown are representative of three independent experiments. 
4.3.2 Processing to p22-FLIP and p43-FLIP fragments is not necessary for NF-κB 
activation by cFLIPL  
Golks et al., demonstrated that p22-FLIP fragment can be generated by procaspase-
8 cleavage of either cFLIPL, or cFLIPS isoform. They also reported that inhibition of 
capsase-8 by zVAD-fmk (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoro- methylketone) 
results in a decrease of NF-κB activation by p43-FLIP and FLIPL, but not p22-FLIP. 
Furthermore, overexpression of p22-FLIP in HEK293T cells was shown to cause much 
stronger NF-κB activation than that observed with cFLIPL. Therefore, it was concluded 
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that cFLIP variants have to be cleaved to p22-FLIP to be capable of inducing the IKK 
complex (Golks et al., 2006). 
Surprisingly, in contrast to the findings of Golk et al., we observed a similar level of 
activation with non-cleavable cFLIPL as with wild-type. Moreover, we found no evidence 
that caspase-8 was required for NF-κB activation by cFLIP variants (Figure 4.1C). 
Together, our data suggested that, in contrast to the current view in the field, p22-FLIP 
might not be simply an active isoform of the cFLIP proteins but is likely to activate IKK 
in a manner distinct from its precursor cFLIPL. 
As the previous report had used a different NF-κB luciferase construct to measure 
NF-κB activation, we sought to determine whether this could explain the discrepancies in 
the results. To do this, we generated two different NF-κB luciferase reporter plasmids: 
one with H2DK response element from MHC class I gene (used in Golk et al.’s report) 
and one with NF-κB binding sites from immunoglobulin kappa light chain (Igk) gene 
(Figure 4.4A). We also replaced the murine c-Fos promoter, used in the previous report, 
with minimal promoter of the cytomegalovirus (CMV), as there is evidence that 
expression of cFLIPL, but not cFLIPS, strongly blocks c-Fos upregulation (Siegmund et 
al., 2001). Figure 4.4C shows that the non-cleavable cFLIPL was no different in activity 
from wild-type with either reporter construct; this agrees with our kinase assay results 
(Figure 3.5A).  
Overall, our findings indicate that processing to p22-FLIP or p43-FLIP is not 
required for NF-κB activation capacity of the cFLIPL. We have shown that cFLIPL 
requires LUBAC while p22-FLIP and cFLIPS depend on a FADD-RIP1 complex to 
stimulate IKK. Therefore, it is plausible to assume that, cFLIPL cleavage to generate p22-
FLIP may switch the mechanism of NF-κB activation at the protein level, without a need 
for de novo synthesis of the cFLIPS isoform. 
It is worth mentioning that upon vFLIP transduction of Jurkat cells, we observed a 
strong induction of p22-FLIP production (Figure 4.4D). However, as shown in the 
previous chapter, p22-FLIP overexpression does not activate the NF-κB pathway in these 
cells (Figure 3.8I). Thus, it is likely that p22-FLIP also plays a role in cellular mechanisms 
other than the NF-κB signalling. 
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Figure 4.4. Non-cleavable mutant of cFLIPL activates NF-κB pathway in levels 
comparable to that of wild-type cFLIPL and p22-FLIP. A) Schematic representation 
of the NF-κB reporter vectors. Two different NF-κB luciferase plasmids were constructed 
to compare the activaties of the cFLIP variants: one with 4 repeats of NF-κB response 
element of immunoglobin kappa light chain (IgK) gene and another with 4 repeats of an 
NF-κB binding site of the mouse MHC classI H2DK gene. B) Immunoblot comparing 
the expression levels of p22-FLIP, cFLIPS, cFLIPL and nc-FLIPL. C) NF-κB luciferase 
assay comparing the NF-κB activation levels induced by WT- or nc-FLIPL. The luciferase 
reporter assays were performed as described in Figure 4.3D. Results shown are 
representative of four independent experiments and the values represent mean±SD of 
triplicates within an experiment; ns: statistically not significant. D) WT and NEMO KO 
Jurkat cells were transduced with LVs encoding GFP or vFLIP. Forty-eight hours later, 
cells were lysed and analysed for cFLIP expression levels by western blotting. 
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4.3.3 Cellular FLIP variants require TAK1 to induce IKK 
As discussed previously, the kinase TAK1 has been identified as a critical activator 
of IKK, phosphorylating the activation loops of the kinase subunits in response to a 
variety of signals (Shambharkar et al., 2007; Wang et al., 2001), and the kinase MEKK3 
has also been reported to fulfil this role in some circumstances (Huang et al., 2004b; Yang 
et al., 2001a). In order to investigate the role of these IKK-Ks in FLIP-induced NF-κB 
activation, we produced HEK293T cells with stably knocked-down TAK1 or MEKK3 
(Figure 4.4A). To prevent the possible compensative effect of these kinases on each other, 
we also generated double TAK1/MEKK3 KD cells (DKD)(Figure 4.5A).  
As shown in Figure 4.5B, silencing of TAK1 in HEK293T cells severely disrupted 
the TNFα-mediated activation of the NF-κB, while MEKK3 was not required. TAK1 was 
clearly necessary for activation of IKK by all the cFLIP variants, though both kinases 
were dispensable for vFLIP and Tax activation (Figure 4.5C). The requirement for TAK1 
in the cFLIP-mediated pathways suggests that the active kinase identified in Figure 3.5A 
has been phosphorylated and activated by TAK1. The lack of a requirement for TAK1 in 
vFLIP activation has been reported (Matta et al., 2012) although its role in Tax activation 
of IKK has been controversial (Suzuki et al., 2007; Wu and Sun, 2007). Interestingly, we 
could detect a partial decrease for NF-κB activation by both vFLIP and Tax in the double 
knock-down cells, suggesting that these kinases may have important but redundant roles. 
Since, even in the DKD cells, activity of these oncoproteins is not completely abrogated, 
another possibility is that these IKK-Ks contribute to the magnitude of IKK signalling 
but not its initiation. 
To further confirm these experimental data in a different cell line, we acquired a 
MEKK3 −/− MEF cell line and additionally knocked-down TAK1 in these cells (Figure 
4.6A). For the KD of the murine TAK1, three different shRNAs were designed and 
cloned into LVs, of which shRNA No.3 resulted in the most efficient TAK1 silencing and 
was used for the experiments. Similar to what seen in HEK293T cells, none of the kinases 
were required for Tax-mediated activation and only a small, but statistically significant 
decrease could be detected when both kinases were lacking (Figure 4.6B). On the other 
hand, in MEFs, activation of the vFLIP was inhibited in part by the knockdown of 
TAK1. This discrepancy between the results obtained with HEK293T and MEFs suggests 
that the IKK-Ks might function in a cell type-specific manner. Nevertheless, whether the 
action of IKK-Ks is an absolute requirement for vFLIP activation of IKK or it is merely 
required for signal amplification remains an important unanswered question. This 
question has been addressed in Chapter5.  
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Figure 4.5. Cellular FLIPs require TAK1 for the activation of the NF-κB pathway. 
A) shRNA-mediated stable silencing of TAK1, or MEKK3 or both kinases in the 
HEK293T cells was validated with western blotting. B) Cells were further transduced 
with NF-κB Luc LV at an MOI of 10 to develop NF-κB sensor version of the cell lines.  
Luciferase reporter assays were then performed 6 hours following stimulation with TNFα 
(10ng/ml) or C) Forty-eight hours following transduction with control (eGFP) or test 
lentivectors (MOI=10). Results shown are mean ±SD of a representative experiment out 
of three, performed in triplicates. The two-tailed Student’s t-test was used to determine 
the statistical differences between two groups; *** denotes p<0.001. 
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Figure 4.6. Analysis of vFLIP-, Tax- and TNFα-induced NF-κB activation in WT 
or TAK1 KD versions of the MEKK3+/+ and MEKK3−/− mouse embryonic 
fibroblasts. A) Successful knockdown of TAK1 in WT and MEKK3 KO MEFs was 
validated by western blotting. B) MEFs were transduced with NF-κB luciferase LV at an 
MOI of 50 to generate NF-κB sensor cell lines. Luciferase reporter assays were performed 
using Bright-Glo detection system 6 hours following stimulation with TNFα (10 ng/ml) 
or 48 hours after transduction with LVs expressing GFP, or vFLIP, or Tax (MOI=20). 
Results shown are representative of two independent experiments, performed in 
triplicates.  The two-tailed Student’s t-test was used to determine the statistical differences 
between two groups; * p<0.05 and *** p<0.001. 
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4.4 Discussion 
The data presented here show that all cFLIP variants can activate IKK via the 
ubiquitin binding domain of NEMO. The cFLIPL isoform requires the LUBAC 
ubiquitination complex, but does not require caspase-8 or cFLIPL cleavage. In contrast, 
cFLIPS and the cleavage product p22-FLIP form a stable complex with FADD and RIP1, 
which are required for IKK activation. This evidence for different pathways of NF-κB 
activation demonstrates that p22-FLIP is not simply the effector of cFLIPL, though 
cFLIPL cleavage to generate p22-FLIP may switch the mechanism of NF-κB activation. 
These cFLIPS/FADD/RIP1 or p22-FLIP/FADD/RIP1 complexes are reminiscent 
of a cytoplasmic complex, termed the ripoptosome, induced by treatments of human 
tumour cells that deplete or inhibit cIAP proteins (Feoktistova et al., 2011; Tenev et al., 
2011b). This depletion leads to the formation of a RIP1/FADD/procaspase-8 complex. 
cIAPs inhibit formation of this complex by ubiquitinating RIP1. In the absence of FLIP 
proteins, procaspase-8 molecules homodimerise in the ripoptosome, promoting cell death 
by apoptosis. Recruitment of cFLIPL to this complex leads to partial caspase-8 activation 
resulting in cell survival (Oberst et al., 2010). cFLIPS, on the other hand, has been 
reported to block caspase-8 activation and facilitate cell death through necroptosis 
(Feoktistova et al., 2011). As previously mentioned, cFLIPs have also been reported to 
associate with and regulate a ripoptosome-like complex formed following TNF, TRAIL 
and Fas signalling (Lavrik et al., 2008; Micheau and Tschopp, 2003; Varfolomeev et al., 
2005).  
Our data shows that constitutive expression of cFLIP variants leads to formation of 
a FLIP/FADD/RIP1 complex that leads to NF-κB activation. The relationship between 
other complexes and this NF-κB activating complex remains to be determined, but we 
have clearly shown that caspase-8 is not required for NF-κB activation by any of the 
cFLIP variants. This is in contrast to some previous studies showing that caspase-8 is 
indispensable for cFLIPL-mediated activation of NF-κB, especially following the Fas-
signalling (Golks et al., 2006; Hu et al., 2000; Kataoka and Tschopp, 2004). There is 
evidence, however, that after cleaving cFLIPL to p43-FLIP, caspase-8 is not required for 
downstream steps of FasL-induced IKK activation (Matsuda et al., 2014; Neumann et al., 
2010). Taken together, we conclude that caspase-8 is not a part of IKK-inducing complex 
used by different cFLIP variants, but it is required for signalling pathways which depend 
on cFLIP cleavage to induce or amplify IKK signalling (e.g, TCR and FasL signalling in T 
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cells mediated by p22- and p43-FLIP fragments) (Dohrman et al., 2005; Golks et al., 2006; 
Koenig et al., 2014; Neumann et al., 2010).  
FADD-RIP1 and FADD-cFLIP bindings are mediated via homotypic DD and 
DED interactions, respectively (Lavrik et al., 2005; Park et al., 2013). Thus, it is likely that 
FADD acts as an adaptor protein connecting the short forms of cFLIP to ubiquitinated 
RIP1 which then can bind to and induce IKK complex. Interestingly, mutating the 
FADD binding domain of cFLIP resulted in complete blockade of their NF-κB activation 
while FADD knockdown had much milder effect. It is possible that residual amounts of 
FADD in the KD cells are sufficient to mediate cFLIPS and p22-FLIP induced signalling. 
Another explanation for this could be that other DD (death domain)-containing proteins 
such as TRADD may partially compensate for the lack of FADD. Indeed, TRADD is a 
known binding partner of both FADD (Hsu et al., 1996b) and RIP1 (Hsu et al., 1996a). 
We have provided evidence that FADD functions downstream of short forms of cFLIP 
to stimulate IKK, though further research is needed to determine the exact role of FADD 
in this context.  
To our surprise, mutation of the putative FADD binding domain in cFLIPL 
prevented activation of IKK, whilst this isoform did not require FADD for its action, 
suggesting that this domain interacts with a different effector to trigger LUBAC activity. 
This effector may be TRAF2, which has been reported to interact with the N-terminal 
region of cFLIPL, and to be required for its NF-κB activation (Kataoka and Tschopp, 
2004). Nevertheless, whether cFLIPL could directly associate with a subunit of LUBAC 
remains to be tested. 
We found that, unlike cFLIPs, KSHV vFLIP does not associate with FADD. Due 
to its sequence similarities to cellular FLIP, vFLIP was initially thought to protect cells 
from death receptor induced apoptosis through preventing caspase-8 activation at the 
DISC (Bertin et al., 1997; Hu et al., 1997a).  Consistent with this idea, overexpression of 
vFLIP was shown to protect HeLa cells from Fas-induced apoptosis (Bélanger et al., 
2001). Similarly, RNAi-mediated silencing of vFLIP was found to sensitise BC3 cells to 
Fas-mediated apoptosis (Guasparri et al., 2004). However, since NF-κB activation also 
protects against cell death by up-regulating a multitude of pro-survival genes (Luo et al., 
2005), it was not clear whether the cytoprotective role of vFLIP is due to its ability to 
directly block caspase-8 activation or because of its NF-κB activation capacity.  
Interestingly, emerging evidence indicates that vFLIP is unable to protect NEMO 
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deficient cells from DR-induced cell death, suggesting that vFLIP is primarily an inducer 
of NF-κB rather than a caspase-8 inhibitor (Tolani et al., 2014; and data from an 
unpublished study by Chris Davis, Collins lab). Our results showing a lack of interaction 
between FADD and vFLIP further supports this concept as binding to FADD is essential 
for cFLIP-mediated inhibition of caspase-8 activity. Nevertheless, one study reported that 
vFLIP can directly bind to procaspase-8 and reduce its cleavage into its active p10 and 
p18 fragments (Bélanger et al., 2001). 
The role of RIP1 in FLIP-induced IKK activation remains controversial. It was 
initially reported that RIP1 interacts with cFLIPL via its C-terminal caspase-like domain 
(Kataoka et al., 2000). Although, in a marked contrast, a recent study showed that under 
physiological conditions RIP1 interacts with caspase-8, but not cFLIPL, and in fact, the C-
terminal p12 domain of cFLIPL inhibits this interaction (Matsuda et al., 2014). Matusda et 
al., showed that NF-κB activation induced by c-FLIPL or its uncleavable form (D376A) 
could not be inhibited by overexpressing death domian of RIP1 (aa 559–671). On the 
other hand, FasL-induced NF-κB signalling which depends on p43-FLIP was repressed by 
RIP1(559-671). Similarly, we have shown that RIP1 is indispensable for activation of IKK 
by the catalytic p22-FLIP fragment, but not full-length cFLIPL. Therefore, one could infer 
that cFLIPL processing to either p22-FLIP or p43-FLIP acts as a critical switch point 
between RIP1-independent and RIP1-dependent FLIP-induced NF-κB activation 
pathways. 
Despite using different signalling intermediates, all cFLIP variants converge on 
TAK1 to phosphorylate and activate IKK. In TNF signalling, recruitment of TAK1 to 
IKK occurs through K63 ubiquitin chains bound to TRAF2 or RIP1 (Ea et al., 2006; 
Ishitani et al., 2003).  Considering that we and others have shown the requirement of 
cFLIP variants for both proteins (p22-FLIP and cFLIPS for RIP1, and cFLIPL and p43-
FLIP for TRAF2 (Kataoka and Tschopp, 2004; Koenig et al., 2014)), it would be 
important to examine whether these proteins mediate the co-localisation of TAK1 and 
IKK within cFLIP-induced signalling. 
In contrast to cFLIPs, neither vFLIP nor Tax required TAK1 or MEKK3 to induce 
IKK. This strongly suggested a mechanism of activation which is independent of IKK-
activating kinases. Nevertheless, partial decrease of their NF-κB activation in double 
MEKK3/TAK1 knockdown cells indicates that IKK-Ks may play a role in achieving 
optimal levels of activation in cells. It is also possible that these viral oncoproteins are able 
142 
 
to use several IKKs interchangeably. These concepts have been further addressed in the 
next chapter.  
In summary, data presented here show that KSHV vFLIP and different variants of 
cellular FLIPs, despite their similar tandem DEDs, activate NF-κB by remarkably 
divergent mechanisms. This could have multiple applications when designing specific 
therapeutics for blocking pathological NF-κB activation in viral and non-viral 
tumourigenesis, while avoiding the deleterious effects on normal cellular functions. 
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CHAPTER 
5 
 
5. Probing the Mechanism of IKK Activation 
of the KSHV vFLIP 
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5.1 Introduction 
Results in Chapters 3 and 4 demonstrated that vFLIP does not require ubiquitin 
signalling or the IKK kinases TAK1 or MEKK3 to achieve IKK activation. Clearly, 
however, an as yet unidentified IKK kinase might be involved (Figure 5.1A). 
Furthermore, the phosphatase PP2A was reported to interact with a similar region of 
NEMO to vFLIP, and Tax was reported to interact with PP2A in the IKK complex and 
inhibit its activity (Fu et al., 2003; Hong et al., 2007). One hypothesis might be that vFLIP 
binding to NEMO would either inhibit PP2A binding, or inhibit PP2A activity (Figure 
5.1B). Furthermore, the ubiquitin binding proteins A20 and ABIN1 are known to interact 
with NEMO and inhibit IKK activity (Mauro et al., 2006; Zhang et al., 2000). In the case 
of A20 this is believed to be a direct binding to NEMO that prevents TAK1 recruitment, 
rather than dependent on the deubiquitination activity of A20 (Skaug et al., 2011). 
Therefore, a further hypothesis might be that vFLIP binding prevents A20 and/or 
ABIN1 interaction with NEMO, thereby blocking IKK inhibition. One approach to 
testing whether vFLIP recruits an upstream activator or blocks an inhibitor would be to 
test shRNA knockdown of candidate activators or inhibitors on the activity of vFLIP. 
However, this would be time consuming and likely require combinations of shRNAs. We 
therefore started to examine the activation of an immunoprecipitated IKK complex by 
recombinant vFLIP in this Chapter. This is a first step towards attempting activation of 
recombinant IKK by recombinant vFLIP which would provide conclusive proof that 
vFLIP acts independently of other activators or inhibitors. 
In this chapter we also considered how vFLIP might activate IKK by direct binding 
to NEMO. When our group published the structure of vFLIP bound to a small fragment 
of NEMO, we proposed that this interaction might cause a major conformational change 
in NEMO leading to activation (Bagnéris et al., 2008) (Figure 5.1C). In our present 
experiments we considered this possibility and also whether the kinase subunits required 
T loop phosphorylation which has been reported for chronic activation of IKK by Tax 
(Carter et al., 2001). This activating phosphorylation could be the result of trans-
autophosphorylation by the kinase subunits. Such trans-autophosphorylation can be 
observed with isolated, monomeric IKKβ in vitro (Hauenstein et al., 2014), so vFLIP 
binding to NEMO would need to enhance the likelihood of such an event. 
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Figure 5.1. Possible mechanisms underlying vFLIP-mediated activation of IKK. A) 
vFLIP may function as a signalling adaptor to recruit upstream IKK-Ks to phosphorylate 
IKKs. B) vFLIP may block binding and function of proteins which repress activation of 
IKK (e.g., phosphatase or deubiquitinases), leading to its constitutive  activation. C) 
vFLIP binding to NEMO may cause conformational changes which can then transmit to 
IKKα/β-binding regions of NEMO, affecting spatial conformation of the catalytic IKKs, 
favouring their activation by trans-autophosphorylation. D) Recognition of vFLIP by 
NEMO may induce multimerisation or re-orientation of the IKK complexes, positioning 
the catalytic IKKs for trans-autophosphorylation. 
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5.2 Aims of the chapter 
• Examine whether vFLIP can directly activate IKK, independent of the upstream 
signalling mediators. 
• Examine whether the phosphorylation of the catalytic IKKs is required for 
vFLIP-mediated IKK signalling. 
• Investigate the possible mechanism of IKK activation by vFLIP. 
 
5.3 Results 
5.3.1 Recombinant vFLIP, but not p22-FLIP, can activate IKK when added to cell 
lysates................... 
So far, we have demonstrated that vFLIP and p22-FLIP exhibit very different 
requirements for ubiquitination, signalling intermediates and IKK-Ks in their activation of 
IKK. In order to further probe the mechanism of action of these proteins, we set up an in 
vitro IKK activation assay, originally established by Mukherjee et al (Mukherjee et al., 
2006). This assay is initiated by the addition of a purified activator of the IKK signalling 
pathway to S100 extract of resting cells in the presence of an ATP-regenerating system, 
followed by termination of the reaction by addition of SDS sample buffer. The activation 
of IKK complex is then assessed by immunoblotting for the phosphorylated form of the 
endogenous IκBα.  
Here, we produced recombinant vFLIP and p22-FLIP proteins and added them to 
S100 lysates of the HEK293T cells, in a concentration range of 0.25 µM to 2 µM. Figure 
5.2 shows that recombinant vFLIP induced phosphorylation of the kinase subunits of 
IKK, and that IKK became activated in the lysate as IκBα was phosphorylated. This 
occurred within 10 minutes of incubation with the lysate; in contrast recombinant p22-
FLIP could not activate IKK under these conditions (Figure 5.2). Similar direct activation 
of the IKK kinase in cell lysates supplemented with recombinant Tax has been reported 
(Mukherjee et al., 2008). Taken together with our previous results showing the 
requirement for several signalling intermediates by the p22-FLIP, it is conceivable that 
p22-FLIP activation of IKK relies on signalling complexes which are usually restrained by 
the cellular architecture.  
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Figure 5.2. Recombinant KSHV vFLIP activates IKK when added to cell lysate. A) 
IKK activation by rec-vFLIP or rec-p22FLIP was analysed using an in vitro IκBα 
phosphorylation assay. Briefly, resting HEK293T cells were lysed in HTX buffer (See 
section 2.9) and the S100 fractions were extracted. The lysates were then incubated with 
an ATP-generating buffer and increasing concentrations of recombinant vFLIP or p22-
FLIP at 37 oC for 10 min. Activation of the IKK complex was detected by 
immunoblotting against pIκBα and pIKKα/β. The blot was re-probed for total IKKα/β 
to ensure equal loading of protein. 
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5.3.2 Recombinant vFLIP can activate immuno-isolated IKK complexes in a cell-
free assay system 
We next sought to examine whether the vFLIP-induced activation of IKK in cell 
lysates was a consequence of direct and specific action of the recombinant vFLIP on the 
IKK complex. This is relevant as we have previously shown that, in KSHV-infected cells, 
the subunits of the IKK complex and HSP90 are the only detectable proteins in complex 
with vFLIP. Furthermore, studies by ourselves and other groups aimed at identifying a 
signalling constituent upstream of the IKK complex that would be necessary for vFLIP-
mediated activation of IKK has been unsuccessful.  
To test this hypothesis, we immunoprecipitated the IKK complex from 
unstimulated HEK293T cells using an anti-NEMO antibody and then, incubated them 
with varying concentrations of rec-vFLIP under two different conditions: one group were 
incubated at room temperature for one hour, while the other group were incubated 
overnight at 4 oC. Subsequently, the immune complexes were thoroughly washed with 
kinase wash buffer and subjected to the IKK kinase assay using GST-IκBα(1-54) and γ32P-
ATP as substrates. Due to technical problems, I was unable to perform this experiment 
with recombinant-cFLIP.  
As Figure 5.3 shows, in both incubation conditions, rec-vFLIP was able to activate 
the immunoprecipitated IKK complex and the levels of pGST-IκBα correlated well with 
the concentrations of the added recombinant vFLIP. These data strongly suggest that 
vFLIP can directly activate the IKK complex without a requirement for upstream 
MAP3Ks. Nevertheless, in the previous chapter, we observed that silencing of the IKK-
Ks could partially inhibit vFLIP-mediated NF-κB activation in some settings. Therefore, 
we conclude that, in cells, IKK-Ks are more likely required for maximal IKK signalling 
following its direct MAP3K-independent activation by the vFLIP. 
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Figure 5.3. Direct in vitro activation of the IKK complex by recombinant vFLIP. 
IKK complex from unstimulated HEK293T cells (2x106/reaction) was 
immunoprecipitaed using an antibody against NEMO (0.5 µg/sample). The isolated 
complexes were then washed twice with kinase lysis buffer and once with kinase wash 
buffer (KWB). Next, the IKK-bound beads were divided into equal fractions, re-
suspended with 500 µl of the KWB and incubated with increasing concentrations of 
recombinant vFLIP (0.15-4.0 µM) for 1 hour at room temperature, or overnight at 4 oC. 
Finally, in vitro IKK kinase assays were performed on immunoprecipitated complexes as 
previously described using γ32p-ATP and GST-IκBα(1–54) as substrates. Relative band 
intensity of phosphorylated GST-IκBα was measured by ImageQuant TL Plus7.0 software 
(GE Healthcare). A value of 1.0 represents band intensity obtained in the control 
experiment. Data shown are representative of two independent experiments. 
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5.3.3 Phosphorylation of the IKKs at the activation loop is crucial for vFLIP-
induced IKK activation 
It is now well-established that phosphorylation of the IKKα/β at their activation 
loop (residues S176 and S180 for IKKα, and residues S177 and S181 for IKKβ) is an 
essential step for their activation following inflammatory stimuli (Ling et al., 1998; 
Mercurio et al., 1997; Régnier et al., 1997; Woronicz et al., 1997; Zandi et al., 1997). The 
phosphorylation of T-loop is believed to cause conformational changes that render the 
catalytic domains of IKKα/β active (Hayden and Ghosh, 2008). Nevertheless, tumour-
specific somatic mutations of IKKβ have been recently reported which result in its 
constitutive activation independently of the T-loop phosphorylation (Kai et al., 2014). For 
example, K171E or K171T mutation of IKKβ, originally found in malignancies such as 
splenic marginal zone B-cell lymphoma (Rossi et al., 2011, 2012) and multiple myeloma 
(Chapman et al., 2011), were recently shown to render the IKKβ constitutively active 
without a requirement for activation loop phosphorylation. It has been proposed that 
these mutations mimic the structural alterations induced by the T-loop phosphorylation 
(Kai et al., 2014).  
Considering this information and that vFLIP can activate the IKK complex in the 
absence of upstream kinases, we asked whether phosphorylation of the catalytic IKKs 
were required for their activation by the vFLIP? In other words, could vFLIP-binding to 
NEMO cause activatory conformational changes on IKKα/β which bypass the 
requirement for the T-loop phosphorylation? To test this hypothesis, we examined 
whether dephosphorylation of the vFLIP-bound IKK complex would inhibit its catalytic 
capacity. 
To this end, we immunoprecipitated the active IKK complexes from vFLIP and 
p22-FLIP-transduced HEK293T cells and washed them thoroughly with high salt wash 
buffer. The immune complexes were then treated with increasing concentrations of 
lambda protein phosphatase (LPP or λPP), an Mn2+-dependent protein phosphatase with 
activity towards serine, threonine and tyrosine residues (Zhuo et al., 1993). The in vitro 
phosphatase assay was terminated by adding high concentrations of Na3VO4 (25mM). 
Subsequently, the immunoprecipitates were washed three times to remove any remaining 
LPP and subjected to IKK kinase assay.  
As shown in Figure 5.4A, pre-treatment with LPP led to a marked decrease in the 
activity of both cFLIP and vFLIP-activated IKKs; the kinase activity levels inversely 
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correlated with the amount of LPP used. This implies that both activators require the 
phosphorylataion of the T-loop of the catalytic IKKs to switch on the IKK complex. 
However, a major caveat to this assumption is that LPP may also remove phosphate 
groups from other phospho-acceptor residues in the IKKα, β and γ, with yet unidentified 
activatory roles. 
As mentioned previously, mutation of the IKK activation loop serines to alanine 
(IKKβ S177/S181AA) impedes the kinase activity while their replacement with 
phosphomimetic glutamate residues (IKKβ S177/S181EE) renders the kinase 
constitutively active (Mercurio et al., 1997). In extension to the previous experiment, we 
also tested whether mutations of the T-loop phosphorylation sites would alter the vFLIP-
induced IKK activity. To do this, we overexpressed vFLIP in HEK293T cells in 
combination with either WT IKKβ, or IKKβ SSAA, or IKKβ SSEE. Empty vector-
transfected and TNFα-treated cells were used as negative and positive controls, 
respectively. NF-κB activity was then measured by means of a co-transfected NF-κB-
responsive luciferase reporter system.  
Similar to the result with TNFα stimulation, vFLIP-induced NF-κB activation was 
lower when co-expressed with IKKβ SSAA, as compared with the WT IKKβ, while it was 
higher when co-transfected with the active mutant, IKKβ SSEE (Figure 5.4B). Overall, 
these data suggest that vFLIP-mediated activation of the IKK relies on phosphorylation 
of the activation loop serines.  
It has to be noted that even the overexpression of the IKKβ SSAA causes a 
considerable NF-κB activation in cells. This is presumably caused by enforced 
oligomerisation or re-orientation of the endogenous IKKα/β by the overexpressed 
mutant counterparts. Therefore, precise investigation of this hypothesis would require 
usage of double IKKα/β KO cells to overcome the problem of inducing high basal NF-
κB activation which may mask the vFLIP-induced signals.  
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Figure 5.4. Phosphorylation of the IKKs at their activation loop is required for 
vFLIP-mediated activation of the IKK complex. A) HEK293T cells seeded in 6-well 
plates (2x106/well) were transfected with either 1µg of an empty expression vector, 3µg of 
pCDNA3-vFLIP, or 1µg of   pCDNA3-p22FLIP. Forty-eight hours later, cells were lysed 
in 1ml of kinase lysis buffer and immunoprecipitated with an antibody against NEMO 
(0.5µg/sample). The immune complexes were then washed twice with high salt wash 
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buffer and two additional times with kinase wash buffer lacking the phosphatase 
inhibitors. Next, the anti-NEMO immunoprecipitates were incubated in phosphatase 
reaction buffer (total volume of 50 µl) containing increasing concentrations of LPP (4, 40 
and 400 U) for 30 min at 30 oC. The reactions were terminated by adding high 
concentrations of Na3VO4 (25 mM) and NaF (20 mM). Finally, the immune complex were 
washed twice with kinase wash buffer and subjected to IKK kinase assay.  B) HEK293T 
cells were transiently transfected with 1µg of an empty vector or pCDNA3-vFLIP in 
combination with 300ng of WT or mutant versions of IKKβ. NF-κB activity was 
measured 24 hours later by means of a co-transfected NF-κB reporter system (400ng of 
pGL.IgK and 100ng of pRL.TK). The results shown are representative of two 
independent experiments. IKKβAA: IKKβ S177/S181AA, and IKKβEE: IKKβ 
S177/S181EE. 
 
 
5.3.4 Dimeric vFLIP-vFLIP interactions within the vFLIP-IKK signalosome are 
crucial for vFLIP activation of IKK 
We previously demonstrated that vFLIP can directly activate IKK, in the absence of 
upstream kinases. It was also shown that that vFLIP is able to activate C-terminally 
truncated NEMO (NEMO ∆254). Together, this led us to hypothesise that binding to 
vFLIP, might induce conformational changes in the NEMO which then transmit to the 
N-terminal IKKα/β binding regions, leading to changes in proximity or conformation of 
the catalytic IKKs, favouring their activation by trans-autophosphorylation. To investigate 
this hypothesis, we collaborated with Tracey Barrett (School of Crystollography, Birkbeck 
College) and Chris Kay (Institute of Structural and Molecular Biology, UCL) who 
compared the solution structure of free and vFLIP-bound NEMO using electron 
paramagnetic resonance (EPR). The EPR data revealed that apart from a localised 
twisting near the vFLIP-binding region, NEMO does not undergo major structural 
alterations in response to binding, excluding the induction of conformational changes as a 
potential mechanism of vFLIP-mediated IKK activation (manuscript submitted).  
In addition to conformational change-induced activation, oligomerisation of IKK 
has been also proposed as a means of its activation (See 1.2). The recent crystal structure 
of the human IKKβ suggested a head-to-head orientation of kinase domains for trans-
autophosphorylation that arises through oligomerisation (Figure 5.5A). We, therefore, 
wondered whether vFLIP could lock IKKβ subunits into this configuration, promoting 
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their oligomerisation-induced activation. To address this question, Tracey Barrett re-
analysed the X-ray diffraction data from the vFLIP-NEMO crystals. She found that 
vFLIP-NEMO complexes pack against one another throughout the crystal to generate 
higher order oligomers whose configuration could bring the catalytic IKKs into close 
proximity, leading to their cross-phosphorylation (Figure 5.5B).  
A close inspection of their arrangement suggests that these oligomers are stabilised 
by both vFLIP-vFLIP and vFLIP-NEMO interactions (Figure 5.6A and B). The latter 
interactions occur at two distinct vFLIP-NEMO interfaces: here referred to as interface1 
and interface2 (Figure 5.6C). In chapter 3, we demonstrated that mutations such as 
NEMO F238/D242RR which disrupt the interface1 interactions completely abolish the 
formation of vFLIP-NEMO complexes and the subsequent IKK activation. 
To gain further insights into the mechanism of IKK activation used by vFLIP, we 
introduced mutations in vFLIP that would disrupt interactions involved in its dimerisation 
interface (D102R and E104R), or the vFLIP-NEMO interface2 (R12E) or both 
(R12E/E104R). As shown in Figure 5.7A, while none of these mutations affected the 
ability of vFLIP to form complex with NEMO, they all showed a considerably reduced 
capacity to activate IKK, as revealed by immunoblotting against pIκBα. Consistently, the 
NF-κB luciferase activities induced by vFLIP mutants were significantly lower as 
compared with the WT vFLIP (Figure 5.7B). In summary, these preliminary data 
demonstrate the importance of vFLIP-vFLIP and vFLIP-NEMO interactions that are 
required for the assembly of the higher order oligomers, suggesting the multimerisation-
induced IKK activation as a possible mechanism of action utilised by the KSHV vFLIP. 
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Figure 5.5. Multimerisation of the vFLIP-NEMO complexes within the crystal. A) 
Human IKKβ dimers adopt open conformations that permit higher order oligomerisation 
within the crystal.  A separate colour has been assigned to ribbon diagram of each IKKβ 
subunit. Association of two neighbouring IKKβ dimers gives rise to two unique 
intersubunit interfaces: (i) the V-shaped interface and (ii) the anti-parallel interface. Within 
the higher order complex, neighbouring tetrameric IKKβ assemblies interact 
156 
 
symmetrically in a way that they contact one another through their V-shaped interfaces 
and two kinase domains (KD) are positioned within close proximity to one another, 
facilitating for their trans-autophosphorylation . Reproduced from (Polley et al., 2013). B) 
Within the vFLIP-NEMO crystal, there is an oligomer consistent with the head-to-head 
orientation of IKKβ subunits observed in (A). Courtesy of Dr. Tracey Barret. 
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Figure 5.6. Interactions involved in the formation of higher order vFLIP-NEMO 
assemblies. A) Three interaction interfaces are detected within the vFLIP-NEMO 
crystals. These include two vFLIP-NEMO contact regions (here referred to as interface 1 
and 2) and a dimeric vFLIP-vFLIP contact interface. The vFLIP-NEMO interaction 
interface1 has been discussed previously in Section 3.1.2. B) The vFLIP-vFLIP 
interactions are mediated by salt bridges between R108, D102 and D17 of one monomer 
with E104 and R111 of a second vFLIP monomer (form an adjacent vFLIP-NEMO 
complex). This interaction region is in a close proximity to vFLIP-NEMO interaction 
interface2 . C) The intermolecular contacts within the vFLIP-NEMO interaction interface 
(2) include a network of salt bridges between E222, Q208 and Q217 of NEMO and R12, 
R43 and E9 of vFLIP, respectively. 
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Figure 5.7. Mutations in the vFLIP-vFLIP and vFLIP-NEMO(2) interaction 
interfaces impair the vFLIP-induced activation of IKK. A) HEK293T cells seeded in 
6-well plates (2x106 cells/well) were transfected with 1µg of pCDNA3 vectors encoding 
WT vFLIP or the mutant versions: vFLIP R12E, or R12E/E104R, or D102/E104RR. 
Forty-eight hours later, whole cell lysates were extracted and subjected to 
immunoprecipitation (IP) with anti-NEMO (N) or an isotype-matched control IgG (I), 
followed by immunoblotting (IB) with the indicated antibodies. While none of the 
mutations affected the ability of vFLIP to form complex with NEMO, they all showed a 
considerably reduced capacity to activate IKK, as revealed by reduced levels of IκBα 
phosphorylation. B) 2x105  HEK293T cells were co-transfected with an NF-κB luciferase 
reporter construct (300ng/well) and a Renilla Luc reporter vector (100ng/well) along with 
an empty vector or pCDNA3 vectors (500ng/well) expressing the WT and mutant 
versions of the vFLIP. NF-κB activity was measured 24 hours later, as described 
previously. Results shown are representative of three independent experiments, 
performed in triplicates. Error bars indicate SD of the mean values compared by two-
tailed unpaired Student’s t-test; * p<0.05, ** p<0.01 and *** p<0.001. 
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5.3.5 A stapled peptide derived from HLX2 region of NEMO can efficiently block 
vFLIP-binding to IKK and its subsequent activation 
The crystal structure of the vFLIP-NEMO complex revealed that a very important 
aspect of the vFLIP-mediated IKK activation is the recognition of α-helical structure of 
the NEMO HLX2 by two clefts in the vFLIP DED2 (see 3.1.2). It was then evident that 
further characterisation of the biochemical and structural traits of the complex would 
require strategies to simulate the vFLIP-NEMO interactions. In order to achieve this goal, 
Tracey Barrett in collaboration with David Selwood (Division of Medicine, UCL) 
designed a stapled peptide containing the minimal vFLIP-binding sequence of the NEMO 
(amino acids 226-247) (Figure 5.8A). Stapled peptides (SP) incorporate a hydrocarbon 
cross-linker or “staple” which forces them to maintain their natural α-helical shape. 
Therefore, these peptides retain their ability to bind to target proteins and serve as 
valuable molecular tools to interrogate the native protein-protein interactions (Bernal and 
Katz, 2014; Walensky et al., 2004).  
Structural studies by Tracey Barrett’s group indicated that interactions between 
stapled NEMO peptide and vFLIP directly mimetic of those involving NEMO and 
extend to conservation of the NEMO-NEMO dimer interface (Figure 5.8B and C). In 
keeping with these findings, preliminary ITC (isothermal titration calorimetry) data 
suggested a vFLIP-binding affinity for stapled peptide comparable to that of NEMO. It 
was also shown that the stapled NEMO helix could competitively inhibit formation of 
vFLIP-NEMO complexes in solution (Tracey Barrett, unpublished data). Based on these 
findings, we set out to investigate whether this peptide could also block the vFLIP-
induced IKK activation. 
To test this, we extracted cell lysates of the WT or vFLIP-expressing Jurkat cells 
and incubated them with stapled NEMO peptide (50 µM) or DMSO (as negative control) 
at 4 oC overnight. We then immunoprecipitated IKK from cell extracts using an anti-
NEMO antibody and measured its ability to phosphorylate recombinant IκBα. Figure 5.9 
shows that stapled peptide not only disrupted the vFLIP-NEMO binding in cell lysates 
but also repressed the vFLIP-induced, but not basal, IKK activities.  
Because of their enhanced cell permeability and resistance to protease degradation, 
stapled peptides may be cell permeable and are therefore possible therapeutics. More 
experiments are required to confirm that the stapled NEMO peptide does not have any 
non-specific effects on physiological cytokine-induced IKK signalling. In addition, the in 
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vivo efficacy of the peptide remains to be examined. Nevertheless, our preliminary data 
suggests that this peptide could have therapeutic potential against KS-induced tumours. 
Clearly also the peptide is a useful experimental tool as we can demonstrate that removal 
of vFLIP from the IKK complex reverses its activation. 
 
Figure 5.8. Crystal structure of the stapled NEMO peptide. A) Primary sequence and 
α-helical structure of the NEMO SP. The all-hydrocarbon staple has been incorporated 
into the peptide sequence at the i, i+4 positions, highlighted in violet. B) The GB1-
vFLIP-NEMO interface. GB1-vFLIP is represented as stick model and NEMO is shown 
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as brown ribbon representation. C) Interactions between SP and vFLIP directly mimic of 
those involving NEMO (right panel) and extend to conservation of the NEMO-NEMO 
dimer interface. This is revealed by superimposition of vFLIP-bound SP and NEMO 
dimers (left panel). 
 
Figure 5.9. The stapled NEMO peptide efficiently inhibits the vFLIP-induced IKK 
activation by blocking the interaction of vFLIP with NEMO. Cytoplasmic extracts 
of wild-type or vFLIP-expressing Jurkat cells (2x106) were prepared and incubated with 
the staple peptide (SP) or DMSO at 4 oC overnight. Subsequently, IKK complexes were 
immunoprecipitated using an anti-NEMO antibody (0.5µg/sample) and subjected to an in 
vitro kinase assay as described previously. The same membrane was immunoblotted using 
the indicated antibodies to assess the vFLIP-NEMO interactions and to ensure of equal 
protein loading. The relative activities of the IKK complex are expressed as the intensity 
of the pGST-IκBα band, normalised to the levels of IKK complex as detected by the anti-
IKKα/β antibody. 
 
 
162 
 
 
5.4 Summary 
The results in this chapter suggest a possible mechanism for vFLIP activation of 
IKK. We propose that vFLIP binding to NEMO causes oligomerisation of IKK 
complexes leading to trans-autophosphorylation of the kinase subunits and activation. 
This is not implausible as direct activation of IKK by addition of free ubiquitin chains has 
been reported, which could reflect a similar mechanism (Xia et al., 2009). A recent study 
demonstrates that TAK1 phosphorylation of S177 primes IKK for trans-
autophosphorylation on S181 in the T-loop (Zhang et al., 2014). Further analysis will be 
necessary to determine whether vFLIP activation causes both S177 and S181 
phosphorylation. 
There is also a wealth of further information that can be obtained from using the in 
vitro activation system where recombinant vFLIP can be added to purified IKK. A more 
suitable purification system for the kinase would involve a cleavable tag, and the kinase 
purity could then be established using Mass Spectrometry. Some specificity analyses using 
vFLIP and NEMO mutants are necessary. It will also be possible to measure the rate of 
activation, the conditions required for activation (pH, temperature, ionic composition) 
and also whether the stapled peptide can reverse vFLIP activation of purified IKK. One 
might predict that the latter will not occur rapidly if the kinase is sufficiently pure as a 
phosphatase will be required. As stated in the introduction it may be possible eventually to 
reconstitute a recombinant kinase of IKKα/β, NEMO and HSP90 and then examine 
activation by recombinant vFLIP. 
Finally, the demonstration that the vFLIP-NEMO interaction can be inhibited by a 
stapled peptide is an encouraging start to the development of a therapy for Kaposi’s 
sarcoma. The next steps will be to examine whether the existing peptide is cell permeable, 
and if so whether it reduces the viability of KS transformed B cell lines. 
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6.1 Insight into vFLIP activation of IKK 
My experiments demonstrated that vFLIP activation of IKK does not require the 
upstream kinases TAK1 or MEKK3. This led to the hypothesis that vFLIP binding to 
NEMO might cause a conformational change in the kinase complex leading to 
intramolecular autophosphorylation of the IKKα/β subunits. We then collaborated with 
Dr. Tracey Barrett and Prof. Chris Kay to solve the solution structure of NEMO, in the 
absence or presence of vFLIP, by electron paramagnetic resonance (EPR) (manuscript 
submitted). This showed that NEMO remains a parallel alpha-helical coiled-coil when 
vFLIP binds, with vFLIP causing only local perturbation in the structure. Polley et al., 
then published a structure for human IKKβ, which showed that this kinase subunit of 
IKK can form oligomers in the crystal and in solution (Polley et al., 2013). They 
demonstrated the presence of kinase domain interactions within these oligomers, that 
were important both for phosphorylation of the activation loop in trans, and kinase 
activation (Polley et al., 2013). This led Dr. Tracey Barrett to revisit the X-ray diffraction 
data from the vFLIP/NEMO crystals. She found signals corresponding to vFLIP-vFLIP 
interactions, causing oligomerisation of the vFLIP-NEMO complexes. The parallel 
configuration of these oligomers could bring IKKα/β subunits into proximity similar to 
that detected by Polley et al, which could lead to intermolecular activation by 
phosphorylation of the activation loop in trans. My preliminary data shows that mutation 
of residues that are involved in the vFLIP-vFLIP interactions inhibits vFLIP activation of 
IKK in vivo. 
This provides a logical new hypothesis to be further tested. Previous work from our 
lab and others showed that IKK was detected in cell lysate as a high molecular weight 
complex by gel filtration (Field et al., 2003). Our lab showed that vFLIP is incorporated in 
a saturable manner into this complex and that vFLIP does not change the size of the 
complex (Field et al., 2003).  When vFLIP was immunoprecipitated and the proteins in 
the IP were identified we found only vFLIP, IKKα, β and γ and HSP90 (Field et al., 
2003). While these experiments were not quantitative, similar amounts of the five proteins 
were detected. Therefore it seems logical that IKK exists as a multimer: perhaps some 
level of intermolecular activation by autophosphorylation occurs in the basal state, 
accounting for its basal activity. When vFLIP is incorporated into this multimer it brings 
at least some of the IKK subunits into an optimal configuration for intermolecular 
activation by phosphorylation of the activation loop in trans. 
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To further test this hypothesis I intend to further analyse vFLIP mutants in the 
predicted dimerisation surfaces for their ability to dimerise, bind to IKK and activate IKK 
in vitro and in vivo. I can also analyse the IKKβ dimerisation mutants reported by Polley et 
al., for their ability to respond to vFLIP. These data may also be extended to HTLV-1 
Tax. While purification of recombinant Tax has not been possible, I have demonstrated 
that Tax does not require TAK1 or MEKK3 to activate IKK and that it can act on an N-
terminal fragment of NEMO. Tax dimerisation has been reported (Fryrear et al., 2009; Jin 
and Jeang, 1997; Tie et al., 1996) and it would therefore be interesting to examine Tax 
dimerisation mutants for their ability to activate IKK. Finally, in the long term, it would 
be of great value to reconstitute a recombinant IKK that can respond to vFLIP. 
6.2 Insight into cFLIP activation of IKK 
It has been reported that a proteolytic fragment of both cFLIPL and cFLIPS, p22-
cFLIP, could bind directly to NEMO and activate IKK (Golks et al., 2006). Indeed when 
our lab, with collaborators, published the crystal structure of vFLIP bound to NEMO 
they proposed that p22-cFLIP might bind to the same site (Bagnéris et al., 2008). My 
experiments showed a different and complex mechanism of activation of IKK by cFLIP 
family members. One common feature between all of them was that they required 
ubiquitin recognition by the ubiquitin-binding domain of NEMO and also the upstream 
kinase TAK1.  
Activation of IKK by overexpression of cFLIPL required the linear ubiquitination 
complex LUBAC. This is a similar mechanism in essence to that utilised by TLRs and 
cytokines (Emmerich et al., 2013; Gerlach et al., 2011; Sasaki et al., 2013). The recent 
publication of Fujita et al suggests that LUBAC interacts specifically with NEMO, leading 
to NEMO’s linear ubiquitination (Fujita et al., 2014). It has not yet been established how 
this leads to TAK1 activation of IKK in molecular terms, though ubiquitin chains can 
directly activate TAK1 (Xia et al., 2009). I found that the activity of IKK 
immunoprecipitated from TNF-treated cells appeared higher than that of vFLIP 
expressing cells (Figure 3.5A). Perhaps the LUBAC/TAK1 activation pathway results in 
transient phosphorylation of all the IKK enzymes with the high molecular weight 
multimer, whereas vFLIP does not? 
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In the case of cFLIPS and p22-cFLIP I found a novel activation mechanism of 
IKK, involving a FLIP/FADD/RIP1 complex. One question that remains is whether 
these FLIP variants cause ubiquitination of RIP1, and if so, by what mechanism? I will 
start to address this by immunoprecipitating RIP1 (as in Figure 4.3) and immunoblotting 
with antibodies against K63 and linear ubiquitin linkages. If this is the case then it 
provides an explanation for why cFLIPs and p22-cFLIP cause activation of IKK via 
ubiquitin recognition by the ubiquitin-binding domain of NEMO, but again does not 
address how TAK1 is recruited. Note that I also found that the activity of IKK 
immunoprecipitated from p22-FLIP expressing cells appeared higher than that of vFLIP 
expressing cells (Figure 3.5A), again suggesting more optimal phosphorylation of the 
IKKα/β activation loop.  
RIP1 is a kinase which forms filamentous structures, together with RIP3 kinase, 
which are involved in TNF-induced cell necroptosis (He et al., 2009; Zhang et al., 2009a). 
However, a soluble complex between the recombinant death domains of FADD and 
RIP1 has also been prepared (Park et al., 2013). Presumably cFLIPS and p22-cFLIP could 
interact with FADD via DED homotypic interactions, perhaps in a trimeric complex with 
RIP1. Further mutational analysis of the three proteins could be used to determine 
whether this is the case. It could also be possible to prepare a recombinant 
RIP1/FADD/cFLIP complex which could be ubiquitinated then used to activate IKK in 
cell lysate. This might provide a physiological in vitro method of ubiquitin-dependent IKK 
activation. 
6.3 Therapeutic importance of our findings in viral and non-viral 
tumours 
The expression of cFLIP proteins is tightly regulated in normal cells. At the 
transcriptional level cFLIP isoforms are upregulated by NF-κB activation, so they 
positively regulate their own expression (Kreuz and Siegmund, 2001; Micheau et al., 
2001). cFLIPS is particularly more prone to ubiquitination and displays a considerably 
shorter half-life compared to cFLIPL (Poukkula et al., 2005); the stability of cFLIPR is 
similar to cFLIPS (Golks et al., 2005). p22-FLIP is more stable than cFLIPS as it lacks this 
C-terminal sequence (Golks et al., 2006). By using over-expression of cFLIP in our 
experiments we have over-ridden some of these control mechanisms, there is however 
evidence for overexpression of cFLIP isoforms in tumour cells (See 1.3.7), which is the 
situation that we have mimicked.  
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Upregulation of cFLIP expression has been reported in many types of human solid 
tumours and lymphomas, and there is evidence that the level of cFLIP may determine 
clinical outcome (Ullenhag et al., 2007; Valente et al., 2006; Valnet-Rabier et al., 2005). 
cFLIP inhibition or down-regulation has therefore been proposed as a potential cancer 
therapy, with the assumption that this will operate by sensitising tumour cells to Fas, 
TRAIL- or TNF-induced cell death [reviewed in (Safa and Pollok, 2011)]. However, 
tumour cells may also be dependent on cFLIP activation of NF-κB for their survival 
(DiDonato et al., 2012; Karin et al., 2002). Indeed, it is now well-established that the 
tumourigenic capacity of the KSHV substantially relies on the vFLIP-mediated 
constitutive activation of IKK, leading to upregulation of NF-κB-dependent survival 
genes (Ballon et al., 2011; Guasparri et al., 2004; Keller et al., 2006). 
Accumulating evidence indicate that in different malignancies, different cFLIP 
isoforms are overexpressed [reviewed in (Shirley and Micheau, 2010)]. While, for example, 
cFLIPL is mainly upregulated in B-cell chronic lymphocytic leukaemia (B-CLL), tissue 
samples from lung adenocarcinoma patients show increased levels of cFLIPS, but not 
cFLIPL (MacFarlane et al., 2002; Olsson et al., 2001; Salon et al., 2006). Hence, 
understanding the isoform-specific mechanism of action of the FLIP proteins is critical 
for designing novel targeted therapeutics against the associated tumours.  
Specific inhibitors of IKK (In particular IKKβ) that can selectivity block NF-κB 
activation are being developed by multiple pharmaceutical companies (Karin et al., 2004). 
However, due to global effects of the NF-κB pathway in cellular functions, the clinical 
utility of such therapeutic agents is likely to be limited by their potential toxicity. For 
instance, in vivo administration of ML120B, a small molecule selective inhibitor of IKKβ, 
resulted in a rapid depletion of T and B cells (Nagashima et al., 2006). Taken together, 
therefore, we believe that our dissection of the different mechanisms of NF-κB activation 
by cFLIP variants and KSHV vFLIP (Figure 6.1) will allow the development of reagents 
to inhibit these pathways selectively and thereby assess their role in FLIP-driven 
tumourigenesis.  
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Figure 6.1. Our working model of IKK activation by the KSHV vFLIP and cellular 
FLIPs. All cFLIP isoforms critically depend on UBAN domain of NEMO and the IKK- 
activating enzyme, TAK1 for their activation of IKK. p22-FLIP can be generated by 
procaspase-8 cleavage of both cFLIPL and cFLIPS isoforms. The short variants of cFLIP, 
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cFLIPS and p22-FLIP, associate with a preformed RIP1/FADD complex to signal to 
IKK. It is possible that RIP1-bound non-degradative polyubiquitin chains connect these 
cFLIP variants to UBAN domain of NEMO. Alternatively, the RIP1/FADD/cFLIP 
complexes may recruit E3 ligases which can then ubiquitinate NEMO or another 
unidentified protein that is capable of binding to and activating the NEMO UBAN. In 
contrast to short variants, cFLIPL-mediated activation of IKK depends on LUBAC and 
can be inhibited by the activity of the deubiquitinase, CYLD. KSHV vFLIP, unlike 
cellular FLIPs, does not require intermediate signalling components upstream of IKK. 
Instead, vFLIP-induced activation of IKK is most likely to occur through oligomerisation 
and re-orientation of IKK complexes, leading to formation of higher order complexes 
which would allow for trans-autophosphortylation of the catalytic IKKα/β subunits. 
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